<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002112" GROUP_ID="INCONT" ID="184699091410302437" MERGED_FROM="" MODIFIED="2008-11-06 11:45:11 +0100" MODIFIED_BY="June Cody" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Short title (no longer in use): Desmopressin for enuresis&lt;/p&gt;&lt;p&gt;Next update - change desmo vs alarm Wille shoudl be 16/24 vs 4/22&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-28 17:21:20 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0002" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-11-06 11:45:11 +0100" MODIFIED_BY="June Cody">
<TITLE>Desmopressin for nocturnal enuresis in children</TITLE>
<CONTACT MODIFIED="2008-11-06 11:45:11 +0100" MODIFIED_BY="June Cody"><PERSON ID="7513" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Cathryn</FIRST_NAME><MIDDLE_INITIALS>MA</MIDDLE_INITIALS><LAST_NAME>Glazener</LAST_NAME><POSITION>Reader</POSITION><EMAIL_1>c.glazener@abdn.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Health Services Research Unit</DEPARTMENT><ORGANISATION>University of Aberdeen</ORGANISATION><ADDRESS_1>3rd Floor, Health Sciences Building</ADDRESS_1><ADDRESS_2>Foresterhill</ADDRESS_2><CITY>Aberdeen</CITY><ZIP>AB25 2ZD</ZIP><REGION>Scotland</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1224 553732</PHONE_1><PHONE_2>+44 1224 551102</PHONE_2><FAX_1>+44 1224 554580</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-06 11:45:11 +0100" MODIFIED_BY="June Cody"><PERSON ID="7513" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Cathryn</FIRST_NAME><MIDDLE_INITIALS>MA</MIDDLE_INITIALS><LAST_NAME>Glazener</LAST_NAME><POSITION>Reader</POSITION><EMAIL_1>c.glazener@abdn.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Health Services Research Unit</DEPARTMENT><ORGANISATION>University of Aberdeen</ORGANISATION><ADDRESS_1>3rd Floor, Health Sciences Building</ADDRESS_1><ADDRESS_2>Foresterhill</ADDRESS_2><CITY>Aberdeen</CITY><ZIP>AB25 2ZD</ZIP><REGION>Scotland</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1224 553732</PHONE_1><PHONE_2>+44 1224 551102</PHONE_2><FAX_1>+44 1224 554580</FAX_1></ADDRESS></PERSON><PERSON ID="14219" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jonathan</FIRST_NAME><MIDDLE_INITIALS>HC</MIDDLE_INITIALS><LAST_NAME>Evans</LAST_NAME><POSITION>Consultant Paediatric Nephrologist</POSITION><EMAIL_1>jevans1@ncht.trent.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Nephrology</DEPARTMENT><ORGANISATION>Nottingham University Hospitals NHS Trust</ORGANISATION><ADDRESS_1>Hucknall Road</ADDRESS_1><CITY>Nottingham</CITY><ZIP>NG25 0SA</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 969 1169 ext: 47428</PHONE_1><PHONE_2>+44 115 962 7759</PHONE_2></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-10 13:24:34 +0100" MODIFIED_BY="Cathryn Glazener" NOTES="&lt;p&gt;Minor update: 8/22/06&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 5/10/06&lt;/p&gt;&lt;p&gt;Conclusions changed: 4/8/02&lt;/p&gt;" NOTES_MODIFIED="2008-10-10 13:24:34 +0100" NOTES_MODIFIED_BY="Cathryn Glazener">
<UP_TO_DATE>
<DATE DAY="10" MONTH="5" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="10" MONTH="5" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="3" YEAR="2006"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2008-10-10 13:31:01 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;br&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-10 13:31:01 +0100" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="16" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-10 13:31:01 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-10 13:31:01 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="10" YEAR="2006"/>
<DESCRIPTION>
<P>Minor update Issue 3 2006. Includes 5 new trials, and the previous tentative conclusions regarding alarms were strengthened: there is now firmer evidence that alarms are more effective (lower relapse rates) than desmopressin after treatment stops. There is no statistically significant evidence to suggest that combining desmopressin and alarm treatment is more effective than alarm treatment alone. Desmopressin appeared to be better than imipramine during treatment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-10 13:30:59 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="5" YEAR="2004"/>
<DESCRIPTION>
<P>Minor update Issue 3, 2004. Six new studies were excluded and one new trial (Gibb 2004) was included. The conclusions were, however, unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-10-10 13:25:19 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="5" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment. The review was updated for Issue 3, 2002. 18 new trials were added, and the data from some old trials recalculated to include relapse rates and failure rates together.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Chief Scientist Office, Sottish Executive Health Department</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>National Health Service Research and Development Programme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-28 16:44:53 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Desmopressin for bedwetting in children</TITLE>
<SUMMARY_BODY>
<P>Bedwetting is a distressing and stressful condition for children and their families. Some children take longer than others to stop bedwetting. Up to 20% still wet at the age of five years, but by the age of 16 only 2% or less do so. Desmopressin is a drug which reduces bedwetting by reducing the amount of urine produced at night. It is taken before bedtime, and the children are also advised not to drink more than 240 ml (8 ounces) of fluid in the evening. However, it only works on the nights when it is used, so does not cure the problem in the long term. </P>
<P>When desmopressin is used, most of the children have fewer wet nights (one night less on average per week) and more become dry (19% compared with only 2% using dummy treatment in five trials involving 288 children). However, many children start wetting again when treatment stops. On the other hand, more children remain dry when alarm treatment is finished (54% after alarm compared with 35% after desmopressin in two trials involving 119 children). Adding desmopressin to alarm treatment did not result in better cure rates after the end of treatment (51% remained dry after combination treatment compared with 45% after alarm alone). </P>
<P>Those using desmopressin (or their parents) should be warned that over-drinking before bedtime should be avoided as this may lead to serious, but rare, adverse effects. Drugs called tricyclic antidepressants have a similar effect to desmopressin and are cheaper, but have more adverse effects. There are few adverse effects with alarms, other than short-term disruption for the family. In summary, alarms take longer to reduce bed-wetting, but their effect may persist longer than desmopressin.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-10-10 13:38:09 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Enuresis (bed-wetting) is a socially disruptive and stressful condition which affects from 15% to 20% of five year olds, and up to 2% of young adults.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of desmopressin on nocturnal enuresis in children, and to compare desmopressin with other interventions.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Incontinence Group Specialised Trials Register (searched 10 May 2006). The reference list of the original version of this review was also searched.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised controlled trials of desmopressin for nocturnal enuresis in children were included in the review. Trials focused solely on daytime wetting were excluded.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers independently assessed the quality of the eligible trials and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-10-10 13:38:09 +0100" MODIFIED_BY="[Empty name]">
<P>Forty seven randomised controlled trials involving 3448 children (of whom 2210 received desmopressin) met the inclusion criteria. The quality of many of the trials was poor.</P>
<P>Desmopressin was effective in reducing bed-wetting during treatment, compared with placebo (e.g. 20 µg: 1.34 fewer wet nights per week; 95% confidence interval (CI) 1.11 to 1.57), and children were more likely to become dry (e.g. 118/146, 81% versus 140/142, 98% still wet; relative risk (RR) for failure to achieve 14 dry nights with 20 µg was 0.84; 95% CI 0.79 to 0.91). However, there was no difference between the two patient groups after treatment was finished. There was no clear dose-related effect of desmopressin, but the evidence was limited. Data which compared oral and nasal administration were too few to be conclusive.</P>
<P>In four small trials, there were no significant differences between desmopressin and alarms during treatment when these were used separately, but the chance of failure or relapse after treatment stopped was lower after an alarm in two small trials (40/62, 65% versus 26/57, 46%; RR 1.42, 95% CI 1.05 to 1.91).</P>
<P>Although children had fewer wet nights during treatment when they used desmopressin combined with alarm treatment compared with alarms alone (WMD -0.83, 95% CI -1.11 to -0.55), there were no significant differences either in failure rates during treatment (RR 0.88; 95% CI 0.73 to 1.05) or for relapse after treatment stopped (105/213, 49% versus 118/214, 55%: RR 0.91, 95% CI 0.76 to 1.08).</P>
<P>Comparison with some tricyclic drugs (e.g. amitriptyline) suggested that they might be as effective as desmopressin, although in two trials children were less likely to achieve 14 dry nights with imipramine than desmopressin (RR 0.44, 95% CI 0.27 to 0.73) but there was not enough information about subsequent relapse. There were more side effects with the tricyclics. Desmopressin may be better than diclofenac or indomethacin.</P>
<P>There was not enough information to evaluate the relative effects of behavioural or complementary treatments against desmopressin.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Desmopressin rapidly reduced the number of wet nights per week experienced by children, but the limited evidence available suggested that this was not sustained after treatment stopped. Comparison with alternative treatments suggested that desmopressin and tricyclics had similar clinical effects during treatment, but that alarms may produce more sustained benefits. However, based on the available limited evidence, these conclusions are only tentative. Children should be advised not to drink more than 240 ml (8 ounces) of fluid during the evening before desmopressin treatment in order to avoid the possible risk of water intoxication.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-28 16:44:53 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-10-10 13:33:39 +0100" MODIFIED_BY="[Empty name]">
<P>This is one of seven reviews of interventions for bed-wetting, or non-organic nocturnal enuresis. The others focus on: tricyclics and related drugs (<LINK REF="REF-Glazener-2004e" TYPE="REFERENCE">Glazener 2004e</LINK>); other drugs (<LINK REF="REF-Glazener-2004c" TYPE="REFERENCE">Glazener 2004c</LINK>); alarms (<LINK REF="REF-Glazener-2004a" TYPE="REFERENCE">Glazener 2004a</LINK>); simple behavioural interventions (<LINK REF="REF-Glazener-2004d" TYPE="REFERENCE">Glazener 2004d</LINK>); complex behavioural interventions (<LINK REF="REF-Glazener-2004b" TYPE="REFERENCE">Glazener 2004b</LINK>); and miscellaneous and complementary therapy (in preparation). All seven reviews were based on the work of Lister-Sharp and her colleagues at the Centre for Reviews and Dissemination at the University of York, United Kingdom (<LINK REF="REF-Lister_x002d_Sharp-1997" TYPE="REFERENCE">Lister-Sharp 1997</LINK>).</P>
<P>Nocturnal enuresis is the involuntary loss of urine at night, in the absence of organic disease, at an age when a child could reasonably be expected to be dry (by consensus, at a developmental age of five years) (<LINK REF="REF-APA-1980" TYPE="REFERENCE">APA 1980</LINK>; <LINK REF="REF-WHO-1992" TYPE="REFERENCE">WHO 1992</LINK>). Although bed-wetting is pathologically benign and has a high rate of spontaneous remission, it may bring social and emotional stigma, stress and inconvenience to both the children with enuresis and their families (<LINK REF="REF-Fitzwater-1992" TYPE="REFERENCE">Fitzwater 1992</LINK>). Children who wet the bed may experience parental disapproval, sibling teasing and repeated treatment failure, which may lower self-esteem (<LINK REF="REF-Warzak-1993" TYPE="REFERENCE">Warzak 1993</LINK>). The children may also be at increased risk of emotional and physical abuse (<LINK REF="REF-Warzak-1993" TYPE="REFERENCE">Warzak 1993</LINK>). Consequently, it is important that enuresis is properly managed on 'humane grounds' (<LINK REF="REF-Moffatt-1994" TYPE="REFERENCE">Moffatt 1994</LINK>).</P>
<P>Although daytime wetting is a significant problem, and is often associated with bed-wetting, it is usually considered separately. It has been suggested that there are different aetiologies underlying the two conditions (<LINK REF="REF-Jarvelin-1989" TYPE="REFERENCE">Jarvelin 1989</LINK>). If daytime symptoms are present, investigations to identify physical causes such as urinary tract dysfunction, congenital malformation and neurogenic disorders are usually necessary (<LINK REF="REF-Djurhuus-1992" TYPE="REFERENCE">Djurhuus 1992</LINK>). An organic cause is more often found in children with daytime wetting: more structural abnormalities and functional disorders of the urinary tract were found in daytime wetters than controls (<LINK REF="REF-Jarvelin-1990" TYPE="REFERENCE">Jarvelin 1990</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="2">Prevalence and causes</HEADING>
<P>Nocturnal enuresis is a complaint that affects many families. Estimating the prevalence of nocturnal enuresis is difficult, however, because there is variation in methods of diagnosis and definitions (<LINK REF="REF-de-Jonge-1973" TYPE="REFERENCE">de Jonge 1973</LINK>; <LINK REF="REF-Krantz-1994" TYPE="REFERENCE">Krantz 1994</LINK>). In the United Kingdom, the generally quoted prevalence rates are that 15% to 20% of five year olds, 7% of seven year olds, 5% of ten year olds, 2% to 3% of 12 to 14 year olds and 1% to 2% of those aged 15 and over wet the bed twice a week on average (<LINK REF="REF-Blackwell-1989" TYPE="REFERENCE">Blackwell 1989</LINK>; <LINK REF="REF-Rutter-1973" TYPE="REFERENCE">Rutter 1973</LINK>). The incidence of nocturnal enuresis is particularly high amongst children in residential care (<LINK REF="REF-Morgan-1970" TYPE="REFERENCE">Morgan 1970</LINK>). About 1% of adults remain enuretic. Without treatment, about 15% of bed-wetting children become dry each year (<LINK REF="REF-Forsythe-1974" TYPE="REFERENCE">Forsythe 1974</LINK>).</P>
<P>The causes of nocturnal enuresis are unclear (<LINK REF="REF-Lister_x002d_Sharp-1997" TYPE="REFERENCE">Lister-Sharp 1997</LINK>). Genetic (<LINK REF="REF-APA-1980" TYPE="REFERENCE">APA 1980</LINK> 1980; <LINK REF="REF-Bakwin-1971" TYPE="REFERENCE">Bakwin 1971</LINK>; <LINK REF="REF-Bakwin-1973" TYPE="REFERENCE">Bakwin 1973</LINK>; <LINK REF="REF-Eiberg-1995" TYPE="REFERENCE">Eiberg 1995</LINK>), physiological (<LINK REF="REF-Djurhuus-1992" TYPE="REFERENCE">Djurhuus 1992</LINK>; <LINK REF="REF-Norgaard-1993" TYPE="REFERENCE">Norgaard 1993</LINK>) and psychological (<LINK REF="REF-Devlin-1991" TYPE="REFERENCE">Devlin 1991</LINK>; <LINK REF="REF-Moffatt-1989" TYPE="REFERENCE">Moffatt 1989</LINK>; <LINK REF="REF-Rutter-1973" TYPE="REFERENCE">Rutter 1973</LINK>; <LINK REF="REF-Shaffer-1977" TYPE="REFERENCE">Shaffer 1977</LINK>) factors, as well as delay in maturation of the mechanism for bladder control (<LINK REF="REF-Jarvelin-1989" TYPE="REFERENCE">Jarvelin 1989</LINK>; <LINK REF="REF-Koff-1995" TYPE="REFERENCE">Koff 1995</LINK>), have been suggested. Other factors which may contribute to bed-wetting include: constipation, sleep apnoea, upper airway obstructive symptoms (<LINK REF="REF-Maizels-1993" TYPE="REFERENCE">Maizels 1993</LINK>), diet and intake of mild caffeine drinks with diuretic effects (e.g. cola) (<LINK REF="REF-Blackwell-1989" TYPE="REFERENCE">Blackwell 1989</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Interventions</HEADING>
<P>Pharmacological, psychological/behavioural and a variety of 'unconventional' interventions are commonly used for people who wet the bed.</P>
<P>Pharmacological interventions include desmopressin, tricyclic drugs (amitriptyline, dothiepin, doxepin, trimipramine, clomipramine, desipramine, imipramine, lofepramine, nortriptyline and protriptyline) (<LINK REF="REF-Glazener-2004e" TYPE="REFERENCE">Glazener 2004e</LINK>); drugs related to the tricyclics (viloxazine, desipramine, mianserin and maprotiline) (<LINK REF="REF-Glazener-2004e" TYPE="REFERENCE">Glazener 2004e</LINK>); and amphetamine, diazepam and oxybutynin (<LINK REF="REF-Glazener-2004c" TYPE="REFERENCE">Glazener 2004c</LINK>). However, some of these drugs are now contraindicated. Simple behavioural interventions include reward systems (such as star charts), lifting, scheduled wakening (<LINK REF="REF-Glazener-2004d" TYPE="REFERENCE">Glazener 2004d</LINK>), and alarms and over-learning (after successful alarm treatment) (<LINK REF="REF-Glazener-2004a" TYPE="REFERENCE">Glazener 2004a</LINK>). Complex behavioural interventions include multidimensional behavioural treatment such as dry bed training or full spectrum home training (<LINK REF="REF-Glazener-2004b" TYPE="REFERENCE">Glazener 2004b</LINK>). Less common interventions include: psychotherapy, retention control training, surgery, fluid deprivation and complementary therapies.</P>
<P>This review is restricted to pharmacological treatment with desmopressin, or to any other intervention that is compared with, or used in combination with, desmopressin.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Desmopressin</HEADING>
<P>Desmopressin is an analogue of the human pituitary hormone arginine vasopressin. Its antidiuretic effect results from increased reabsorption of water from the kidney, leading to a reduced volume of more concentrated urine entering the bladder (<LINK REF="REF-Djurhuus-1992" TYPE="REFERENCE">Djurhuus 1992</LINK>). In 1972, desmopressin was introduced in a dropper bottle allowing drops to be placed into the nose. It has also become available as a measured dose spray giving doses in multiples of 10 µg; a single dose pipette giving doses in multiples of 20 µg; and 0.2 mg oral tablets. Generally, 20 µg to 40 µg is given intranasally at bedtime irrespective of age and body weight (<LINK REF="REF-Harris-1989" TYPE="REFERENCE">Harris 1989</LINK>). Although initially prescribed for short-term treatment, longer-term treatment may be considered appropriate for some children. It has been recommended that after three months, treatment should be withdrawn for at least one week pending reassessment (<LINK REF="REF-BNF-2002" TYPE="REFERENCE">BNF 2002</LINK>).</P>
<P>About 10% of intranasal desmopressin is absorbed from the nasal mucosa. The maximum plasma concentration of desmopressin is reached within an hour, and the biological effect lasts for 10 to 12 hours (<LINK REF="REF-Harris-1989" TYPE="REFERENCE">Harris 1989</LINK>).</P>
<P>A review of the adverse effects of desmopressin for nocturnal enuresis noted that 22 adverse experiences, most commonly nasal irritation and nose bleeds, were reported in seven published studies (<LINK REF="REF-Hjalmas-1993" TYPE="REFERENCE">Hjalmas 1993</LINK>). Twelve additional published studies reported no adverse effects. Although 21 cases of water intoxication were spontaneously reported by physicians and patients prior to 1993, the authors of the review concluded that desmopressin produces few, mostly mild, adverse effects in children treated for nocturnal enuresis (<LINK REF="REF-Hjalmas-1993" TYPE="REFERENCE">Hjalmas 1993</LINK>).</P>
<P>Water intoxication is potentially the most serious complication. It is associated with over-drinking at bedtime, and its symptoms include headache, nausea, hyponatraemia, cerebral oedema and convulsions. Current guidelines recommend that not more than 240 ml (8 ounces) of fluid should be consumed on any night when desmopressin is used (<LINK REF="REF-Bernstein-1997" TYPE="REFERENCE">Bernstein 1997</LINK>; <LINK REF="REF-Robson-1994" TYPE="REFERENCE">Robson 1994</LINK>; <LINK REF="REF-Robson-1996" TYPE="REFERENCE">Robson 1996</LINK>).</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the effects of desmopressin for the treatment of children with nocturnal enuresis. </P>
<P>The following comparisons were made: <BR/>(1) desmopressin versus no active treatment / placebo; <BR/>(2) lower versus higher doses of desmopressin;<BR/>(3) oral versus nasal administration of desmopressin; <BR/>(4) desmopressin versus other drugs, alone or in combination;<BR/>(5) desmopressin alone versus alarm treatment alone; <BR/>(6) desmopressin alone versus desmopressin supplemented by alarm treatment;<BR/>(7) desmopressin supplemented by alarm treatment versus alarm treatment alone;<BR/>(8) desmopressin versus behavioural methods, alone or in combination; <BR/>(9) desmopressin versus complementary treatment . </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-28 16:44:53 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised or quasi-randomised controlled trials of desmopressin with any comparable control groups for the treatment of nocturnal enuresis.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Children (as defined by trialists, usually as less than 16 years of age) suffering from nocturnal enuresis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any trial that used desmopressin in at least one arm of the study. </P>
<P>Comparisons were made with no active treatment, other types of drugs, and alarm or behavioural interventions, either alone or in combination with desmopressin.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The outcomes considered in this review were: </P>
<UL>
<LI>mean number of wet nights per week during treatment; </LI>
<LI>number of children failing to attain 14 consecutive dry nights during treatment; </LI>
<LI>mean number of wet nights per week when children were followed up after treatment ends; </LI>
<LI>number of children failing during treatment and/or relapsing after treatment ends; </LI>
<LI>adverse effects.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-28 16:44:53 +0000" MODIFIED_BY="[Empty name]">
<P>This review has drawn on the search strategy developed for the Incontinence Review Group. Relevant trials were identified from the Group's Specialised Register of controlled trials which is described, along with the group search strategy, under the Incontinence Group's details in <I>The Cochrane Library</I> (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/INCONT/frame.html">For more details please see the &#8216;Specialized Register&#8217; section of the Group&#8217;s module in The Cochrane Library</A>). The register contains trials identified from MEDLINE, CINAHL, the Cochrane Central Register of Controlled Trials (CENTRAL) and hand searching of journals and conference proceedings. The Incontinence Group Specialised Trials Register was searched using the Group's own keyword system. The search terms used were:</P>
<P>({design.cct*} OR {design.rct*})<BR/>AND <BR/>{topic.enuresis*}<BR/>(All searches were of the keyword field of Reference Manager 9.5N, ISI ResearchSoft.)<BR/>
<BR/>Date of the most recent search of the register for this review: 10 May 2006.</P>
<P>The trials in the Incontinence Group's trials register are also contained in CENTRAL.</P>
<P>The reference list of a previous systematic review of enuresis treatments was also searched (<LINK REF="REF-Lister_x002d_Sharp-1997" TYPE="REFERENCE">Lister-Sharp 1997</LINK>).</P>
<P>No language restriction or other limits were imposed on the searches.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-10 13:34:11 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Identification of primary studies </HEADING>
<P>The titles, and where possible, abstracts of all studies located by the searches were checked to identify any potentially relevant studies. Full papers were then obtained and assessed to identify those which met the inclusion criteria.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment</HEADING>
<P>A range of both general and more specific quality issues were noted, including:<BR/>
</P>
<UL>
<LI>level of concealment of random allocation in the trials;</LI>
<LI>whether data to assess the comparability of groups at baseline were given, including baseline levels of wetting;</LI>
<LI>use of a 'washout' period if a crossover design was employed;</LI>
<LI>intention-to-treat analysis;</LI>
<LI>whether outcomes were clearly defined;</LI>
<LI>blinding;</LI>
<LI>a follow up of at least three months;</LI>
<LI>the use of appropriate statistical techniques;</LI>
<LI>whether useful data (e.g. means and standard deviations) were presented;</LI>
<LI>whether children with daytime wetting were specifically excluded;</LI>
<LI>whether children who had physical (organic) causes for their enuresis were specifically excluded.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>The data were extracted using a standard form. Included data were processed as described in the Cochrane Reviewers' Handbook (<LINK REF="REF-Clarke-2003" TYPE="REFERENCE">Clarke 2003</LINK>). Where appropriate, the results were converted to the mean and standard deviation of the number of wet nights per week; the number of children failing to achieve cure during treatment, defined as 14 consecutive dry nights; or the number of children who were not cured during treatment plus those who relapsed after stopping active treatment (to allow for possible differences in initial 'success' rates). When a mean value was reported with no standard deviation, we entered the data into 'Other Data Tables'.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>We calculated, where possible, weighted mean differences (WMD) and relative risks (RR) plus 95% confidence intervals (CI). A fixed effect model was used to calculate the pooled estimates and the 95% CIs (<LINK REF="REF-Berlin-1989" TYPE="REFERENCE">Berlin 1989</LINK>). The WMDs were weighted by the inverse of the variance and reported as differences in the number of wet nights per week. Negative values indicated fewer wet nights in the intervention group at the left-hand side of the tables. Differences between trials were further investigated when statistically significant heterogeneity was apparent either at the 10% probability level, using the chi squared test or assessment of the I-squared statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>), or from visual inspection of the results. If there was no obvious reason for the heterogeneity, or it persisted despite the removal of outlying trials, a random effects model could have been used.</P>
<P>Crossover trials were indicated by the symbol # after the trial ID. These were analysed as if they were parallel groups, but a sensitivity analysis was carried out by excluding these trials to determine if their inclusion biased the findings.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-10 13:36:29 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-10-10 13:34:37 +0100" MODIFIED_BY="[Empty name]">
<P>Of 75 studies identified as potentially relevant, 28 were excluded: 21 were not randomised controlled trials (RCTs); five included some adults with detrusor overactivity or daytime wetting, or both; one did not use desmopressin therapeutically (<LINK REF="STD-Bogaert-2005" TYPE="STUDY">Bogaert 2005</LINK>); and one switched children between treatment groups. In this minor update (Issue 3 2006), 2 of the 28 were new excluded studies (<I>see</I> Characteristics of Excluded Studies). Of the remaining included trials, 18 (<LINK REF="STD-Bradbury-1995" TYPE="STUDY">Bradbury 1995</LINK>; <LINK REF="STD-Faraj-1999" TYPE="STUDY">Faraj 1999</LINK>; <LINK REF="STD-Folwell-1997_x0023_" TYPE="STUDY">Folwell 1997#</LINK>; <LINK REF="STD-Hamano-2000" TYPE="STUDY">Hamano 2000</LINK>; <LINK REF="STD-Kahan-1998" TYPE="STUDY">Kahan 1998</LINK>; <LINK REF="STD-Leebeek-2001" TYPE="STUDY">Leebeek 2001</LINK>; <LINK REF="STD-Longstaffe-2000" TYPE="STUDY">Longstaffe 2000</LINK>; <LINK REF="STD-Muller-2001_x0023_" TYPE="STUDY">Muller 2001#</LINK>; <LINK REF="STD-Natochin-2000" TYPE="STUDY">Natochin 2000</LINK>; <LINK REF="STD-Neveus-1999_x0023_" TYPE="STUDY">Neveus 1999#</LINK>; <LINK REF="STD-Radmayr-2001" TYPE="STUDY">Radmayr 2001</LINK>; <LINK REF="STD-Rodriguez-2001" TYPE="STUDY">Rodriguez 2001</LINK>; <LINK REF="STD-Schulman-2001a" TYPE="STUDY">Schulman 2001a</LINK>; <LINK REF="STD-Schulman-2001b" TYPE="STUDY">Schulman 2001b</LINK>; <LINK REF="STD-Sener-1998" TYPE="STUDY">Sener 1998</LINK>; <LINK REF="STD-Skoog-1997" TYPE="STUDY">Skoog 1997</LINK>; <LINK REF="STD-Vertucci-1997" TYPE="STUDY">Vertucci 1997</LINK>; <LINK REF="STD-Yap-1998_x0023_" TYPE="STUDY">Yap 1998#</LINK>) were RCTs added in the previous update (<LINK REF="REF-Glazener-2002" TYPE="REFERENCE">Glazener 2002</LINK>). Two others (<LINK REF="STD-Dimson-1986_x0023_" TYPE="STUDY">Dimson 1986#</LINK>; <LINK REF="STD-Stenberg-1994_x0023_" TYPE="STUDY">Stenberg 1994#</LINK>) had been excluded in the first published version of this review (<LINK REF="REF-Glazener-2000" TYPE="REFERENCE">Glazener 2000</LINK>), and one more was added in the second update (<LINK REF="STD-Gibb-2004" TYPE="STUDY">Gibb 2004</LINK>). In the third update (Issue 3 2006), a further five RCTs have been added (<LINK REF="STD-Fera-2004" TYPE="STUDY">Fera 2004</LINK>; <LINK REF="STD-Hoashi-1995" TYPE="STUDY">Hoashi 1995</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>; <LINK REF="STD-Uygur-1997_x0023_" TYPE="STUDY">Uygur 1997#</LINK>).</P>
<P>The 47 included trials were described in 44 reports (three reports described two separate trials each). Seventeen trials used a crossover design (indicated by symbol #). All the trials, bar two (<LINK REF="STD-Rodriguez-2001" TYPE="STUDY">Rodriguez 2001</LINK>; <LINK REF="STD-Hoashi-1995" TYPE="STUDY">Hoashi 1995</LINK>), gave measures of baseline wetting, and all but three specifically excluded children with organic causes of enuresis (<LINK REF="STD-Fera-2004" TYPE="STUDY">Fera 2004</LINK>; <LINK REF="STD-Radmayr-2001" TYPE="STUDY">Radmayr 2001</LINK>; <LINK REF="STD-Yap-1998_x0023_" TYPE="STUDY">Yap 1998#</LINK>). However, all three of these trials included only children with monosymptomatic nocturnal enuresis, and excluded children with daytime wetting (<LINK REF="STD-Fera-2004" TYPE="STUDY">Fera 2004</LINK>; <LINK REF="STD-Radmayr-2001" TYPE="STUDY">Radmayr 2001</LINK>; <LINK REF="STD-Yap-1998_x0023_" TYPE="STUDY">Yap 1998#</LINK>). In general, sample sizes were small, ranging from 10 to 182 with an average of about 73 children. Out of a total of 3448 children, 2210 received treatment with desmopressin.</P>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>Two studies included some older children or adults (<LINK REF="STD-Janknegt-1997" TYPE="STUDY">Janknegt 1997</LINK>; <LINK REF="STD-Rittig-1988_x0023_" TYPE="STUDY">Rittig 1988#</LINK>), while another focused on adolescents who had failed previous treatment (<LINK REF="STD-Stenberg-1994_x0023_" TYPE="STUDY">Stenberg 1994#</LINK>). Only seven of the trials excluded children who had previously received treatment for their enuresis (<LINK REF="STD-Faraj-1999" TYPE="STUDY">Faraj 1999</LINK>; <LINK REF="STD-Fera-2004" TYPE="STUDY">Fera 2004</LINK>; <LINK REF="STD-Kahan-1998" TYPE="STUDY">Kahan 1998</LINK>; <LINK REF="STD-Muller-2001_x0023_" TYPE="STUDY">Muller 2001#</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>; <LINK REF="STD-Radmayr-2001" TYPE="STUDY">Radmayr 2001</LINK>; <LINK REF="STD-Sener-1998" TYPE="STUDY">Sener 1998</LINK>). The remainder either failed to report this factor (9 trials) or included some children who had failed previous drug or behavioural treatments (31 trials). Of the latter, all the children in one trial had previously failed to improve with desmopressin (<LINK REF="STD-Gibb-2004" TYPE="STUDY">Gibb 2004</LINK>). In another trial, a baseline trial of desmopressin was used to select out those children who failed to respond to desmopressin: only responders were enrolled in the crossover RCT (<LINK REF="STD-Uygur-1997_x0023_" TYPE="STUDY">Uygur 1997#</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dosage of desmopressin</HEADING>
<P>Some trials used dose titration until dry nights were achieved (<LINK REF="STD-Birkasova-1978_x0023_" TYPE="STUDY">Birkasova 1978#</LINK>; <LINK REF="STD-Faraj-1999" TYPE="STUDY">Faraj 1999</LINK>; <LINK REF="STD-Fera-2004" TYPE="STUDY">Fera 2004</LINK>; <LINK REF="STD-Hamano-2000" TYPE="STUDY">Hamano 2000</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Radmayr-2001" TYPE="STUDY">Radmayr 2001</LINK>; <LINK REF="STD-Rittig-1988_x0023_" TYPE="STUDY">Rittig 1988#</LINK>; <LINK REF="STD-Rodriguez-2001" TYPE="STUDY">Rodriguez 2001</LINK>; <LINK REF="STD-Rushton-1995" TYPE="STUDY">Rushton 1995</LINK>; <LINK REF="STD-Schulman-2001b" TYPE="STUDY">Schulman 2001b</LINK>; <LINK REF="STD-Stenberg-1994_x0023_" TYPE="STUDY">Stenberg 1994#</LINK>; <LINK REF="STD-Terho-1991_x0023_" TYPE="STUDY">Terho 1991#</LINK>; <LINK REF="STD-Uygur-1997_x0023_" TYPE="STUDY">Uygur 1997#</LINK>), or compared a variety of doses of active drug (<LINK REF="STD-Kjoller-1984" TYPE="STUDY">Kjoller 1984</LINK>; <LINK REF="STD-Janknegt-1990_x0023_" TYPE="STUDY">Janknegt 1990#</LINK>; <LINK REF="STD-Janknegt-1997" TYPE="STUDY">Janknegt 1997</LINK>; <LINK REF="STD-Miller-1990a" TYPE="STUDY">Miller 1990a</LINK>; <LINK REF="STD-Miller-1990b" TYPE="STUDY">Miller 1990b</LINK>; <LINK REF="STD-Neveus-1999_x0023_" TYPE="STUDY">Neveus 1999#</LINK>; <LINK REF="STD-Schulman-2001a" TYPE="STUDY">Schulman 2001a</LINK>; <LINK REF="STD-Skoog-1997" TYPE="STUDY">Skoog 1997</LINK>). One reduced the dose from 40 µg to 20 µg for the second three weeks of the trial (<LINK REF="STD-Leebeek-2001" TYPE="STUDY">Leebeek 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Route of administration and comparators</HEADING>
<P>Intranasal administration was used in all but ten of the trials: oral tablets were specified in ten (<LINK REF="STD-Fera-2004" TYPE="STUDY">Fera 2004</LINK>; <LINK REF="STD-Janknegt-1997" TYPE="STUDY">Janknegt 1997</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>;<LINK REF="STD-Neveus-1999_x0023_" TYPE="STUDY">Neveus 1999#</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>; <LINK REF="STD-Schulman-2001a" TYPE="STUDY">Schulman 2001a</LINK>; <LINK REF="STD-Schulman-2001b" TYPE="STUDY">Schulman 2001b</LINK>; <LINK REF="STD-Skoog-1997" TYPE="STUDY">Skoog 1997</LINK>; <LINK REF="STD-Stenberg-1994_x0023_" TYPE="STUDY">Stenberg 1994#</LINK>; <LINK REF="STD-Yap-1998_x0023_" TYPE="STUDY">Yap 1998#</LINK>), and two different routes of administration were compared in one (<LINK REF="STD-Fjellestad-1987_x0023_" TYPE="STUDY">Fjellestad 1987#</LINK>). Twenty trials included other interventions:<BR/>
</P>
<UL>
<LI>other drugs (<LINK REF="STD-Burke-1995" TYPE="STUDY">Burke 1995</LINK>; <LINK REF="STD-Hoashi-1995" TYPE="STUDY">Hoashi 1995</LINK>; <LINK REF="STD-Holt-1986" TYPE="STUDY">Holt 1986</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Natochin-2000" TYPE="STUDY">Natochin 2000</LINK>; <LINK REF="STD-Sener-1998" TYPE="STUDY">Sener 1998</LINK>; <LINK REF="STD-Vertucci-1997" TYPE="STUDY">Vertucci 1997</LINK>);</LI>
<LI>alarms (<LINK REF="STD-Bradbury-1995" TYPE="STUDY">Bradbury 1995</LINK>; <LINK REF="STD-Faraj-1999" TYPE="STUDY">Faraj 1999</LINK>; <LINK REF="STD-Gibb-2004" TYPE="STUDY">Gibb 2004</LINK>; <LINK REF="STD-Leebeek-2001" TYPE="STUDY">Leebeek 2001</LINK>; <LINK REF="STD-Longstaffe-2000" TYPE="STUDY">Longstaffe 2000</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>; <LINK REF="STD-Rodriguez-2001" TYPE="STUDY">Rodriguez 2001</LINK>; <LINK REF="STD-Sukhai-1989_x0023_" TYPE="STUDY">Sukhai 1989#</LINK>; <LINK REF="STD-Wille-1986" TYPE="STUDY">Wille 1986</LINK>);</LI>
<LI>other behavioural treatment (<LINK REF="STD-Fera-2004" TYPE="STUDY">Fera 2004</LINK>; <LINK REF="STD-Hamano-2000" TYPE="STUDY">Hamano 2000</LINK>; <LINK REF="STD-Kahan-1998" TYPE="STUDY">Kahan 1998</LINK>); and</LI>
<LI>complementary treatment (laser acupuncture) (<LINK REF="STD-Radmayr-2001" TYPE="STUDY">Radmayr 2001</LINK>).</LI>
</UL>
<P>One ongoing trial has yet to be completed (<LINK REF="STD-Hjalmas-2001" TYPE="STUDY">Hjalmas 2001</LINK>).</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Of the 47 identified RCTs which included desmopressin in at least one arm, only 15 described a secure randomised method of allocation (e.g. by computer allocation or use of sealed opaque envelopes) (<LINK REF="STD-Birkasova-1978_x0023_" TYPE="STUDY">Birkasova 1978#</LINK>; <LINK REF="STD-Bradbury-1995" TYPE="STUDY">Bradbury 1995</LINK>; <LINK REF="STD-Burke-1995" TYPE="STUDY">Burke 1995</LINK>; <LINK REF="STD-Dimson-1986_x0023_" TYPE="STUDY">Dimson 1986#</LINK>; <LINK REF="STD-Folwell-1997_x0023_" TYPE="STUDY">Folwell 1997#</LINK>; <LINK REF="STD-Leebeek-2001" TYPE="STUDY">Leebeek 2001</LINK>; <LINK REF="STD-Longstaffe-2000" TYPE="STUDY">Longstaffe 2000</LINK>; <LINK REF="STD-Neveus-1999_x0023_" TYPE="STUDY">Neveus 1999#</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>; <LINK REF="STD-Schulman-2001a" TYPE="STUDY">Schulman 2001a</LINK>; <LINK REF="STD-Schulman-2001b" TYPE="STUDY">Schulman 2001b</LINK>; <LINK REF="STD-Stenberg-1994_x0023_" TYPE="STUDY">Stenberg 1994#</LINK>; <LINK REF="STD-Sukhai-1989_x0023_" TYPE="STUDY">Sukhai 1989#</LINK>; <LINK REF="STD-Uygur-1997_x0023_" TYPE="STUDY">Uygur 1997#</LINK>; <LINK REF="STD-Yap-1998_x0023_" TYPE="STUDY">Yap 1998#</LINK>). A further 31 trials did not provide adequate details for this to be assessed (although some used double-blind placebo controls and others were crossover trials), and one trial used a quasi-randomised method (<LINK REF="STD-Natochin-2000" TYPE="STUDY">Natochin 2000</LINK>). </P>
<P>There were 17 crossover trials, identified by the symbol # (<LINK REF="STD-Birkasova-1978_x0023_" TYPE="STUDY">Birkasova 1978#</LINK>; <LINK REF="STD-Dimson-1986_x0023_" TYPE="STUDY">Dimson 1986#</LINK>; <LINK REF="STD-Fjellestad-1987_x0023_" TYPE="STUDY">Fjellestad 1987#</LINK>; <LINK REF="STD-Folwell-1997_x0023_" TYPE="STUDY">Folwell 1997#</LINK>; <LINK REF="STD-Janknegt-1990_x0023_" TYPE="STUDY">Janknegt 1990#</LINK>; <LINK REF="STD-Muller-2001_x0023_" TYPE="STUDY">Muller 2001#</LINK>; <LINK REF="STD-Neveus-1999_x0023_" TYPE="STUDY">Neveus 1999#</LINK>; <LINK REF="STD-Post-1983a_x0023_" TYPE="STUDY">Post 1983a#</LINK>; <LINK REF="STD-Post-1983b_x0023_" TYPE="STUDY">Post 1983b#</LINK>; <LINK REF="STD-Rittig-1988_x0023_" TYPE="STUDY">Rittig 1988#</LINK>; <LINK REF="STD-Stenberg-1994_x0023_" TYPE="STUDY">Stenberg 1994#</LINK>; <LINK REF="STD-Sukhai-1989_x0023_" TYPE="STUDY">Sukhai 1989#</LINK>; <LINK REF="STD-Terho-1984_x0023_" TYPE="STUDY">Terho 1984#</LINK>; <LINK REF="STD-Terho-1991_x0023_" TYPE="STUDY">Terho 1991#</LINK>; <LINK REF="STD-Tuvemo-1978_x0023_" TYPE="STUDY">Tuvemo 1978#</LINK>; <LINK REF="STD-Uygur-1997_x0023_" TYPE="STUDY">Uygur 1997#</LINK>; <LINK REF="STD-Yap-1998_x0023_" TYPE="STUDY">Yap 1998#</LINK>). One other crossover trial compared desmopressin with imipramine, but only results from the first arm of the trial were used, which in effect formed parallel groups (<LINK REF="STD-Vertucci-1997" TYPE="STUDY">Vertucci 1997</LINK>). Because of their crossover design, none of the crossover trials could address longer-term post-treatment effects. A further 21 trials used double-blind placebos to ensure blinding to treatment (<LINK REF="STD-Aladjem-1982" TYPE="STUDY">Aladjem 1982</LINK>; <LINK REF="STD-Burke-1995" TYPE="STUDY">Burke 1995</LINK>; <LINK REF="STD-Gibb-2004" TYPE="STUDY">Gibb 2004</LINK>; <LINK REF="STD-Hoashi-1995" TYPE="STUDY">Hoashi 1995</LINK>; <LINK REF="STD-Holt-1986" TYPE="STUDY">Holt 1986</LINK>; <LINK REF="STD-Janknegt-1997" TYPE="STUDY">Janknegt 1997</LINK>; <LINK REF="STD-Kahan-1998" TYPE="STUDY">Kahan 1998</LINK>; <LINK REF="STD-Kjoller-1984" TYPE="STUDY">Kjoller 1984</LINK>; <LINK REF="STD-Leebeek-2001" TYPE="STUDY">Leebeek 2001</LINK>; <LINK REF="STD-Longstaffe-2000" TYPE="STUDY">Longstaffe 2000</LINK>; <LINK REF="STD-Martin-1993" TYPE="STUDY">Martin 1993</LINK>; <LINK REF="STD-Miller-1990a" TYPE="STUDY">Miller 1990a</LINK>; <LINK REF="STD-Miller-1990b" TYPE="STUDY">Miller 1990b</LINK>; <LINK REF="STD-Natochin-2000" TYPE="STUDY">Natochin 2000</LINK>; <LINK REF="STD-Rushton-1995" TYPE="STUDY">Rushton 1995</LINK>; <LINK REF="STD-Schulman-2001a" TYPE="STUDY">Schulman 2001a</LINK>; <LINK REF="STD-Schulman-2001b" TYPE="STUDY">Schulman 2001b</LINK>; <LINK REF="STD-Segni-1982" TYPE="STUDY">Segni 1982</LINK>; <LINK REF="STD-Sener-1998" TYPE="STUDY">Sener 1998</LINK>; <LINK REF="STD-Skoog-1997" TYPE="STUDY">Skoog 1997</LINK>; <LINK REF="STD-Uygur-1997_x0023_" TYPE="STUDY">Uygur 1997#</LINK>). In the remainder of the studies, blinding to treatment allocation was not possible because the treatments were too dissimilar. </P>
<P>Two trials failed to report systematic baseline measures of wetting (<LINK REF="STD-Hoashi-1995" TYPE="STUDY">Hoashi 1995</LINK>; <LINK REF="STD-Rodriguez-2001" TYPE="STUDY">Rodriguez 2001</LINK>), and three failed to exclude children with organic (physical) causes for their bed-wetting (<LINK REF="STD-Fera-2004" TYPE="STUDY">Fera 2004</LINK>; <LINK REF="STD-Radmayr-2001" TYPE="STUDY">Radmayr 2001</LINK>; <LINK REF="STD-Yap-1998_x0023_" TYPE="STUDY">Yap 1998#</LINK>), but all these trials excluded children with daytime wetting. Three trials included some children with daytime wetting but excluded children with organic (physical) causes (<LINK REF="STD-Bradbury-1995" TYPE="STUDY">Bradbury 1995</LINK>; <LINK REF="STD-Gibb-2004" TYPE="STUDY">Gibb 2004</LINK>; <LINK REF="STD-Martin-1993" TYPE="STUDY">Martin 1993</LINK>). Daytime wetting was specifically excluded or reported separately in 27 trials, and not mentioned in another 17. </P>
<P>Only three trials reported using a washout period between the two arms of a crossover trial (<LINK REF="STD-Fjellestad-1987_x0023_" TYPE="STUDY">Fjellestad 1987#</LINK>; <LINK REF="STD-Sukhai-1989_x0023_" TYPE="STUDY">Sukhai 1989#</LINK>; <LINK REF="STD-Yap-1998_x0023_" TYPE="STUDY">Yap 1998#</LINK>), while another interposed a 'placebo' arm between the first and second active arms (<LINK REF="STD-Janknegt-1990_x0023_" TYPE="STUDY">Janknegt 1990#</LINK>). Children who did not respond in one trial (<LINK REF="STD-Schulman-2001a" TYPE="STUDY">Schulman 2001a</LINK>) received placebo treatment during a two-week washout phase before being randomly assigned again in a second trial (<LINK REF="STD-Schulman-2001b" TYPE="STUDY">Schulman 2001b</LINK>). </P>
<P>Ten trials reported continuous data without a measure of dispersion such as a standard deviation (<LINK REF="STD-Dimson-1986_x0023_" TYPE="STUDY">Dimson 1986#</LINK>; <LINK REF="STD-Fjellestad-1987_x0023_" TYPE="STUDY">Fjellestad 1987#</LINK>; <LINK REF="STD-Leebeek-2001" TYPE="STUDY">Leebeek 2001</LINK>; <LINK REF="STD-Miller-1990a" TYPE="STUDY">Miller 1990a</LINK>; <LINK REF="STD-Miller-1990b" TYPE="STUDY">Miller 1990b</LINK>; <LINK REF="STD-Muller-2001_x0023_" TYPE="STUDY">Muller 2001#</LINK>; <LINK REF="STD-Rittig-1988_x0023_" TYPE="STUDY">Rittig 1988#</LINK>; <LINK REF="STD-Terho-1991_x0023_" TYPE="STUDY">Terho 1991#</LINK>; <LINK REF="STD-Uygur-1997_x0023_" TYPE="STUDY">Uygur 1997#</LINK>; <LINK REF="STD-Vertucci-1997" TYPE="STUDY">Vertucci 1997</LINK>). Further data are being sought from the authors of some trials. Only two of the included trials provided a power calculation of the sample size, which helps to define the minimum sample size required to detect a true difference between the treatment groups (<LINK REF="STD-Janknegt-1990_x0023_" TYPE="STUDY">Janknegt 1990#</LINK>; <LINK REF="STD-Leebeek-2001" TYPE="STUDY">Leebeek 2001</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-10 13:36:29 +0100" MODIFIED_BY="[Empty name]">
<P>(1) Twenty nine trials compared desmopressin with placebo treatment (<LINK REF="STD-Aladjem-1982" TYPE="STUDY">Aladjem 1982</LINK>; <LINK REF="STD-Birkasova-1978_x0023_" TYPE="STUDY">Birkasova 1978#</LINK>; <LINK REF="STD-Dimson-1986_x0023_" TYPE="STUDY">Dimson 1986#</LINK>; <LINK REF="STD-Fjellestad-1987_x0023_" TYPE="STUDY">Fjellestad 1987#</LINK>; <LINK REF="STD-Folwell-1997_x0023_" TYPE="STUDY">Folwell 1997#</LINK>; <LINK REF="STD-Janknegt-1990_x0023_" TYPE="STUDY">Janknegt 1990#</LINK>; <LINK REF="STD-Kjoller-1984" TYPE="STUDY">Kjoller 1984</LINK>; <LINK REF="STD-Longstaffe-2000" TYPE="STUDY">Longstaffe 2000</LINK>; <LINK REF="STD-Martin-1993" TYPE="STUDY">Martin 1993</LINK>; <LINK REF="STD-Miller-1990a" TYPE="STUDY">Miller 1990a</LINK>; <LINK REF="STD-Miller-1990b" TYPE="STUDY">Miller 1990b</LINK>; <LINK REF="STD-Muller-2001_x0023_" TYPE="STUDY">Muller 2001#</LINK>; <LINK REF="STD-Natochin-2000" TYPE="STUDY">Natochin 2000</LINK>; <LINK REF="STD-Neveus-1999_x0023_" TYPE="STUDY">Neveus 1999#</LINK>; <LINK REF="STD-Post-1983a_x0023_" TYPE="STUDY">Post 1983a#</LINK>; <LINK REF="STD-Post-1983b_x0023_" TYPE="STUDY">Post 1983b#</LINK>; <LINK REF="STD-Rittig-1988_x0023_" TYPE="STUDY">Rittig 1988#</LINK>; <LINK REF="STD-Rushton-1995" TYPE="STUDY">Rushton 1995</LINK>; <LINK REF="STD-Schulman-2001a" TYPE="STUDY">Schulman 2001a</LINK>; <LINK REF="STD-Schulman-2001b" TYPE="STUDY">Schulman 2001b</LINK>; <LINK REF="STD-Segni-1982" TYPE="STUDY">Segni 1982</LINK>; <LINK REF="STD-Sener-1998" TYPE="STUDY">Sener 1998</LINK>; <LINK REF="STD-Skoog-1997" TYPE="STUDY">Skoog 1997</LINK>; <LINK REF="STD-Stenberg-1994_x0023_" TYPE="STUDY">Stenberg 1994#</LINK>; <LINK REF="STD-Terho-1984_x0023_" TYPE="STUDY">Terho 1984#</LINK>; <LINK REF="STD-Terho-1991_x0023_" TYPE="STUDY">Terho 1991#</LINK>; <LINK REF="STD-Tuvemo-1978_x0023_" TYPE="STUDY">Tuvemo 1978#</LINK>; <LINK REF="STD-Uygur-1997_x0023_" TYPE="STUDY">Uygur 1997#</LINK>; <LINK REF="STD-Yap-1998_x0023_" TYPE="STUDY">Yap 1998#</LINK>);<BR/>(2) Two trials compared oral with nasal administration (<LINK REF="STD-Fjellestad-1987_x0023_" TYPE="STUDY">Fjellestad 1987#</LINK>; <LINK REF="STD-Faraj-1999" TYPE="STUDY">Faraj 1999</LINK>);<BR/>(3) Seven trials compared desmopressin with tricyclic or other drugs (<LINK REF="STD-Burke-1995" TYPE="STUDY">Burke 1995</LINK>; <LINK REF="STD-Hoashi-1995" TYPE="STUDY">Hoashi 1995</LINK>; <LINK REF="STD-Holt-1986" TYPE="STUDY">Holt 1986</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Natochin-2000" TYPE="STUDY">Natochin 2000</LINK>; <LINK REF="STD-Sener-1998" TYPE="STUDY">Sener 1998</LINK>; <LINK REF="STD-Vertucci-1997" TYPE="STUDY">Vertucci 1997</LINK>);<BR/>(4) Nine trials compared desmopressin with alarms (<LINK REF="STD-Bradbury-1995" TYPE="STUDY">Bradbury 1995</LINK>; <LINK REF="STD-Faraj-1999" TYPE="STUDY">Faraj 1999</LINK>; <LINK REF="STD-Gibb-2004" TYPE="STUDY">Gibb 2004</LINK>; <LINK REF="STD-Leebeek-2001" TYPE="STUDY">Leebeek 2001</LINK>; <LINK REF="STD-Longstaffe-2000" TYPE="STUDY">Longstaffe 2000</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>; <LINK REF="STD-Rodriguez-2001" TYPE="STUDY">Rodriguez 2001</LINK>; <LINK REF="STD-Sukhai-1989_x0023_" TYPE="STUDY">Sukhai 1989#</LINK>; <LINK REF="STD-Wille-1986" TYPE="STUDY">Wille 1986</LINK>);<BR/>(5) Three trials compared desmopressin with behavioural interventions (<LINK REF="STD-Fera-2004" TYPE="STUDY">Fera 2004</LINK>; <LINK REF="STD-Hamano-2000" TYPE="STUDY">Hamano 2000</LINK>; <LINK REF="STD-Kahan-1998" TYPE="STUDY">Kahan 1998</LINK>);<BR/>(6) One trial compared desmopressin with laser acupuncture (<LINK REF="STD-Radmayr-2001" TYPE="STUDY">Radmayr 2001</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Desmopressin versus no active treatment / placebo (see Comparisons 01 and 02, Other Data Tables 01)</HEADING>
<P>Desmopressin was better than placebo treatment in achieving fewer wet nights per week during treatment and more children cured during treatment. Desmopressin was better (fewer wet nights per week) at doses of 10 µg in two trials (WMD -2.30; 95% CI -3.42 to -1.18); 20 µg in 12 trials (WMD -1.34; 95% CI -1.57 to -1.11); 40 µg in six trials (WMD -1.33; 95% CI -1.67 to -0.99); and 60 µg in two trials (WMD -1.50; 95% CI -1.92 to -1.08, Comparison 01.01). This held true in a sensitivity analysis when the crossover trials were excluded (e.g. WMD for 20 µg in seven trials -1.21; 95% CI -1.49 to -0.95, Comparison 08.01). Thus, desmopressin significantly reduced bed-wetting by about one to two nights a week, irrespective of whether the crossover studies were included. There were also fewer wet nights during desmopressin treatment in trials which used variable doses of the drug (<LINK REF="STD-Birkasova-1978_x0023_" TYPE="STUDY">Birkasova 1978#</LINK>; <LINK REF="STD-Rushton-1995" TYPE="STUDY">Rushton 1995</LINK>), or in trials which failed to provide standard deviations (Other Data Tables 01.02).</P>
<P>Ten trials reported the number of children cured (defined as achieving 14 consecutive dry nights) while taking either desmopressin or placebo. Despite differences in desmopressin dose, the trials were consistent, suggesting that desmopressin increased the chances of cure (RR for failure with 20 µg in five trials was 0.84; 95% CI 0.79 to 0.91: RR for 40 µg in six trials was 0.81; 95% CI 0.74 to 0.88: RR for 60 µg in two trials was 0.94; 95% CI 0.89 to 0.99, Comparison 01.03). A sensitivity analysis excluding the crossover trials supported these findings (Comparison 08.03).</P>
<P>However, the data suggest that this effect was not sustained after treatment had finished. In four trials (<LINK REF="STD-Aladjem-1982" TYPE="STUDY">Aladjem 1982</LINK>; <LINK REF="STD-Kjoller-1984" TYPE="STUDY">Kjoller 1984</LINK>; <LINK REF="STD-Miller-1990a" TYPE="STUDY">Miller 1990a</LINK>; <LINK REF="STD-Miller-1990b" TYPE="STUDY">Miller 1990b</LINK>), there was little difference between the groups in terms of wet nights per week, but the trials were small, the confidence intervals were wide, and two trials did not report standard deviations (Comparison 01.04, Other Data Tables 01.05). Only one small trial reported relapse rates: all the children either failed to respond to treatment or relapsed afterwards (Comparison 01.06) (<LINK REF="STD-Dimson-1986_x0023_" TYPE="STUDY">Dimson 1986#</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Lower versus higher doses of desmopressin (see Comparison 03, Other Data Tables 03)</HEADING>
<P>Eight small trials compared different doses of desmopressin with each other (<LINK REF="STD-Janknegt-1990_x0023_" TYPE="STUDY">Janknegt 1990#</LINK>; <LINK REF="STD-Janknegt-1997" TYPE="STUDY">Janknegt 1997</LINK>; <LINK REF="STD-Kjoller-1984" TYPE="STUDY">Kjoller 1984</LINK>; <LINK REF="STD-Miller-1990a" TYPE="STUDY">Miller 1990a</LINK>; <LINK REF="STD-Miller-1990b" TYPE="STUDY">Miller 1990b</LINK>; <LINK REF="STD-Neveus-1999_x0023_" TYPE="STUDY">Neveus 1999#</LINK>; <LINK REF="STD-Schulman-2001a" TYPE="STUDY">Schulman 2001a</LINK>; <LINK REF="STD-Skoog-1997" TYPE="STUDY">Skoog 1997</LINK>). Two of these trials were crossovers and two did not report standard deviations. There was some evidence that a higher dose was more likely to reduce the numbers of wet nights than a lower dose (e.g. for 20 µg versus 40 µg the WMD for wet nights during treatment was 0.42; 95% CI -0.01 to 0.84: for 20 µg versus 60 µg the WMD was 0.72; 95% CI 0.3 to 0.14, Comparison 02.01, Other Data Tables 02). However, there was no difference in cure rates (Comparison 02.03). One trial reported no difference between two oral doses, but it did not provide any useable data (<LINK REF="STD-Janknegt-1997" TYPE="STUDY">Janknegt 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Oral versus nasal administration of desmopressin (see Comparison 04, Other Data Tables 04)</HEADING>
<P>Only one study compared oral (200 µg) and nasal (20 µg) administration of desmopressin (<LINK REF="STD-Fjellestad-1987_x0023_" TYPE="STUDY">Fjellestad 1987#</LINK>). This was a crossover trial which did not provide standard deviations and involved only 20 children. There were insufficient data to judge whether the two routes were equally effective. Nasal discomfort (two children) and epistaxis (three children) were reported with nasal administration. This did not appear to be specifically linked to desmopressin because it was reported equally by patients from both the other groups who received placebo nose drops (<LINK REF="STD-Fjellestad-1987_x0023_" TYPE="STUDY">Fjellestad 1987#</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Desmopressin versus other drugs (see Comparison 05, Other Data Tables 05)</HEADING>
<P>Seven trials compared desmopressin with other drugs: amitriptyline (<LINK REF="STD-Burke-1995" TYPE="STUDY">Burke 1995</LINK>); imipramine (<LINK REF="STD-Hoashi-1995" TYPE="STUDY">Hoashi 1995</LINK>; <LINK REF="STD-Holt-1986" TYPE="STUDY">Holt 1986</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Vertucci-1997" TYPE="STUDY">Vertucci 1997</LINK>); indomethacin (<LINK REF="STD-Natochin-2000" TYPE="STUDY">Natochin 2000</LINK>); and diclofenac (<LINK REF="STD-Sener-1998" TYPE="STUDY">Sener 1998</LINK>). One trial included an arm which combined amitriptyline with desmopressin (<LINK REF="STD-Burke-1995" TYPE="STUDY">Burke 1995</LINK>) and another combined desmopressin with oxybutynin (<LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>). In two small separate studies, desmopressin performed better than indomethacin (WMD for wet nights per week -1.45; 95% CI -2.37 to -0.53, Comparison 04.01.05) (<LINK REF="STD-Sener-1998" TYPE="STUDY">Sener 1998</LINK>) and diclofenac (RR for failure to achieve 14 dry nights was 0.52; 95% CI 0.30 to 0.89, Comparison 04.02.03) (<LINK REF="STD-Natochin-2000" TYPE="STUDY">Natochin 2000</LINK>) during treatment, but there was no information about relapse rates after treatment ended. There was not enough evidence to clarify whether desmopressin was better than amitriptyline or oxybutynin added to desmopressin: the sample sizes were too small to address the issue reliably, the follow-up information was scant, and the confidence intervals were wide. However, more children achieved dry nights with desmopressin than imipramine during treatment (RR for failure to achieve 14 dry nights 0.44, 95%CI 0.27 to 0.73, Comparison 05.02.04) (<LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>) but there was no information about subsequent relapse.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5, 6, 7. Desmopressin and alarms</HEADING>
<P>Nine trials compared desmopressin with alarm interventions (<LINK REF="STD-Bradbury-1995" TYPE="STUDY">Bradbury 1995</LINK>; <LINK REF="STD-Faraj-1999" TYPE="STUDY">Faraj 1999</LINK>; <LINK REF="STD-Gibb-2004" TYPE="STUDY">Gibb 2004</LINK>; <LINK REF="STD-Leebeek-2001" TYPE="STUDY">Leebeek 2001</LINK>; <LINK REF="STD-Longstaffe-2000" TYPE="STUDY">Longstaffe 2000</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>; <LINK REF="STD-Rodriguez-2001" TYPE="STUDY">Rodriguez 2001</LINK>; <LINK REF="STD-Sukhai-1989_x0023_" TYPE="STUDY">Sukhai 1989#</LINK>; <LINK REF="STD-Wille-1986" TYPE="STUDY">Wille 1986</LINK>). In four trials, desmopressin was compared with an alarm alone (<LINK REF="STD-Faraj-1999" TYPE="STUDY">Faraj 1999</LINK>; <LINK REF="STD-Longstaffe-2000" TYPE="STUDY">Longstaffe 2000</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>; <LINK REF="STD-Wille-1986" TYPE="STUDY">Wille 1986</LINK>). In three other studies, the children used alarms in both arms of the trials supplemented with either desmopressin or placebo (<LINK REF="STD-Gibb-2004" TYPE="STUDY">Gibb 2004</LINK>; <LINK REF="STD-Leebeek-2001" TYPE="STUDY">Leebeek 2001</LINK>; <LINK REF="STD-Sukhai-1989_x0023_" TYPE="STUDY">Sukhai 1989#</LINK>), the latter in a double-blind crossover design with a two-week washout period. In a further three trials, children used alarms in both arms of the trial, supplemented by desmopressin in one arm (<LINK REF="STD-Bradbury-1995" TYPE="STUDY">Bradbury 1995</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>; <LINK REF="STD-Rodriguez-2001" TYPE="STUDY">Rodriguez 2001</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">5. Desmopressin alone versus alarm treatment alone (see Comparison 06) </HEADING>
<P>In four trials, desmopressin was compared with an alarm alone (<LINK REF="STD-Faraj-1999" TYPE="STUDY">Faraj 1999</LINK>; <LINK REF="STD-Longstaffe-2000" TYPE="STUDY">Longstaffe 2000</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>; <LINK REF="STD-Wille-1986" TYPE="STUDY">Wille 1986</LINK>). One small trial reported that at the end of the first week of treatment, there were 1.7 fewer wet nights per week with desmopressin treatment than with alarm treatment (WMD -1.7; 95% CI -2.95 to -0.45, Comparison 06.01.01) (<LINK REF="STD-Wille-1986" TYPE="STUDY">Wille 1986</LINK>). In the final week (after three months) there was no significant difference between desmopressin and alarm groups in terms of wet nights per week (WMD 0.52, 95% CI -0.32 to 1.36, Comparison 06.01.02) (<LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>; <LINK REF="STD-Wille-1986" TYPE="STUDY">Wille 1986</LINK>) or in numbers remaining wet (RR 1.07, 95%CI 0.83 to 1.36, Comparison 06.02.01) (<LINK REF="STD-Faraj-1999" TYPE="STUDY">Faraj 1999</LINK>; <LINK REF="STD-Longstaffe-2000" TYPE="STUDY">Longstaffe 2000</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>). However, the relapse rate was significantly less after the end of alarm treatment (40/62, 65% after desmopressin versus 26/57, 46% after alarm, RR 1.42, 95% CI 1.05 to 1.91, Comparison 06.03.01) (<LINK REF="STD-Wille-1986" TYPE="STUDY">Wille 1986</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>). Where combination of data was possible, the heterogeneity was high.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Desmopressin alone versus desmopressin supplemented by alarm treatment (see Comparison 07)</HEADING>
<P>One small trial tested the effect of adding alarm treatment to desmopressin (<LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>). The data were too few to draw reliable conclusions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. Desmopressin supplemented by alarm treatment versus alarm treatment alone (see Comparison 08)</HEADING>
<P>Six trials addressed this comparison (<LINK REF="STD-Bradbury-1995" TYPE="STUDY">Bradbury 1995</LINK>; <LINK REF="STD-Gibb-2004" TYPE="STUDY">Gibb 2004</LINK>; <LINK REF="STD-Leebeek-2001" TYPE="STUDY">Leebeek 2001</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>; <LINK REF="STD-Rodriguez-2001" TYPE="STUDY">Rodriguez 2001</LINK>; <LINK REF="STD-Sukhai-1989_x0023_" TYPE="STUDY">Sukhai 1989#</LINK>). Desmopressin combined with alarm treatment was associated with fewer wet nights than alarms alone in four trials (WMD -0.83, 95% CI -1.11 to -0.55, Comparison 08.01.01), whether a placebo was used (<LINK REF="STD-Gibb-2004" TYPE="STUDY">Gibb 2004</LINK>; <LINK REF="STD-Sukhai-1989_x0023_" TYPE="STUDY">Sukhai 1989#</LINK>) or not (<LINK REF="STD-Bradbury-1995" TYPE="STUDY">Bradbury 1995</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>). However, this was not reflected in failure rates during treatment: RR for the number of children failing to achieve 14 dry nights was 0.88; 95% CI 0.73 to 1.05, Comparison 08.02.01) with placebo (<LINK REF="STD-Gibb-2004" TYPE="STUDY">Gibb 2004</LINK>; <LINK REF="STD-Leebeek-2001" TYPE="STUDY">Leebeek 2001</LINK>) or without placebo (<LINK REF="STD-Bradbury-1995" TYPE="STUDY">Bradbury 1995</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>; <LINK REF="STD-Rodriguez-2001" TYPE="STUDY">Rodriguez 2001</LINK>): the heterogeneity was high.</P>
<P>After treatment stopped, there were no statistically significant differences in the combined failure and relapse rate: RR 0.91, 95% CI 0.76 to 1.08, Comparison 08.03.01) with placebo (<LINK REF="STD-Gibb-2004" TYPE="STUDY">Gibb 2004</LINK>; <LINK REF="STD-Leebeek-2001" TYPE="STUDY">Leebeek 2001</LINK>) or without (<LINK REF="STD-Bradbury-1995" TYPE="STUDY">Bradbury 1995</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>). However, the trials were small; one was a crossover with a short duration of treatment (<LINK REF="STD-Sukhai-1989_x0023_" TYPE="STUDY">Sukhai 1989#</LINK>); the confidence intervals were wide; and follow-up results were not available for two trials (<LINK REF="STD-Rodriguez-2001" TYPE="STUDY">Rodriguez 2001</LINK>; <LINK REF="STD-Sukhai-1989_x0023_" TYPE="STUDY">Sukhai 1989#</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">8. Desmopressin versus behavioural methods, alone or in combination (see Comparison 09)</HEADING>
<P>Three small trials compared desmopressin alone or in combination with other behavioural methods of managing enuresis (<LINK REF="STD-Fera-2004" TYPE="STUDY">Fera 2004</LINK>; <LINK REF="STD-Hamano-2000" TYPE="STUDY">Hamano 2000</LINK>; <LINK REF="STD-Kahan-1998" TYPE="STUDY">Kahan 1998</LINK>). The interventions were so dissimilar (retention control training alone in one (<LINK REF="STD-Hamano-2000" TYPE="STUDY">Hamano 2000</LINK>), a complex package of psychological therapy with retention control training in another (<LINK REF="STD-Kahan-1998" TYPE="STUDY">Kahan 1998</LINK>) and a mix of toileting, waking with alarm clock, pelvic floor training and diet and fluid changes in the third (<LINK REF="STD-Fera-2004" TYPE="STUDY">Fera 2004</LINK>) that data could not be combined. Thus each comparison was addressed by single arms of the trials only.</P>
<P>There was insufficient evidence to compare desmopressin with retention control training alone (Comparisons 09.01.01, 09.02.01, 09.04.01) (<LINK REF="STD-Hamano-2000" TYPE="STUDY">Hamano 2000</LINK>) or with a complex intervention (Comparisons 09.01.04, 09.02.04) (<LINK REF="STD-Fera-2004" TYPE="STUDY">Fera 2004</LINK>). There was conflicting evidence about the effects of the complex package during treatment (Comparisons 09.01.02 and 03, and 09.02.02 and 03) and afterwards: children recorded fewer wet nights after desmopressin supplemented by the complex package of psychological and behavioural methods, compared to desmopressin alone (WMD -2.10; 95% CI -2.67 to -1.53, Comparison 09.03.02) but this did not reflect in lower failure/relapse rates (RR 0.98; 95% CI 0.91 to 1.06, Comparison 09.04.02) (<LINK REF="STD-Kahan-1998" TYPE="STUDY">Kahan 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">9. Desmopressin versus complementary treatment (see Comparison 10)</HEADING>
<P>One small trial compared desmopressin with laser acupuncture (<LINK REF="STD-Radmayr-2001" TYPE="STUDY">Radmayr 2001</LINK>). However, results were only reported at six months after completing the trial. There was no difference between the groups at follow up, but the numbers were too small to draw reliable conclusions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>Adverse effects of desmopressin reported amongst 1057 children in 14 trials included (number of events in brackets): anorexia (5), bad taste (2), headache (12), nasal discomfort (20), nosebleeds (6), rash/dermatitis/oedema (6), sight disturbance (1), vomiting (3) and other minor problems (44). Some trials reported that side effects (headaches, stomach ache and nasal symptoms) were equally common with active and placebo treatment (<LINK REF="STD-Fjellestad-1987_x0023_" TYPE="STUDY">Fjellestad 1987#</LINK>; <LINK REF="STD-Folwell-1997_x0023_" TYPE="STUDY">Folwell 1997#</LINK>; <LINK REF="STD-Janknegt-1990_x0023_" TYPE="STUDY">Janknegt 1990#</LINK>), or with desmopressin and tricyclics (<LINK REF="STD-Hoashi-1995" TYPE="STUDY">Hoashi 1995</LINK>) or were not due to treatment (<LINK REF="STD-Schulman-2001a" TYPE="STUDY">Schulman 2001a</LINK>; <LINK REF="STD-Schulman-2001b" TYPE="STUDY">Schulman 2001b</LINK>). Four trials reported that most minor side effects resolved as the trials continued (<LINK REF="STD-Schulman-2001a" TYPE="STUDY">Schulman 2001a</LINK>; <LINK REF="STD-Schulman-2001b" TYPE="STUDY">Schulman 2001b</LINK>; <LINK REF="STD-Skoog-1997" TYPE="STUDY">Skoog 1997</LINK>; <LINK REF="STD-Stenberg-1994_x0023_" TYPE="STUDY">Stenberg 1994#</LINK>). Side effects were not mentioned in nine trials (<LINK REF="STD-Faraj-1999" TYPE="STUDY">Faraj 1999</LINK>; <LINK REF="STD-Fera-2004" TYPE="STUDY">Fera 2004</LINK>; <LINK REF="STD-Janknegt-1997" TYPE="STUDY">Janknegt 1997</LINK>; <LINK REF="STD-Longstaffe-2000" TYPE="STUDY">Longstaffe 2000</LINK>; <LINK REF="STD-Muller-2001_x0023_" TYPE="STUDY">Muller 2001#</LINK>; <LINK REF="STD-Neveus-1999_x0023_" TYPE="STUDY">Neveus 1999#</LINK>; <LINK REF="STD-Post-1983a_x0023_" TYPE="STUDY">Post 1983a#</LINK>; <LINK REF="STD-Post-1983b_x0023_" TYPE="STUDY">Post 1983b#</LINK>; <LINK REF="STD-Rodriguez-2001" TYPE="STUDY">Rodriguez 2001</LINK>). The remaining 17 trials reported that there were no adverse effects in a further 865 children (<LINK REF="STD-Aladjem-1982" TYPE="STUDY">Aladjem 1982</LINK>; <LINK REF="STD-Birkasova-1978_x0023_" TYPE="STUDY">Birkasova 1978#</LINK>; <LINK REF="STD-Burke-1995" TYPE="STUDY">Burke 1995</LINK>; <LINK REF="STD-Kjoller-1984" TYPE="STUDY">Kjoller 1984</LINK>; <LINK REF="STD-Leebeek-2001" TYPE="STUDY">Leebeek 2001</LINK>; <LINK REF="STD-Natochin-2000" TYPE="STUDY">Natochin 2000</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>; <LINK REF="STD-Radmayr-2001" TYPE="STUDY">Radmayr 2001</LINK>; <LINK REF="STD-Rushton-1995" TYPE="STUDY">Rushton 1995</LINK>; <LINK REF="STD-Segni-1982" TYPE="STUDY">Segni 1982</LINK>; <LINK REF="STD-Sener-1998" TYPE="STUDY">Sener 1998</LINK>; <LINK REF="STD-Sukhai-1989_x0023_" TYPE="STUDY">Sukhai 1989#</LINK>; <LINK REF="STD-Terho-1984_x0023_" TYPE="STUDY">Terho 1984#</LINK>; <LINK REF="STD-Terho-1991_x0023_" TYPE="STUDY">Terho 1991#</LINK>; <LINK REF="STD-Tuvemo-1978_x0023_" TYPE="STUDY">Tuvemo 1978#</LINK>; <LINK REF="STD-Uygur-1997_x0023_" TYPE="STUDY">Uygur 1997#</LINK>; <LINK REF="STD-Yap-1998_x0023_" TYPE="STUDY">Yap 1998#</LINK>). One of these trials involved another drug, amitriptyline, with and without desmopressin (<LINK REF="STD-Burke-1995" TYPE="STUDY">Burke 1995</LINK>). When reported, more adverse effects were associated with tricyclics (83/480, 17.3 per 100 patients (<LINK REF="REF-Glazener-2004e" TYPE="REFERENCE">Glazener 2004e</LINK>)) than with desmopressin (70/1319, 5.3 per 100 patients).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-10 13:37:50 +0100" MODIFIED_BY="[Empty name]">
<P>This is the third update of the desmopressin review, including 25 new trials identified since the original review was published in 1997 (<LINK REF="REF-Lister_x002d_Sharp-1997" TYPE="REFERENCE">Lister-Sharp 1997</LINK>). The quality of the trials was often poor: small numbers of children were assessed; reporting of data and the method of randomisation were inadequate; and follow up was short or non-existent. In the crossover trials there was a lack of washout phases and, by their design, no follow up was possible. In particular, little information was available about comparisons with non-drug interventions. However, all trials focused on children who did not have an organic cause for their enuresis: in the trials which did not specifically exclude organic causes, any children who had daytime wetting were excluded. Only two trials failed to objectively assess baseline wetting. Seven trials selected children who had not had previous enuresis treatment. The majority of the trials (30/46) included at least some children who had failed with previous treatment, and therefore had been referred to specialist clinics; the remainder did not specify past treatment.</P>
<SUBSECTION>
<HEADING LEVEL="2">Desmopressin compared with placebo</HEADING>
<P>There was clear evidence that desmopressin reduced bed-wetting by approximately one to two wet nights per week, compared to placebo. In addition, people receiving desmopressin were almost twice as likely as those receiving placebo to achieve at least 14 consecutive dry nights. However, after treatment stopped, the limited evidence available suggested that this improvement was not sustained. Ten crossover trials were analysed as if they were parallel groups. However, a sensitivity analysis showed that their exclusion did not affect the conclusion that desmopressin significantly reduced bed-wetting by one to two nights a week while on treatment. Crossover trials were unable to contribute follow-up data after the end of the treatments because the children had received both trial treatments by then.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Dose of desmopressin and route of administration</HEADING>
<P>There were insufficient data to reliably assess whether a higher dose of desmopressin was more effective than a lower dose. To minimise side effects and costs, the lowest dose should be used. In practice, clinicians would increase the dose until the lowest effective dose is achieved. If a higher dose is used with no incremental improvement, the dose should be returned to the lowest effective level. There was not enough evidence to judge whether oral and nasal administration were equally effective, but eight trials used the oral route with no apparent difference in effectiveness. This suggests that equivalent doses may be comparable, irrespective of the route of administration.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Desmopressin compared with other drugs (see also review of tricyclics for enuresis, Glazener 2004e)</HEADING>
<P>The four trials comparing desmopressin with amitriptyline or imipramine were too small to provide definitive results. Desmopressin is more expensive than imipramine, but imipramine has more side-effects, some of them potentially serious. In two other small trials, desmopressin was better than either indomethacin or diclofenac during treatment, but there was no follow-up information (<LINK REF="STD-Natochin-2000" TYPE="STUDY">Natochin 2000</LINK>; <LINK REF="STD-Sener-1998" TYPE="STUDY">Sener 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Desmopressin compared with alarms (see also review of alarms for enuresis Glazener 2004a)</HEADING>
<P>Although nine trials including desmopressin and alarm treatments were identified, the findings were difficult to interpret because of the poor quality (small size and dissimilar outcome measures) and variation in interventions (with or without desmopressin or placebo supplementation) of the trials.</P>
<P>In direct comparisons of desmopressin with alarm treatment, the initial advantage of desmopressin (fewer wet nights) was not sustained: children using alarms had fewer wet nights by the end of the trial, and the subsequent relapse rate was lower after alarm treatment (<LINK REF="STD-Wille-1986" TYPE="STUDY">Wille 1986</LINK>, <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>). While another two small trials demonstrated no significant difference in the failure rate during treatment, follow-up information was not available (<LINK REF="STD-Bradbury-1995" TYPE="STUDY">Bradbury 1995</LINK>; <LINK REF="STD-Rodriguez-2001" TYPE="STUDY">Rodriguez 2001</LINK>).</P>
<P>There is a move towards combining behavioural and drug interventions (<LINK REF="REF-Howe-1992" TYPE="REFERENCE">Howe 1992</LINK>). The rationale is that the rapid onset of action of drugs will augment the more gradual treatment effect of alarms (<LINK REF="STD-Sukhai-1989_x0023_" TYPE="STUDY">Sukhai 1989#</LINK>). Using low doses of desmopressin as an adjunct to alarm treatment might also be used to ensure that the child only wets the bed once each night, which minimises changes of bedding (<LINK REF="REF-Djurhuus-1992" TYPE="REFERENCE">Djurhuus 1992</LINK>). The alternative argument, however, is that by using a drug to reduce the wetting, the child has fewer chances to learn behavioural control with the alarm (<LINK REF="STD-Gibb-2004" TYPE="STUDY">Gibb 2004</LINK>). Although there were indeed fewer wet nights during combination treatment compared with desmopressin alone (Comparison 07.01.01, <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>) and alarm alone (Comparison 08.01.01, <LINK REF="STD-Bradbury-1995" TYPE="STUDY">Bradbury 1995</LINK>; <LINK REF="STD-Gibb-2004" TYPE="STUDY">Gibb 2004</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>; <LINK REF="STD-Sukhai-1989_x0023_" TYPE="STUDY">Sukhai 1989#</LINK>), it was not possible to judge whether this was reflected in lower failure or relapse rates (Comparison 07.03.01, <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>; and Comparison 08.03.01, <LINK REF="STD-Bradbury-1995" TYPE="STUDY">Bradbury 1995</LINK>; <LINK REF="STD-Gibb-2004" TYPE="STUDY">Gibb 2004</LINK>; <LINK REF="STD-Leebeek-2001" TYPE="STUDY">Leebeek 2001</LINK>; <LINK REF="STD-Ng-2005" TYPE="STUDY">Ng 2005</LINK>). This evidence was limited by small numbers and disparate interventions. The use of desmopressin as an adjunct to alarm treatment may be a good way of easing the initial weeks of alarm treatment or for giving families a break, but it is uncertain whether this helps in the long term. This needs to be evaluated by further research.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Desmopressin compared with other behavioural methods</HEADING>
<P>There was no clear evidence to support the use of a complex package of behavioural methods, delivered either with or without desmopressin, in terms of numbers of children cured. Although desmopressin may have contributed to a reduction in the number of wet nights per week during treatment and afterwards, there was no difference in cure rates. This finding needs to be verified with further research. There was not enough evidence to compare desmopressin with retention control training alone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Desmopressin compared with complementary treatments</HEADING>
<P>In one small trial (comparing desmopressin with laser acupuncture), there was no difference in the failure rate six months after the end of the trial, but the numbers were too small to reliably compare the groups (<LINK REF="STD-Radmayr-2001" TYPE="STUDY">Radmayr 2001</LINK>). However, in view of the lack of effect of desmopressin after treatment stops (see comparison of desmopressin with placebo above, Comparisons 01.04 and 01.06, Other Data Tables 01.05), it was not possible to determine if the apparent cure of three quarters of the children in both groups was an effect of both treatments or due to spontaneous cure with time.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Other considerations</HEADING>
<SUBSECTION>
<HEADING LEVEL="3">Relevant outcome measures</HEADING>
<P>Most trials reported outcome criteria in terms of number of wet nights per week. The number achieving 14 dry nights was reported less often, and few trials provided follow-up data or relapse rates. It is likely that parents would prefer a treatment that cured the problem in the long term, rather than simply decreasing the frequency of wet nights during treatment. However, reported outcome measures may reflect different aims of treatment: drugs could be used as a way to reduce the frequency of wetting for a specific purpose such as nights away from home (e.g. on a 'dry for camp' basis, for holidays or staying with friends (<LINK REF="REF-Meadow-1989" TYPE="REFERENCE">Meadow 1989</LINK>)). Some families may find desmopressin useful over winter to overcome laundry problems.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Daytime wetting / organic causes</HEADING>
<P>Only including trials that definitely excluded all children with daytime wetting would have severely limited the review. Only 26 of the 46 trials specifically excluded children with diurnal wetting; the remainder either failed to mention it (17 trials) or failed to exclude it (3 trials). All but one of the trials specifically excluded children with known organic causes for their enuresis. It is likely that the underlying pathologies of monosymptomatic bed-wetting and mixed night and day wetting differ. The former group might be expected to respond better to treatment aimed at the symptom of bed-wetting, whereas the latter might respond better to treatment aimed at the underlying pathology (e.g. urinary tract infection, unstable bladder). Alternative managements for these conditions need to be reviewed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Settings and previous treatment</HEADING>
<P>It should not be assumed that the interventions that are most effective in the trial situation are always the treatments of choice in the clinical situation. Most of the included trials have recruited children from enuresis clinics or are hospital based. Twenty of the trials included at least some children who had already failed previous treatments and were being referred for further advice. These participating families may be especially motivated to tackle bed-wetting. In addition, strict inclusion or exclusion criteria were imposed in many of the trials. Consequently, the children involved were not necessarily representative of the wider population of bed-wetters. Factors that made treatment more likely to be successful included: older age, fewer initial wet nights and larger functional bladder capacity (<LINK REF="REF-Rushton-1996" TYPE="REFERENCE">Rushton 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>The reporting of adverse effects varied. In some trials they were not mentioned, while in others they were reported just as often in placebo groups. Some trials reported no adverse effects in any treatment group. All trials reported that the adverse effects of desmopressin were minor and did not require the treatment to cease. Although there appear to be fewer adverse reactions associated with desmopressin than tricyclic drugs, these are rare but can be serious. The risk of water intoxication should be minimised by restricting evening fluid intake on the nights that desmopressin is used (<LINK REF="REF-Bernstein-1997" TYPE="REFERENCE">Bernstein 1997</LINK>; <LINK REF="REF-Robson-1994" TYPE="REFERENCE">Robson 1994</LINK>; <LINK REF="REF-Robson-1996" TYPE="REFERENCE">Robson 1996</LINK>). Tricyclics are the most common cause of fatal poisoning in children (<LINK REF="REF-Parkin-1972" TYPE="REFERENCE">Parkin 1972</LINK>). Overdose with tricyclics may occur accidentally or when children believe that a greater dosage gives a better effect (<LINK REF="STD-Wille-1986" TYPE="STUDY">Wille 1986</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Costs</HEADING>
<P>In the United Kingdom, 16 weeks of drug treatment (the usual time allowed for fourteen consecutive dry nights to be attained using an alarm (<LINK REF="REF-Butler-1991" TYPE="REFERENCE">Butler 1991</LINK>)) costs (<LINK REF="REF-BNF-2002" TYPE="REFERENCE">BNF 2002</LINK>):</P>
<UL>
<LI>UK£78 for desmopressin nasal spray (20 µg per night) or UK£116 for desmopressin tablets (200 µg);</LI>
<LI>UK£4 for imipramine hydrochloride (25 mg tablet per night) or UK£14 for imipramine syrup (25 mg);</LI>
<LI>enuresis alarms (including batteries and sensor) typically cost UK£33.60, although alarms but not sensors (UK£12) may be reused several times.</LI>
</UL>
<P>
<BR/>Although treatment with tricyclic or related drugs is considerably less expensive than alarms or desmopressin, this does not take into account the administrative or human costs involved in using alarms. Alarm systems may not be returned to clinics and have to be followed up. Alarm treatment is accompanied by broken nights for various family members until success is attained. The Guidelines on Minimum Standards of Practice (<LINK REF="REF-Morgan-1993" TYPE="REFERENCE">Morgan 1993</LINK>) suggest that follow-up supervisory contacts should occur at least every three weeks, with medication reviewed at least monthly. However, this must be considered in light of the lower likelihood of relapse after completing alarm treatment, compared with after desmopressin, tricyclics or related drugs, and the potential for adverse effects with tricyclics.</P>
</SUBSECTION>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Desmopressin rapidly reduced the number of wet nights per week, compared with placebo in children with monosymptomatic nocturnal enuresis, but this effect was not sustained after treatment stopped. Only two small RCTs followed up children treated with desmopressin or an enuresis alarm; those treated with the alarm were more likely to achieve long-term success, but this needs to be confirmed in further research. Children who used alarms supplemented with desmopressin initially had fewer wet nights compared to after alarms alone, but this was not reflected in better cure rates or reduced relapse rates after stopping treatment. Potential difficulties, such as the commitment and time needed to attain success, need to be discussed with families before embarking on alarm treatment. </P>
<P>Treatment with desmopressin is considerably more expensive than with tricyclic drugs, but is associated with fewer adverse effects and less risk of fatal overdose. Although alarm interventions are intermediate in cost and are more disruptive in the short term, they do not have the same risk of side effects. </P>
<P>Patients and their families need to be warned about potential adverse effects associated with desmopressin. In particular, children should be advised not to drink more than 240 ml (8 ounces) of fluid on any night that desmopressin is given in order to avoid the possible risk of water intoxication.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>More trials comparing desmopressin with other methods of management are required, especially with alarms, tricyclic drugs, and other behavioural interventions such as lifting, star charts, reward systems and fluid deprivation. Further trials of desmopressin versus placebo should address the issue of whether the benefits are sustained after stopping treatment. Such trials should focus on children who do not have organic causes of bed-wetting, and should include adequate assessment of baseline levels of wetting. </P>
<P>The trials should use uniform outcome measures such as: the number of wet nights during treatment and after the end of treatment; the number of children achieving 14 consecutive dry nights (cure rate); adverse effects; acceptability of treatment; compliance; and especially relapse rates. </P>
<P>The trials should include children from a variety of backgrounds and populations, particularly those children who have not already failed previous treatment, in order to increase the generalisability of the results. Important demographic factors that should be considered include previous treatment, age, presence of other organic pathology or daytime wetting and family circumstances, as well as co-existing psychological, emotional or behavioural problems. It has been suggested that not all interventions are suitable for all children. Therefore, further research is needed to determine which interventions are appropriate for which patient groups and under what circumstances (for example, as a short-term measure to cover nights away from home), in order to guide choice of treatment. </P>
<P>Children with daytime enuresis are more likely to have specific pathology, such as bladder dysfunction or urinary tract infections. Alternative managements for this condition need to be reviewed. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>This review was originally written for the NHS Centre for Reviews &amp; Dissemination, University of York, by Deborah Lister-Sharp, Susan O'Meara, Matthew Bradley and Trevor Sheldon. It is published as: <I>A Systematic Review of the Effectiveness of Interventions for Managing Childhood Nocturnal Enuresis</I>, CRD Report 11, NHS Centre for Reviews and Dissemination, University of York (<LINK REF="REF-Lister_x002d_Sharp-1997" TYPE="REFERENCE">Lister-Sharp 1997</LINK>). We were especially grateful to Deborah Lister-Sharp for transfer of data, trials and expertise, and were sad to learn of her death. </P>
<P>The York reviewers obtained information from a variety of sources, including organisations, manufacturers and individuals. These are listed in the NHS Centre for Reviews and Dissemination Report, and we acknowledge their contribution to this review. </P>
<P>Extra information was supplied by Dr Yuri Natochin, Professor Christian Radmayr, Dr Seth Schulman and Professor Tack Lee. We are grateful to Penny Dobson (ERIC) for help and encouragement, and for being an external referee. We thank Mr T Matsuoka for a translation from Japanese and Mr HA Glazener for two translations from German. We would also like to thank the Consumer Network at the Australasian Cochrane Centre (ACC) for help with the original synopsis.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>JHCE has received reimbursement for attending a conference, fees for lecturing and a consultancy fee which was paid into a research fund from Ferring Pharmaceuticals, manufacturers of desmopressin.<BR/>
<B>
<BR/>
</B>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>CMAG (the contact reviewer) originally based this review on work done at the NHS Centre for Reviews and Dissemination, University of York, UK (see acknowledgements). CMAG used the data extracted by the York reviewers, converted them into Cochrane Review format, and separated them into seven component intervention reviews (of which this is one). This review includes trials from the York review plus extra ones identified since then. JHCE performed double data abstraction for the new trials, edited the text and provided a clinical perspective and interpretation.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-28 17:21:20 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-10-10 13:40:49 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-10-10 13:39:32 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aladjem-1982" NAME="Aladjem 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Aladjem M, Wohl R, Boichis H, Orda S, Lotan D, Freedman S. Desmopressin in nocturnal enuresis. Arch Dis Child 1982;57(2):137-140. {1564}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aladjem M, Wohl R, Boichis H, Orda S, Lotan D, Freedman S</AU>
<TI>Desmopressin in nocturnal enuresis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1982</YR>
<VL>57</VL>
<NO>2</NO>
<PG>137-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82159111"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Birkasova-1978_x0023_" NAME="Birkasova 1978#" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Birkasova M, Birkas O, Flynn MJ, Cort JH. Desmopressin in the management of nocturnal enuresis in children: a double-blind study. Pediatrics 1978;62(6):970-974. {1578}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Birkasova M, Birkas O, Flynn MJ, Cort JH</AU>
<TI>Desmopressin in the management of nocturnal enuresis in children: a double-blind study</TI>
<SO>Pediatrics</SO>
<YR>1978</YR>
<VL>62</VL>
<NO>6</NO>
<PG>970-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="79095277"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bradbury-1995" NAME="Bradbury 1995" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Bradbury M. Combination therapy for nocturnal enuresis with desmopressin and an alarm device. Scand J Urol Nephrol 1997;Supplementum. 183:61-3. {5212}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bradbury M</AU>
<TI>Combination therapy for nocturnal enuresis with desmopressin and an alarm device</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology</SO>
<YR>1997</YR>
<VL>183</VL>
<PG>61-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97308385"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Bradbury MG, Meadow SR. Combined treatment with enuresis alarm and desmopressin for nocturnal enuresis. Acta Paediatrica 1995;84:1014-1018. {4200}&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bradbury MG, Meadow SR</AU>
<TI>Combined treatment with enuresis alarm and desmopressin for nocturnal enuresis</TI>
<SO>Acta Paediatrica</SO>
<YR>1995</YR>
<VL>84</VL>
<NO>9</NO>
<PG>1014-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96112940"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burke-1995" NAME="Burke 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Burke JR, Mizusawa Y, Chan A, Webb KL. A comparison of amitriptyline, vasopressin, and amitriptyline with vasopressin in nocturnal enuresis. Pediatr Nephrol 1995;9(4):438-440. {4203}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burke JR, Mizusawa Y, Chan A, Webb KL</AU>
<TI>A comparison of amitriptyline, vasopressin, and amitriptyline with vasopressin in nocturnal enuresis</TI>
<SO>Pediatric Nephrology</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>4</NO>
<PG>438-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96021447"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dimson-1986_x0023_" NAME="Dimson 1986#" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Dimson SB. DDAVP and urine osmolality in refractory enuresis. Arch Dis Child 1986;61(11):1104-1107. {1536}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dimson SB</AU>
<TI>DDAVP and urine osmolality in refractory enuresis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1986</YR>
<VL>61</VL>
<NO>11</NO>
<PG>1104-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87075002"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Faraj-1999" NAME="Faraj 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;{8511}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Faraj G, Cochat P, Cavailles ML, Chevallier C</AU>
<TI>[Treatment of isolated nocturnal enuresis: alarm or desmopressin?] [French]</TI>
<SO>Archives de Pediatrie</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>3</NO>
<PG>271-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99207616"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fera-2004" NAME="Fera 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;{19014}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fera P, Glashan R, Lelis MA, Gonzales SR, Nogueira MDP, Almeida F, Srougi M, Bruschini H</AU>
<TI>Immediate outcome of DDAVP versus behavioural modification for treatment of monosymptomatic nocturnal enuresis: a prospective randomized study of 30 patients (Abstract)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>5/6</NO>
<PG>555-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fjellestad-1987_x0023_" NAME="Fjellestad 1987#" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Fjellestad-Paulsen A, Wille S, Harris AS. Comparison of intranasal and oral desmopressin for nocturnal enuresis. Arch Dis Child 1987;62(7):674-677. {1530} see also {4221} pp26-27 and 32-33&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fjellestad-Paulsen A, Wille S, Harris AS</AU>
<TI>Comparison of intranasal and oral desmopressin for nocturnal enuresis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1987</YR>
<VL>62</VL>
<NO>7</NO>
<PG>674-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87325035"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Folwell-1997_x0023_" NAME="Folwell 1997#" YEAR="">
<REFERENCE NOTES="&lt;p&gt;{5201}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Folwell AJ, Macdiarmid SA, Crowder HJ, Lord AD, Arnold EP</AU>
<TI>Desmopressin for nocturnal enuresis: urinary osmolality and response</TI>
<SO>British Journal of Urology</SO>
<YR>1997</YR>
<VL>80</VL>
<NO>3</NO>
<PG>480-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97458898"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gibb-2004" NAME="Gibb 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;{17212}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gibb S, Nolan T, South M, Noad L, Bates G, Vidmar S</AU>
<TI>Evidence against a synergistic effect of desmopressin with conditioning in the treatment of nocturnal enuresis</TI>
<SO>Journal of Pediatrics</SO>
<YR>2004</YR>
<VL>144</VL>
<NO>3</NO>
<PG>351-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamano-2000" NAME="Hamano 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;{11658}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamano S, Yamanishi T, Igarashi T, Ito H, Murakami S</AU>
<TI>Functional bladder capacity as predictor of response to desmopressin and retention control training in monosymptomatic nocturnal enuresis</TI>
<SO>European Urology</SO>
<YR>2000</YR>
<VL>37</VL>
<NO>6</NO>
<PG>718-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20291060"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoashi-1995" NAME="Hoashi 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;ID: 18841&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoashi E, Hibi I, Maekawa K, Yoshida S, Ikoma F, Akashi S et al</AU>
<TI>Clinical evaluation of desmopressin acetate (kw-8008) in patients with primary nocturnal enuresis: double-blind comparative study in comparison with imipramine hydrochloride</TI>
<SO>Kiso to rinsho</SO>
<YR>1995</YR>
<VL>29</VL>
<NO>16</NO>
<PG>4219-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holt-1986" NAME="Holt 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Holt J, Borresen B. Enuresis nocturna in school children in Bodo. A therapeutic trial with a vasopressin analog: desmopressin and imipramine. Tidsskrift for Den Norske Laegeforening 1986;106(8):651-654. {1537}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holt J, Borresen B</AU>
<TI>Enuresis nocturna in school children in Bodo. A therapeutic trial with a vasopressin analog: desmopressin and imipramine</TI>
<SO>Tidsskrift for den Norske Laegeforening</SO>
<YR>1986</YR>
<VL>106</VL>
<NO>8</NO>
<PG>651-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8609028"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janknegt-1990_x0023_" NAME="Janknegt 1990#" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Janknegt RA, Smans AJ. Treatment with desmopressin in severe nocturnal enuresis in childhood. Br J Urol 1990;66(5):535-537.{1504}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janknegt RA, Smans AJ</AU>
<TI>Treatment with desmopressin in severe nocturnal enuresis in childhood</TI>
<SO>British Journal of Urology</SO>
<YR>1990</YR>
<VL>66</VL>
<NO>5</NO>
<PG>535-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91064586"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janknegt-1997" MODIFIED="2008-10-10 13:39:32 +0100" MODIFIED_BY="[Empty name]" NAME="Janknegt 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;{4555}&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Janknegt RA, Zweers HHM, Namdar Z</AU>
<TI>Evaluation of oral desmopressin in the management of primary nocturnal enuresis in adolescents and adults (multi-centre, randomized, double-blind)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>1995</YR>
<VL>14</VL>
<NO>5</NO>
<PG>422-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-10 13:39:32 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Janknegt R, Zweers H, Delaere K, Kloet A, Khoe S, Arendson H. Oral desmopression as a new treatment modality for primary nocturnal enuresis in adolescents and adults: a double-blind randomised, multicentre study. J Urol 1977;157:513-517. {5024}&lt;/p&gt;" NOTES_MODIFIED="2008-10-10 13:39:32 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Janknegt RA, Zweers HM, Delaere KP, Kloet AG, Khoe SG, Arendsen HJ</AU>
<TI>Oral desmopressin as a new treatment modality for primary nocturnal enuresis in adolescents and adults: a double-blind randomized, multicenter study. Dutch Enuresis Study Group</TI>
<SO>Journal of Urology</SO>
<YR>1997</YR>
<VL>157</VL>
<NO>2</NO>
<PG>513-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97149537"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahan-1998" NAME="Kahan 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;{8515} desmo vs psychotherapy (Ronen) - also add to complementary&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahan E, Morel D, Amir J, Zelcer C</AU>
<TI>A controlled trial of desmopressin and behavioral therapy for nocturnal enuresis</TI>
<SO>Medicine</SO>
<YR>1998</YR>
<VL>77</VL>
<NO>6</NO>
<PG>384-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99071765"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kjoller-1984" NAME="Kjoller 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Kjoller SS, Hejl M. Enuresis treated with minurin (DDAVP). A controlled clinical study. Ugeskrift for Laeger 1984;146(43):3281-3282 {1547}&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kjoller SS, Hejl M, Pedersen PS</AU>
<TI>Enuresis treated with minurin (DDAVP). A controlled clinical study</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>1984</YR>
<VL>146</VL>
<NO>43</NO>
<PG>3281-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="85067088"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Pedersen PS, Hejl M, Kjoller SS. Desamino-D-arginine vasopressin in childhood nocturnal enuresis. J Urol 1985;133(1):65-6. {1544}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen PS, Hejl M, Kjoller SS</AU>
<TI>Desamino-D-arginine vasopressin in childhood nocturnal enuresis</TI>
<SO>Journal of Urology</SO>
<YR>1985</YR>
<VL>133</VL>
<NO>1</NO>
<PG>65-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="85058445"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lee-2005" NAME="Lee 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;{20762} Have written to authors, replied with results given separately for daytime and nocturnal wetting.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee T, Suh HJ, Lee HJ, Lee JE</AU>
<TI>Comparison of effects of treatment of primary nocturnal enuresis with oxybutynin plus desmopressin, desmopressin alone or imipramine alone: a randomized controlled clinical trial</TI>
<SO>Journal of Urology</SO>
<YR>2005</YR>
<VL>174</VL>
<NO>3</NO>
<PG>1084-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leebeek-2001" NAME="Leebeek 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;{12147}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leebeek-Groenewegen ANJA, Blom J, Sukhai R, van der Heijden B</AU>
<TI>Efficacy of desmopressin combined with alarm therapy for monosymptomatic nocturnal enuresis</TI>
<SO>Journal of Urology</SO>
<YR>2001</YR>
<VL>166</VL>
<NO>6</NO>
<PG>2456-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21553449"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Longstaffe-2000" NAME="Longstaffe 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;{11928}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Longstaffe S, Moffatt ME, Whalen JC</AU>
<TI>Behavioral and self-concept changes after six months of enuresis treatment: a randomized, controlled trial</TI>
<SO>Pediatrics</SO>
<YR>2000</YR>
<VL>105</VL>
<NO>4:Pt 2</NO>
<PG>935-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20209556"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-1993" NAME="Martin 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Martin Hernandez E, Fernandez Ovies JM, Guzman-Guzman A, Alvarez Aldean J, Barrio Corrales F. Clinical effectiveness and safety of desmopressin in the treatment of infantile enuresis. Rev Esp Pediatr 1993;49(294):497-501. {6643}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin Hernandez E, Fernandez Ovies JM, Guzman-Guzman A, Alvarez Aldean J, Barrio Corrales F</AU>
<TI>Clinical effectiveness and safety of desmopressin in the treatment of infantile enuresis</TI>
<SO>Revista Espanola de Pediatria</SO>
<YR>1993</YR>
<VL>49</VL>
<NO>294</NO>
<PG>497-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1990a" NAME="Miller 1990a" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Miller K, Klauber GT. Desmopressin acetate in children with severe primary nocturnal enuresis. Clin Ther 1990;12(4):357-366. {1506}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller K, Klauber GT</AU>
<TI>Desmopressin acetate in children with severe primary nocturnal enuresis</TI>
<SO>Clinical Therapeutics</SO>
<YR>1990</YR>
<VL>12</VL>
<NO>4</NO>
<PG>357-66</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91029346"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1990b" NAME="Miller 1990b" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Miller K, Klauber GT. Desmopressin acetate in children with severe primary nocturnal enuresis. Clin Ther 1990;12(4):357-366. {1506}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller K, Klauber GT</AU>
<TI>Desmopressin acetate in children with severe primary nocturnal enuresis</TI>
<SO>Clinical Therapeutics</SO>
<YR>1990</YR>
<VL>12</VL>
<NO>4</NO>
<PG>357-66</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91029346"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller-2001_x0023_" NAME="Muller 2001#" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;{17451} Children on desmo less arousable (14/18) vs 4 on placebo more difficult to wake (P=0.03).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eggert P, Fritz A, Stecker B, ller D</AU>
<TI>Desmopressin has an influence on the arousability of children with primary nocturnal enuresis</TI>
<SO>Journal of Urology</SO>
<YR>2004</YR>
<VL>171</VL>
<NO>6 Pt 2</NO>
<PG>2586-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;{18830} No data but concludes no difference in reaction time on desmo, but better recall of words (=short term memory) P=0.012. Translation from HA Glazener&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flokowski H, Cavez-Kattau K, Carlsson G, Muller D, Eggert P</AU>
<TI>Central nervous effect of dDAVP in children with nocturnal enuresis: Effect or side-effect (Abstract)</TI>
<SO>Monatsschrift fur Kinderheilkunde</SO>
<YR>1999</YR>
<VL>147</VL>
<NO>Suppl 2</NO>
<PG>62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;{18829} No data given but concludes children were more difficult to wake with desmopressin (P=0.057). Translation from HA Glazener&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fritz A, Chavez-Kattau K, Eggert P</AU>
<TI>Influence of DDAVP on the ability to wake children with primary Enuresis Nocturna</TI>
<SO>Klinische Padiatrie</SO>
<YR>2000</YR>
<VL>212</VL>
<NO>5</NO>
<PG>S108</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;{12148}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muller D, Florkowski H, Chavez-Kattau K, Carlsson G, Eggert P</AU>
<TI>The effect of desmopressin on short-term memory in children with primary nocturnal enuresis</TI>
<SO>Journal of Urology</SO>
<YR>2001</YR>
<VL>166</VL>
<NO>6</NO>
<PG>2432-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Natochin-2000" NAME="Natochin 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;{9170}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Natochin YV, Kuznetsova AA</AU>
<TI>Nocturnal enuresis: correction of renal function by desmopressin and diclofenac</TI>
<SO>Pediatric Nephrology</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>1</NO>
<PG>42-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20119826"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neveus-1999_x0023_" NAME="Neveus 1999#" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;{9139}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neveus T, Lackgren G, Tuvemo T, Olsson U, Stenberg A</AU>
<TI>Desmopressin resistant enuresis: pathogenetic and therapeutic considerations</TI>
<SO>Journal of Urology</SO>
<YR>1999</YR>
<VL>162</VL>
<NO>6</NO>
<PG>2136-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20034892"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ng-2005" NAME="Ng 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;{20145}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ng CF-N, Wong SN, Hong Kong Childhood Enuresis Study Group</AU>
<TI>Comparing alarms, desmopressin, and combined treatment in Chinese enuretic children</TI>
<SO>Pediatric Nephrology</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>2</NO>
<PG>163-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Post-1983a_x0023_" NAME="Post 1983a#" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Post EM, Richman RA, Blackett PR, Duncan KP, Miller K. Desmopressin response of enuretic children. Effects of age and frequency of enuresis. Am J Dis Child. 1983;137(10):962-963. {1552}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Post EM, Richman RA, Blackett PR, Duncan KP, Miller K</AU>
<TI>Desmopressin response of enuretic children. Effects of age and frequency of enuresis</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1983</YR>
<VL>137</VL>
<NO>10</NO>
<PG>962-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="83305660"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Post-1983b_x0023_" NAME="Post 1983b#" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Post EM, Richman RA, Blackett PR, Duncan KP, Miller K. Desmopressin response of enuretic children. Effects of age and frequency of enuresis. Am J Dis Child. 1983;137(10):962-963. {1552}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Post EM, Richman RA, Blackett PR, Duncan KP, Miller K</AU>
<TI>Desmopressin response of enuretic children. Effects of age and frequency of enuresis</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1983</YR>
<VL>137</VL>
<NO>10</NO>
<PG>962-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="83305660"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Radmayr-2001" NAME="Radmayr 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;{12151}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Radmayr C, Schlager</AU>
<TI>Prospective randomized trial using laser acupuncture versus desmopressin in the treatment of nocturnal enuresis</TI>
<SO>European Urology</SO>
<YR>2001</YR>
<VL>40</VL>
<NO>2</NO>
<PG>201-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21419131"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rittig-1988_x0023_" NAME="Rittig 1988#" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;{3811} see also {9779}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rittig S, Knudsen UB, Sorensen S, Djurhuus JC, Norgaard JP</AU>
<TI>Long range double-blind crossover study of DDAVP intranasal spray in the management of nocturnal enuresis (Abstract)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>3</NO>
<PG>184-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Rittig S, Knudsen UB, Sorensen S, Djurhuus JC, Norgaard JP. Long term double-blind cross over study of desmopressin intranasal spray in the management of nocturnal enuresis. Desmopressin in Enuresis. Proceedings of an International Symposium held at the Royal College of Physicians, London Horus Medical Publications Editor Meadow SR. 1988:43-55. {9779} see also {3811}&lt;/p&gt;" PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Rittig S, Knudsen UB, Sorensen S, Djurhuus JC, Norgaard JP</AU>
<TI>Long term double-blind cross over study of desmopressin intranasal spray in the management of nocturnal enuresis</TI>
<SO>Desmopressin in Enuresis. Proceedings of an International Symposium held at the Royal College of Physicians</SO>
<YR>1988</YR>
<PG>43-55</PG>
<ED>Meadow SR</ED>
<PB>Horus Medical Publications</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodriguez-2001" NAME="Rodriguez 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;11933} desmo + alarm vs alarm&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez do Forno A, Ariceta Iraola G</AU>
<TI>Results of a therapeutic strategy against monosymptomatic nocturnal enuresis background</TI>
<SO>Anales Espanoles de Pediatria</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>1</NO>
<PG>38-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21091002"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rushton-1995" NAME="Rushton 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;{5071}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rushton HG, Belman AB, Skoog S, Zaontz MR, Sihelnik S</AU>
<TI>Predictors of response to desmopressin in children and adolescents with monosymptomatic nocturnal enuresis</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology Supplementum</SO>
<YR>1995</YR>
<VL>173</VL>
<PG>109-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96363556"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Rushton HG, Belman AB, Zaontz M, Skoog SJ, Sihelnik S. Response to desmopressin as a function of urine osmolality in the treatment of monosymptomatic nocturnal enuresis: a double-blind prospective study. J Urol 1995;154(2 Pt 2):749-753. {4205}&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rushton HG, Belman AB, Zaontz M, Skoog SJ, Sihelnik S</AU>
<TI>Response to desmopressin as a function of urine osmolality in the treatment of monosymptomatic nocturnal enuresis: a double-blind prospective study</TI>
<SO>Journal of Urology</SO>
<YR>1995</YR>
<VL>154</VL>
<NO>2 Pt 2</NO>
<PG>749-53</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95333406"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;{4199}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rushton HG, Belman AB, Zaontz MR, Skoog SJ, Sihelnik S</AU>
<TI>The influence of small functional bladder capacity and other predictors on the response to desmopressin in the management of monosymptomatic nocturnal enuresis</TI>
<SO>Journal of Urology</SO>
<YR>1996</YR>
<VL>156</VL>
<NO>2 Pt 2</NO>
<PG>651-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96289410"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Schulman-2001a" NAME="Schulman 2001a" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;{12149} Written to authors 25.03.02&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulman SL, Stokes A, Salzman PM</AU>
<TI>The efficacy and safety of oral desmopressin in children with primary nocturnal enuresis</TI>
<SO>Journal of Urology</SO>
<YR>2001</YR>
<VL>166</VL>
<NO>6</NO>
<PG>2427-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11696804"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Schulman-2001b" NAME="Schulman 2001b" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;{12149} 2nd trial in same paper&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulman SL, Stokes A, Salzman PM</AU>
<TI>The efficacy and safety of oral desmopressin in children with primary nocturnal enuresis</TI>
<SO>Journal of Urology</SO>
<YR>2001</YR>
<VL>166</VL>
<NO>6</NO>
<PG>2472-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11696804"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Segni-1982" NAME="Segni 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Segni G, Salvaggio E, Parenti D, Cataldi L, Auriti C, Rossodivita A. New therapeutic prospect in enuresis: desmopressin (DDAVP). Minerva Pediatrica 1982;34(1-2):45-52. {1563}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Segni G, Salvaggio E, Parenti D, Cataldi L, Auriti C, Rossodivita A et al</AU>
<TI>New therapeutic prospect in enuresis: desmopressin (DDAVP)</TI>
<SO>Minerva Pediatrica</SO>
<YR>1982</YR>
<VL>34</VL>
<NO>1-2</NO>
<PG>45-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82172796"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sener-1998" NAME="Sener 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;{8518} also in other drugs&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sener F, Hasanoglu E, Soylemezoglu O</AU>
<TI>Desmopressin versus indomethacin treatment in primary nocturnal enuresis and the role of prostaglandins</TI>
<SO>Urology</SO>
<YR>1998</YR>
<VL>52</VL>
<NO>5</NO>
<PG>878-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99015738"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skoog-1997" NAME="Skoog 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Skoog SJ, Stokes A, Turner KL. Oral desmopressin: a randomized double-blind placebo controlled study of effectiveness in children with primary nocturnal enuresis. J Urol 1997;158(3 Pt 2):1035-40. {5204}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skoog SJ, Stokes A, Turner KL</AU>
<TI>Oral desmopressin: a randomized double-blind placebo controlled study of effectiveness in children with primary nocturnal enuresis</TI>
<SO>Journal of Urology</SO>
<YR>1997</YR>
<VL>158</VL>
<NO>3 Pt 2</NO>
<PG>1035-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97402759"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stenberg-1994_x0023_" NAME="Stenberg 1994#" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Stenberg A, Lackgren G. Desmopressin tablets in the treatment of severe nocturnal enuresis in adolescents. Pediatrics 1994;94(6):841-846. {4219}. Was excl from desmo (check 2 other stenbergs in excl list as well)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stenberg A, Lackgren G</AU>
<TI>Desmopressin tablets in the treatment of severe nocturnal enuresis in adolescents</TI>
<SO>Pediatrics</SO>
<YR>1994</YR>
<VL>94</VL>
<NO>6 Pt 1</NO>
<PG>841-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95061114"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sukhai-1989_x0023_" NAME="Sukhai 1989#" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Sukhai RN, Mol J, Harris AS. Combined therapy of enuresis alarm and desmopressin in the treatment of nocturnal enuresis. European Journal of Pediatrics. 1989 (Feb);148(5):465-467. {1519}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sukhai RN, Mol J, Harris AS</AU>
<TI>Combined therapy of enuresis alarm and desmopressin in the treatment of nocturnal enuresis</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1989</YR>
<VL>148</VL>
<NO>5</NO>
<PG>465-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="89153190"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terho-1984_x0023_" NAME="Terho 1984#" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Terho P, Kekomaki M. Management of nocturnal enuresis with a vasopressin analogue. J Urol 1984;131(5):925-927. {1549}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terho P, Kekomaki M</AU>
<TI>Management of nocturnal enuresis with a vasopressin analogue</TI>
<SO>Journal of Urology</SO>
<YR>1984</YR>
<VL>131</VL>
<NO>5</NO>
<PG>925-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="84165186"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terho-1991_x0023_" NAME="Terho 1991#" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Terho P. Desmopressin in nocturnal enuresis. J Urol 1991;145(4):818-820. {1501}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terho P</AU>
<TI>Desmopressin in nocturnal enuresis</TI>
<SO>Journal of Urology</SO>
<YR>1991</YR>
<VL>145</VL>
<NO>4</NO>
<PG>818-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91171392"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tuvemo-1978_x0023_" NAME="Tuvemo 1978#" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Tuvemo T. DDAVP in childhood nocturnal enuresis. Acta Paediatr Scand 1978;67(6):753-755. {1580}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tuvemo T</AU>
<TI>DDAVP in childhood nocturnal enuresis</TI>
<SO>Acta Paediatrica Scandinavica</SO>
<YR>1978</YR>
<VL>67</VL>
<NO>6</NO>
<PG>753-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="79058701"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uygur-1997_x0023_" NAME="Uygur 1997#" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;{5207}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uygur MC, Ozgu IH, Ozen H, Ozen S, Toklu C, Ergen A, Tekgul S, Remzi D</AU>
<TI>Long-term treatment of nocturnal enuresis with desmopressin intranasal spray</TI>
<SO>Clinical Pediatrics</SO>
<YR>1997</YR>
<VL>36</VL>
<NO>8</NO>
<PG>455-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vertucci-1997" NAME="Vertucci 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;{5225} desmo vs imipramine&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vertucci P, Lanzi C, Capece G, Fano M, Gallai V, Margari L et al</AU>
<TI>Desmopressin and imipramine in the management of nocturnal enuresis: a multicentre study</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1997</YR>
<VL>51</VL>
<NO>1</NO>
<PG>27-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97301907"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wille-1986" NAME="Wille 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Wille S. Comparison of desmopressin and enuresis alarm for nocturnal enuresis. Arch Dis Child 1986;61(1):30-33. {1538} see also {4221} pp26 and 30-32.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wille S</AU>
<TI>Comparison of desmopressin and enuresis alarm for nocturnal enuresis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1986</YR>
<VL>61</VL>
<NO>1</NO>
<PG>30-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="86157697"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;{4221} linked to {1538}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wille S</AU>
<TI>Primary nocturnal enuresis in children. Background and treatment</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology Supplementum</SO>
<YR>1994</YR>
<VL>156</VL>
<PG>1-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yap-1998_x0023_" NAME="Yap 1998#" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;{8521} crossover desmo vs placebo&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yap HK, Chao SM, Tan AY, Murugasu B, Ong EK, Low EH</AU>
<TI>Efficacy and safety of oral desmopressin in the treatment of primary nocturnal enuresis in Asian children</TI>
<SO>Journal of Paediatrics &amp; Child Health</SO>
<YR>1998</YR>
<VL>34</VL>
<NO>2</NO>
<PG>151-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98248053"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-10-10 13:40:49 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bernasconi-1982" NAME="Bernasconi 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;{9907} Not RCT, desmo&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernasconi S, Monti G</AU>
<TI>[The use of DDAVP (desmopressin) in primary nocturnal enuresis] [Italian]</TI>
<SO>Minerva Pediatrica</SO>
<YR>1982</YR>
<VL>34</VL>
<NO>3</NO>
<PG>131-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82195131"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bogaert-2005" NAME="Bogaert 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;{21054}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bogaert G, Vande Walle J, Mattson S, Schurmans T, Hoebeke P, Deboe V, Norgaard J</AU>
<TI>A pharmacodynamic study in children with primary nocturnal enuresis using a new 'melt' orodispersible formulation of desmopressin (Abstract)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>5/6</NO>
<PG>578-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Butler-2001" NAME="Butler 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;{14387} RCT: No Comparison group: No Intervention: Withdrawal from desmopressin or imipramine treatment, use of alarms optional&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Butler RJ, Holland P, Robinson J</AU>
<TI>Examination of the structured withdrawal program to prevent relapse of nocturnal enuresis</TI>
<SO>Journal of Urology</SO>
<YR>2001</YR>
<VL>166</VL>
<NO>6</NO>
<PG>2463-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21553451"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caione-1994" NAME="Caione 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;{10864}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caione P, Nappo S, Capozza N, Minni B, Ferro F</AU>
<TI>[Primary enuresis in children. Which treatment today?] [Italian]</TI>
<SO>Minerva Pediatrica</SO>
<YR>1994</YR>
<VL>46</VL>
<NO>10</NO>
<PG>437-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95107189"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caione-1995" MODIFIED="2008-10-10 13:40:49 +0100" MODIFIED_BY="[Empty name]" NAME="Caione 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;{5206}&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Caione P, Arena F, Biraghi M, Cigna RM, Chendi D, Chiozza ML et al</AU>
<TI>Nocturnal enuresis and daytime wetting: a multicentric trial with oxybutynin and desmopressin</TI>
<SO>European Urology</SO>
<YR>1997</YR>
<VL>31</VL>
<NO>4</NO>
<PG>459-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97331576"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-10 13:40:49 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Caione P, Giorgi PL, Passerini-Glazel G, Chiozza ML, Artibani W, Del Gado R, Di Toro R, Ferrara P, Fois A, Graziottin A, et al. Desmopressin (DDAVP) and oxybutinin in nocturnal enuresis: results of a multicentre trial. Proceedings of the International Children's Continence Society 1995;77-81. {6674}&lt;/p&gt;" NOTES_MODIFIED="2008-10-10 13:40:49 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Caione P, Giorgi PL, Passerini-Glazel G, Chiozza ML, Artibani W, Del Gado R et al</AU>
<TI>Desmopressin (DDAVP) and oxybutynin in nocturnal enuresis: results of a multicentre trial</TI>
<SO>Proceedings of the International Children's Continence Society, Sydney, Australia</SO>
<YR>1995</YR>
<PG>77-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capozza-1991" NAME="Capozza 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Capozza N, Creti G, De Gennaro M, Minni B, Caione P. The treatment of nocturnal enuresis. A comparative study between desmopressin and acupuncture used alone or in combination. [Italian]. Minerva Pediatrica 1991;43(9):459-464. {1497}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capozza N, Creti G, De Gennaro M, Minni B, Caione P</AU>
<TI>The treatment of nocturnal enuresis. A comparative study between desmopressin and acupuncture used alone or in combination</TI>
<SO>Minerva Pediatrica</SO>
<YR>1991</YR>
<VL>43</VL>
<NO>9</NO>
<PG>577-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92099996"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiozza-1999" NAME="Chiozza 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;{8510} Wrote to authors 8.2.02&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiozza ML, Del Gado R, Di Toro R, Ferrara P, Fois A, Giorgi P et al</AU>
<TI>Italian multicentre open trial on DDAVP spray in nocturnal enuresis</TI>
<SO>Scandinavian Journal of Urology and Nephrology</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>1</NO>
<PG>42-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99200136"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eckford-1994" NAME="Eckford 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Eckford SD, Swami KS, Jackson SR, Abrams PH. Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis. Br J Urol 1994;74(6):733-735. {4215}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eckford SD, Swami KS, Jackson SR, Abrams PH</AU>
<TI>Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis</TI>
<SO>British Journal of Urology</SO>
<YR>1994</YR>
<VL>74</VL>
<NO>6</NO>
<PG>733-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95128628"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-1992" NAME="Evans 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Evans JH, Meadow SR. Desmopressin for bed wetting; length of treatment, vasopressin secretion and response. Arch Dis Child 1992;67(2):184-188. {218}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans JH, Meadow SR</AU>
<TI>Desmopressin for bed wetting; length of treatment, vasopressin secretion and response</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1992</YR>
<VL>67</VL>
<NO>2</NO>
<PG>184-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92181153"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferrie-1984" NAME="Ferrie 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Ferrie BG, MacFarlane J, Glen ES. DDAVP in young enuretic patients: a double blind trial. Br J Urol 1984;56(4):376-378.{1546}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferrie BG, MacFarlane J, Glen ES</AU>
<TI>DDAVP in young enuretic patients: a double-blind trial</TI>
<SO>British Journal of Urology</SO>
<YR>1984</YR>
<VL>56</VL>
<NO>4</NO>
<PG>376-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="85200487"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1959" NAME="Jones 1959" YEAR="1959">
<REFERENCE NOTES="&lt;p&gt;{7727}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones K, Tibbetts RW</AU>
<TI>Pituitary snuff, propantheline and placebos in the treatment of enuresis</TI>
<SO>Journal of Mental Science</SO>
<YR>1959</YR>
<VL>105</VL>
<PG>371-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="7727"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Key-1992" NAME="Key 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Key DW, Bloom DA, Sanvordenker J. Low-dose DDAVP in nocturnal enuresis. Clin Pediatr 1992;31(5):299-301.{6616}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Key DW, Bloom DA, Sanvordenker J</AU>
<TI>Low-dose DDAVP in nocturnal enuresis</TI>
<SO>Clinical Pediatrics</SO>
<YR>1992</YR>
<VL>31</VL>
<NO>5</NO>
<PG>299-301</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92257830"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2001" NAME="Kim 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;{14357}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim KM, Kang J, Ha IS, Chung HI</AU>
<TI>Therapeutic effects of imipramine and DDAVP in the children with primary monosymptomatic nocturnal enuresis: a randomized prospective study</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>4</NO>
<PG>379-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knudsen-1989" NAME="Knudsen 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;{4513}&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Knudsen UB, Rittig S, Pedersen JB, Norgaard JP, Djurhuus JC</AU>
<TI>Long-term treatment of nocturnal enuresis with desmopressin - influence on urinary output and haematological parameters</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>1989</YR>
<VL>8</VL>
<NO>4</NO>
<PG>348-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marson-1955" NAME="Marson 1955" YEAR="1955">
<REFERENCE NOTES="&lt;p&gt;{7732}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marson FGW</AU>
<TI>Posterior pituitary snuff treatment of nocturnal enuresis</TI>
<SO>Br Med J</SO>
<YR>1955</YR>
<VL>1</VL>
<PG>1194-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matthieson-1994" NAME="Matthieson 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Matthiesen TB, Rittig S, Djurhuus JC, Norgaard JP. A dose titration and an open 6-week efficacy and safety study of desmopressin tablets in the management of nocturnal enuresis. J Urol 1994;151(2):460-463. {1486}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthiesen TB, Rittig S, Djurhuus JC, Norgaard JP</AU>
<TI>A dose titration and an open 6-week efficacy and safety study of desmopressin tablets in the management of nocturnal enuresis</TI>
<SO>Journal of Urology</SO>
<YR>1994</YR>
<VL>151</VL>
<NO>2</NO>
<PG>460-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94111227"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1988" NAME="Miller 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Miller K, Goldberg S, Atkin B. Nocturnal enuresis: experience with long term use of intranasally administered desmopressin in enuresis. Proceedings of an International Symposium held at the Royal College of Physicians, London. In: Meadow SR, Horus Medical Publications 1988;56-62. {NIR}&lt;/p&gt;" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Miller K, Goldberg S, Atkin B</AU>
<TI>Nocturnal enuresis: experience with long term use of intranasally administered desmopressin in enuresis.</TI>
<SO>Proceedings of an International Symposium held at the Royal College of Physicians</SO>
<YR>1989</YR>
<PG>56-62</PG>
<ED>Meadow SR</ED>
<PB>Horus Medical Publications</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1989" NAME="Miller 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Miller K, Goldberg S, Atkin B. Nocturnal enuresis: experience with long-term use of intranasally administered desmopressin. J Pediatr 1989;114(4 Pt2):723-726. (6620}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller K, Goldberg S, Atkin B</AU>
<TI>Nocturnal enuresis: experience with long-term use of intranasally administered desmopressin</TI>
<SO>Journal of Pediatrics</SO>
<YR>1989</YR>
<VL>114</VL>
<NO>4 Pt 2</NO>
<PG>723-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="89177842"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monda-1995" NAME="Monda 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Monda JM, Husmann DA. Primary nocturnal enuresis: a comparison among observation, imipramine, desmopressin acetate and bed-wetting alarm systems. J Urol 1995;154(2 Pt2):745-748. {2989}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monda JM, Husmann DA</AU>
<TI>Primary nocturnal enuresis: a comparison among observation, imipramine, desmopressin acetate and bed-wetting alarm systems</TI>
<SO>Journal of Urology</SO>
<YR>1995</YR>
<VL>154</VL>
<NO>2 Pt 2</NO>
<PG>745-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95333405"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petersen-1996" NAME="Petersen 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;{5956}&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Petersen T, Bang R, Norgard JP, Djurhuus JC</AU>
<TI>Desmopressin in the treatment of urinary frequency and incontinence in patients with MS. A randomized, placebo-controlled, double-blind, cross-over study</TI>
<SO>European Journal of Neurology</SO>
<YR>1996</YR>
<VL>3 Suppl 2</VL>
<PG>17-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramsden-1982" NAME="Ramsden 1982" YEAR="1982`">
<REFERENCE NOTES="&lt;p&gt;{10969} see also {1565}&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Ramsden PD, Hindmarsh JR, Bowditch JDP, Price DA, Yeates WK</AU>
<TI>DDAVP for adult enuresis - a preliminary report</TI>
<SO>Proceedings of the International Continence Society (ICS), 9th Annual Meeting</SO>
<YR>1979</YR>
<PG>91, 249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Ramsden PD, Hindmarsh JR, Price DA, Yeates WK, Bowditch JD. DDAVP for adult enuresis - a preliminary report. Br J Urol 1982;54(3):256-258. {1565}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramsden PD, Hindmarsh JR, Price DA, Yeates WK, Bowditch JD</AU>
<TI>DDAVP for adult enuresis - a preliminary report</TI>
<SO>British Journal of Urology</SO>
<YR>1982</YR>
<VL>54</VL>
<NO>3</NO>
<PG>256-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82258008"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-2002" NAME="Robinson 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;{14525}&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Robinson D, Dixon A, Cardozo L, Anders K</AU>
<TI>Does being in control make life better? The use of desmopressin in daytime urinary incontinence (Abstract)</TI>
<SO>Proceedings of the International Continence Society (ICS), 32nd Annual Meeting, Heidelberg, Germany 28-30 August</SO>
<YR>2002</YR>
<PG>270-1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="14525"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Snajderova-2001" NAME="Snajderova 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;{12138}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Snajderova M, Lehotska V, Kernova T, Kocnarova N, Archmanova E, Janda P et al</AU>
<TI>Desmopressin in a long-term treatment of children with primary nocturnal enuresis--a symptomatic therapy?</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2001</YR>
<VL>160</VL>
<NO>3</NO>
<PG>197-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="12138"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steffens-1993" NAME="Steffens 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Steffens J, Netzer M, Isenberg E, Alloussi S, Ziegler M. Vasopressin deficiency in primary nocturnal enuresis. Results of a controlled prospective study. Eur Urol 1993;24(3):366-370. {70}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steffens J, Netzer M, Isenberg E, Alloussi S, Ziegler M</AU>
<TI>Vasopressin deficiency in primary nocturnal enuresis. Results of a controlled prospective study</TI>
<SO>European Urology</SO>
<YR>1993</YR>
<VL>24</VL>
<NO>3</NO>
<PG>366-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94085451"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stenberg-1993" NAME="Stenberg 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Stenberg A, Lackgren G. Treatment with oral desmopressin in adolescents with primary nocturnal enuresis. Efficacy and long-term effect. Clin Pediatr (Phila) 1993;Spec No:25-27. {1483}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stenberg A, Lackgren G</AU>
<TI>Treatment with oral desmopressin in adolescents with primary nocturnal enuresis. Efficacy and long-term effect</TI>
<SO>Clinical Pediatrics</SO>
<YR>1993</YR>
<VL>Spec No</VL>
<NO>July</NO>
<PG>25-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94313799"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stenberg-1995" NAME="Stenberg 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Stenberg A, Lackgren G. Desmopressin tablet treatment in nocturnal enuresis. Scand J Urol Nephrol Suppl 1995;173:95-99.{5067}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stenberg A, Lackgren G</AU>
<TI>Desmopressin tablet treatment in nocturnal enuresis</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology Supplementum</SO>
<YR>1995</YR>
<VL>173</VL>
<PG>95-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96363553"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-1981" NAME="Taylor 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;{10974}&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Taylor MC, Bates CP</AU>
<TI>DDAVP in the management of nocturnal frequency and enuresis due to bladder instability</TI>
<SO>Proceedings of the International Continence Society (ICS), 11th Annual Meeting</SO>
<YR>1981</YR>
<PG>144-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wood-1994" NAME="Wood 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Wood CM, Butler RJ, Penney MD, Holland PC. Pulsatile release of arginine vasopressin (AVP) and it's effect on response to desmopressin in enuresis. Scand J Urol Nephrol Suppl 1994;163:93-101.{4214}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wood CM, Butler RJ, Penney MD, Holland PC</AU>
<TI>Pulsatile release of arginine vasopressin (AVP) and its effect on response to desmopressin in enuresis</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology Supplementum</SO>
<YR>1994</YR>
<VL>163</VL>
<PG>93-101</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95183927"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Hjalmas-2001" NAME="Hjalmas 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;{8517}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hjalmas K, Hanson E, Hellstrom AL, Kruse S, Sillen U</AU>
<TI>Long-term treatment with desmopressin in children with primary monosymptomatic nocturnal enuresis: an open multicentre study. Swedish Enuresis Trial (SWEET) Group</TI>
<SO>British Journal of Urology</SO>
<YR>1998</YR>
<VL>82</VL>
<NO>5</NO>
<PG>704-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99053322"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;{5068}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hjalmas K</AU>
<TI>SWEET, the Swedish Enuresis Trial</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology Supplementum</SO>
<YR>1995</YR>
<VL>173</VL>
<PG>89-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96363552"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-28 17:21:20 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-28 17:09:08 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-APA-1980" MODIFIED="2008-10-28 16:55:54 +0000" MODIFIED_BY="[Empty name]" NAME="APA 1980" NOTES="&lt;p&gt;American Psychiatric Association. Functional enuresis. In: APA, ed. Diagnostic and Statistical Manual of Mental Disorders. 3rd edition (revised)&lt;/p&gt;" NOTES_MODIFIED="2008-10-28 16:55:54 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="BOOK_SECTION">
<AU>American Psychiatric Association</AU>
<TI>Functional enuresis</TI>
<SO>Diagnostic and Statistical Manual of Mental Disorders (DSM)</SO>
<YR>1980</YR>
<EN>3rd (revised)</EN>
<ED>American Psychiatric Association</ED>
<PB>American Psychiatric Publishing Inc</PB>
<CY>Arlington (VA)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bakwin-1971" NAME="Bakwin 1971" NOTES="&lt;p&gt;Bakwin H. Enuresis in twins. Am J Dis Child 1971;121(3):222-5.{6644}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Bakwin H</AU>
<TI>Enuresis in twins</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1971</YR>
<VL>121</VL>
<NO>3</NO>
<PG>222-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="71158021"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bakwin-1973" NAME="Bakwin 1973" NOTES="&lt;p&gt;Bakwin H. The genetics of enuresis. In: Kolvin I, MacKeith RC, Meadow SR, eds. Bladder control and enuresis. London: William Heinemann Medical Books 1973.{9926}&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Bakwin H</AU>
<TI>The genetics of enuresis</TI>
<SO>Bladder control and enuresis</SO>
<YR>1973</YR>
<ED>Kolvin I, MacKeith RC, Meadow SR</ED>
<PB>William Heinemann Medical Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berlin-1989" NAME="Berlin 1989" NOTES="&lt;p&gt;{7750}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Berlin JA, Laird NM, Sacks HS, Chalmers TC</AU>
<TI>A comparison of statistical methods for combining event rates from clinical trials</TI>
<SO>Statistics in Medicine</SO>
<YR>1989</YR>
<VL>8</VL>
<NO>2</NO>
<PG>141-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="89203035"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bernstein-1997" NAME="Bernstein 1997" NOTES="&lt;p&gt;Bernstein SA, Williford SL. Intranasal desmopressin-associated hyponatremia: a case report and literature review. [Review] [21 refs]. J Fam Pract 1997;44(2):203-8.{5015}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein SA, Williford SL</AU>
<TI>Intranasal desmopressin-associated hyponatremia: a case report and literature review</TI>
<SO>Journal of Family Practice</SO>
<YR>1997</YR>
<VL>44</VL>
<NO>2</NO>
<PG>203-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97192932"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Blackwell-1989" NAME="Blackwell 1989" NOTES="&lt;p&gt;Blackwell C. A guide to enuresis: A guide to treatment of enuresis for professionals. Bristol: ERIC 1989.{4035}&lt;/p&gt;" TYPE="BOOK">
<AU>Blackwell C</AU>
<SO>A guide to enuresis: A guide to treatment of enuresis for professionals</SO>
<YR>1989</YR>
<PG>1-86</PG>
<PB>ERIC</PB>
<CY>Bristol</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BNF-2002" NAME="BNF 2002" TYPE="BOOK">
<AU>British National Formulary</AU>
<SO>British National Formulary</SO>
<YR>March 2002</YR>
<VL>43</VL>
<PB>British Medical Association and the Royal Pharmaceutical Society of Great Britain</PB>
<CY>London</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISBN: 0 85369 510 5 ISBN: 0 7279 1613 0"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Butler-1991" NAME="Butler 1991" NOTES="&lt;p&gt;Butler RJ. Establishment of working definitions in nocturnal enuresis. Archives of Disease in Childhood 1991;66:267-271.{6661}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Butler RJ</AU>
<TI>Establishment of working definitions in nocturnal enuresis</TI>
<SO>Archives of Diseases in Childhood</SO>
<YR>1991</YR>
<VL>66</VL>
<NO>2</NO>
<PG>267-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91158344"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2003" NAME="Clarke 2003" TYPE="BOOK_SECTION">
<AU>Clarke M, Oxman AD, editors</AU>
<TI>Optimal search strategy for RCTs. Appendix 5c.2. Cochrane Reviewers Handbook 4.1.6 (updated January 2003)</TI>
<SO>The Cochrane Library, Issue 1</SO>
<YR>2003</YR>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Jonge-1973" NAME="de Jonge 1973" NOTES="&lt;p&gt;de Jonge GA. Epidemiology of enuresis: A survey of the literature. In: Kolvin I, MacKeith RC, Meadow SR, eds. Bladder control and enuresis. London: William Heinemann Medical Books 1973.{9927}&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>de Jonge GA</AU>
<TI>Epidemiology of enuresis: A survey of the literature</TI>
<SO>Bladder control and enuresis</SO>
<YR>1973</YR>
<ED>Kolvin I, MacKeith RC, Meadow SR</ED>
<PB>William Heinemann Medical Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Devlin-1991" NAME="Devlin 1991" NOTES="&lt;p&gt;Devlin JB. Prevalence and risk factors for childhood nocturnal enuresis. Ir Med J 1991;84(4):118-20.{6643}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Devlin JB</AU>
<TI>Prevalence and risk factors for childhood nocturnal enuresis</TI>
<SO>Irish Medical Journal</SO>
<YR>1991</YR>
<VL>84</VL>
<NO>4</NO>
<PG>118-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92283629"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Djurhuus-1992" NAME="Djurhuus 1992" NOTES="&lt;p&gt;Djurhuus JC, Norgaard JP, Rittig S. Monosymptomatic bed wetting. Scand J Urol Nephrol Suppl 1992;141:7-19.{6639}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Djurhuus JC, Norgaard JP, Rittig S</AU>
<TI>Monosymptomatic bedwetting</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology Supplementum. 141</SO>
<YR>1992</YR>
<VL>141</VL>
<PG>7-19</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92302804"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Eiberg-1995" NAME="Eiberg 1995" NOTES="&lt;p&gt;Eiberg H, Berendt I, Mohr J. Assignment of dominant inherited nocturnal enuresis (ENUR1) to chromosome 13Q. Nat Genet 1995;10(3):354-6.{6645}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Eiberg H, Berendt I, Mohr J</AU>
<TI>Assignment of dominant inherited nocturnal enuresis (ENUR1) to chromosome 13q</TI>
<SO>Nature Genetics</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>3</NO>
<PG>354-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95400306"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fitzwater-1992" NAME="Fitzwater 1992" NOTES="&lt;p&gt;Fitzwater D, Macknin ML. Risk/benefit ratio in enuresis therapy. Clin Pediatr (Phila) 1992;31(5):308-10.{5876}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Fitzwater D, Macknin ML</AU>
<TI>Risk/benefit ratio in enuresis therapy</TI>
<SO>Clinical Pediatrics</SO>
<YR>1992</YR>
<VL>31</VL>
<NO>5</NO>
<PG>308-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92257832"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Forsythe-1974" NAME="Forsythe 1974" NOTES="&lt;p&gt;Forsythe WI, Redmond A. Enuresis and spontaneous cure rate. A study of 1129 enuretics. Arch Dis Child 1974;49(4):259-63. {6641}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Forsythe WI, Redmond A</AU>
<TI>Enuresis and spontaneous cure rate. A study of 1129 enuretics</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1974</YR>
<VL>49</VL>
<NO>4</NO>
<PG>259-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="74169219"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glazener-2004a" MODIFIED="2008-10-28 17:02:20 +0000" MODIFIED_BY="[Empty name]" NAME="Glazener 2004a" NOTES="&lt;p&gt;Glazener CMA, Evans JHC, Peto RE. Alarm interventions for nocturnal enuresis in children. &lt;i&gt;Cochrane Database of Systematic Reviews&lt;/i&gt; 2005, Issue 2. Art. No.: CD002911. DOI: 10.1002/14651858.CD002911.pub2&lt;/p&gt;" NOTES_MODIFIED="2008-10-28 17:02:20 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Glazener CMA, Evans JH, Peto RE</AU>
<TI>Alarm interventions for nocturnal enuresis in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-10-28 16:58:23 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 16:58:23 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD002911. DOI: 10.1002/14651858.CD002911.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glazener-2004b" MODIFIED="2008-10-28 17:00:23 +0000" MODIFIED_BY="[Empty name]" NAME="Glazener 2004b" NOTES="&lt;p&gt;Glazener CMA, Evans JHC, Peto RE. Complex behavioural and educational interventions for nocturnal enuresis in children. &lt;i&gt;Cochrane Database of Systematic Reviews&lt;/i&gt; 2004, Issue 1. Art. No.: CD004668. DOI: 10.1002/14651858.CD004668&lt;/p&gt;" NOTES_MODIFIED="2008-10-28 17:00:23 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Glazener CMA, Evans JHC, Peto RE</AU>
<TI>Complex behavioural and educational interventions for nocturnal enuresis in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-10-28 16:59:37 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 16:59:37 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD004668. DOI: 10.1002/14651858.CD004668"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glazener-2004c" MODIFIED="2008-10-28 17:05:24 +0000" MODIFIED_BY="[Empty name]" NAME="Glazener 2004c" NOTES="&lt;p&gt;Glazener CMA, Evans JHC, Peto RE. Drugs for nocturnal enuresis in children (other than desmopressin and tricyclics). &lt;i&gt;Cochrane Database of Systematic Reviews&lt;/i&gt; 2003, Issue 4. Art. No.: CD002238. DOI: 10.1002/14651858.CD002238&lt;/p&gt;" NOTES_MODIFIED="2008-10-28 17:05:24 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Glazener CMA, Evans JHC, Peto RE</AU>
<TI>Drugs for nocturnal enuresis in children (other than desmopressin and tricyclics)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-10-28 17:05:24 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 17:05:24 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD002238. DOI: 10.1002/14651858.CD002238"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glazener-2004d" MODIFIED="2008-10-28 17:07:09 +0000" MODIFIED_BY="[Empty name]" NAME="Glazener 2004d" NOTES="&lt;p&gt;Glazener CMA, Evans JHC. Simple behavioural and physical interventions for nocturnal enuresis in children. &lt;i&gt;Cochrane Database of Systematic Reviews&lt;/i&gt; 2004, Issue 2. Art. No.: CD003637. DOI: 10.1002/14651858.CD003637.pub2&lt;/p&gt;" NOTES_MODIFIED="2008-10-28 17:07:09 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Glazener CMA, Evans JE</AU>
<TI>Simple behavioural interventions for nocturnal enuresis in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-10-28 17:06:21 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 17:06:21 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD003637. DOI: 10.1002/14651858.CD003637.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glazener-2004e" MODIFIED="2008-10-28 17:09:08 +0000" MODIFIED_BY="[Empty name]" NAME="Glazener 2004e" NOTES="&lt;p&gt;Glazener CMA, Evans JHC, Peto R. Tricyclic and related drugs for nocturnal enuresis in children. &lt;i&gt;Cochrane Database of Systematic Reviews&lt;/i&gt; 2003, Issue 3. Art. No.: CD002117. DOI: 10.1002/14651858.CD002117&lt;/p&gt;" NOTES_MODIFIED="2008-10-28 17:09:08 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Glazener CMA, Evans JH, Peto RE</AU>
<TI>Tricyclic and related drugs for nocturnal enuresis in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-10-28 17:09:06 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 17:09:06 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD002117. DOI: 10.1002/14651858.CD002117"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harris-1989" NAME="Harris 1989" NOTES="&lt;p&gt;Harris AB. Clinical experience with desmopressin: efficacy and safety in central diabetes insipidus and other conditions. Journal of Pediatrics 1989;114(4 II suppl):711-8. {6654}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Harris AS</AU>
<TI>Clinical experience with desmopressin: efficacy and safety in central diabetes insipidus and other conditions</TI>
<SO>Journal of Paediatrics</SO>
<YR>1989</YR>
<VL>114</VL>
<NO>4 pt 2</NO>
<PG>711-18</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="89177840"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" NOTES="&lt;p&gt;re I-squared statistic&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>British Medical Journal</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hjalmas-1993" NAME="Hjalmas 1993" NOTES="&lt;p&gt;Hjalmas K, Bengtsson B. Efficacy, safety, and dosing of desmopressin for nocturnal enuresis in Europe. Clin Pediatr (Phila) 1993;Spec No:25-30. {6655}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hjalmas K, Bengtsson B</AU>
<TI>Efficacy, safety, and dosing of desmopressin for nocturnal enuresis in Europe</TI>
<SO>Clinical Pediatrics</SO>
<YR>1993</YR>
<VL>Spec No</VL>
<PG>19-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94313798"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Howe-1992" NAME="Howe 1992" NOTES="&lt;p&gt;Howe AC, Walker CE. Behavioural management of toilet training, enuresis and encopresis. Pediatr Clin North Am 1992;39(3):413-32. {6659}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Howe AC, Walker CE</AU>
<TI>Behavioural management of toilet training, enuresis and encopresis</TI>
<SO>Pediatric Clinics of North America</SO>
<YR>1992</YR>
<VL>39</VL>
<NO>3</NO>
<PG>413-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92244694"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jarvelin-1989" MODIFIED="2008-10-10 13:41:30 +0100" MODIFIED_BY="[Empty name]" NAME="Jarvelin 1989" NOTES="&lt;p&gt;Jarvelin MR. Developmental history and neruological findings in enuretic children. Dev Med Child Neruol 1989;31(6):728-36. {6638}&lt;/p&gt;" NOTES_MODIFIED="2008-10-10 13:41:30 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Jarvelin MR</AU>
<TI>Developmental history and neurological findings in enuretic children</TI>
<SO>Developmental Medicine &amp; Child Neurology</SO>
<YR>1989</YR>
<VL>31</VL>
<NO>6</NO>
<PG>728-36</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="90092792"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jarvelin-1990" NAME="Jarvelin 1990" NOTES="&lt;p&gt;Jarvelin MR, Huttunen NP, Seppanen J, Seppanen U, Moilanen I. Screening of urinary tract abnormalities among day and nightwetting children. Scand J Urol Nephrol 1990;24(3):181-9. {332}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Jarvelin MR, Huttunen NP, Seppanen J, Seppanen U, Moilanen I</AU>
<TI>Screening of urinary tract abnormalities among day and nightwetting children</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology</SO>
<YR>1990</YR>
<VL>24</VL>
<NO>3</NO>
<PG>181-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91047829"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Koff-1995" NAME="Koff 1995" NOTES="&lt;p&gt;Koff SA. Why is desmopressin sometimes ineffective at curing bedwetting? Scand J Urol Nephrol Suppl 1995;173:103-7. {6647}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Koff SA</AU>
<TI>Why is desmopressin sometimes ineffective at curing bedwetting?</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology</SO>
<YR>1995</YR>
<VL>173</VL>
<NO>Suppl</NO>
<PG>103-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96363555"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Krantz-1994" NAME="Krantz 1994" NOTES="&lt;p&gt;Krantz I, Jylkas E, Ahlberg BM, Wedel H. On the epidemiology of nocturnal enuresis-a critical review of methods used in descriptive epidemiological studies on nocturnal enuresis. Scand J Urol Nephrol Suppl 1994;163:75-82. {6640}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Krantz I, Jylkas E, Ahlberg BM, Wedel H</AU>
<TI>On the epidemiology of nocturnal enuresis-a critical review of methods used in descriptive epidemiological studies on nocturnal enuresis</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology</SO>
<YR>1994</YR>
<VL>163</VL>
<NO>Suppl</NO>
<PG>75-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95183925"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Maizels-1993" NAME="Maizels 1993" NOTES="&lt;p&gt;Maizels M, Gandhi K, Keating B, Rosenbaum D. Diagnosis and treatment for children who cannot control urination. Curr Probl Pediatr 1993;23(10):402-50. {6663}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Maizels M, Gandhi K, Keating B, Rosenbaum D</AU>
<TI>Diagnosis and treatment for children who cannot control urination</TI>
<SO>Current Problems in Pediatrics</SO>
<YR>1993</YR>
<VL>23</VL>
<NO>10</NO>
<PG>402-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94116304"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Meadow-1989" NAME="Meadow 1989" NOTES="&lt;p&gt;Meadow SR, Evans JH. Desmopressin for enuresis: useful in the short term. BMJ 1989;298:1596-7. {5879}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Meadow SR, Evans JH</AU>
<TI>Desmopressin for enuresis</TI>
<SO>British Medical Journal</SO>
<YR>1989</YR>
<VL>298</VL>
<NO>6688</NO>
<PG>1596-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="89336083"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moffatt-1989" NAME="Moffatt 1989" NOTES="&lt;p&gt;Moffatt ME. Nocturnal enuresis: psychologic implications of treatment and nontreatment. J Pediatr 1989;114(4 Pt2):697-704. {6664}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Moffatt ME</AU>
<TI>Nocturnal enuresis: psychologic implications of treatment and nontreatment</TI>
<SO>Journal of Pediatrics</SO>
<YR>1989</YR>
<VL>114</VL>
<NO>4 Pt 2</NO>
<PG>697-704</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="89177838"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moffatt-1994" NAME="Moffatt 1994" NOTES="&lt;p&gt;Moffatt ME. Nocturnal enuresis-is there a rationale for treatment? Scand J Urol Nephrol Suppl 1994;163:55-66. {6652}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Moffatt ME</AU>
<TI>Nocturnal enuresis-is there a rationale for treatment?</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology</SO>
<YR>1994</YR>
<VL>163</VL>
<PG>55-66</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95183922"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Morgan-1970" NAME="Morgan 1970" NOTES="&lt;p&gt;Morgan R. The treatment of enuresis amongst child clients of a social services department. British Journal of Social Work 1970;9(2):217-31. {9930}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Morgan R</AU>
<TI>The treatment of enuresis amongst child clients of a social services department</TI>
<SO>British Journal of Social Work</SO>
<YR>1970</YR>
<VL>9</VL>
<NO>2</NO>
<PG>217-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morgan-1993" NAME="Morgan 1993" NOTES="&lt;p&gt;Morgan R. Guidelines in the minimum standards of practice in the treatment of enuresis. In: Centre ER, ed 1993. {9931}&lt;/p&gt;" TYPE="BOOK">
<AU>Morgan R</AU>
<SO>Guidelines in the Minimum Standards of Practice in the Treatment of Enuresis</SO>
<YR>1993</YR>
<PB>Enuresis Resource and Information Centre</PB>
<CY>Bristol</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norgaard-1993" NAME="Norgaard 1993" NOTES="&lt;p&gt;Norgaard JP, Djurhuus JC. The pathophysiology of enuresis in children and young adults. Clin Pediatr (Phila) 1993;Spec No:5-9. {6646}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Norgaard JP, Djurhuus JC</AU>
<TI>The pathophysiology of enuresis in children and young adults</TI>
<SO>Clinical Pediatrics</SO>
<YR>1993</YR>
<VL>Spec No</VL>
<PG>5-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94313804"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parkin-1972" NAME="Parkin 1972" NOTES="&lt;p&gt;{5877}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Parkin JM, Fraser MS</AU>
<TI>Poisoning as a complication of enuresis</TI>
<SO>Developmental Medicine &amp; Child Neurology</SO>
<YR>1972</YR>
<VL>14</VL>
<NO>6</NO>
<PG>727-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="73066898"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Robson-1994" NAME="Robson 1994" NOTES="&lt;p&gt;95106314 Division of Pediatric Nephrology, Children's Hospital, Calgary, Alberta, Canada A literature search revealed 23 studies that have reported on the type or frequency of side effects or complications associated with the use of desmopressin (DDAVP, Rhone-Poulenc Rorer Pharmaceuticals Inc, Collegeville, Pennsylvania) for the treatment of enuresis. Thirty-one (4.3%) side effects were reported in 717 patients. Seizure secondary to water intoxication is a potential complication of treatment with desmopressin and was reported in six patients, usually in association with excess fluid intake during the evening or day preceding the use of desmopressin. Desmopressin appears to have a favorable safety profile. Patients should be specifically instructed not to ingest excess fluids during the evening prior to administration of desmopressin. [References: 33] 16679-58-6 (Desmopressin) {4216}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Robson WL, Leung AK</AU>
<TI>Side effects and complications of treatment with desmopressin for enuresis [Review]</TI>
<SO>Journal of the National Medical Association</SO>
<YR>1994</YR>
<VL>86</VL>
<NO>10</NO>
<PG>775-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robson-1996" NAME="Robson 1996" NOTES="&lt;p&gt;Robson WL, Norgaard JP, Leung AK. Hyponatremia in patients with nocturnal enuresis treated with DDAVP. Eur J Pediatr 1996;155(11):959-62. {5030}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Robson WL, Norgaard JP, Leung AK</AU>
<TI>Hyponatremia in patients with nocturnal enuresis treated with DDAVP</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>155</VL>
<NO>11</NO>
<PG>959-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97068637"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rushton-1996" NAME="Rushton 1996" NOTES="&lt;p&gt;{4199}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rushton HG, Belman AB, Zaontz MR, Skoog SJ, Sihelnik S</AU>
<TI>The influence of small functional bladder capacity and other predictors on the response to desmopressin in the management of monosymptomatic nocturnal enuresis</TI>
<SO>Journal of Urology</SO>
<YR>1996</YR>
<VL>156</VL>
<NO>2 Pt 2</NO>
<PG>651-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96289410"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rutter-1973" NAME="Rutter 1973" NOTES="&lt;p&gt;Rutter M, Yule W, Graham P. Enuresis and behavioural deviance. Some epidemiological considerations. In Kolvin I, MacKeith RC, Meadow SR, eds. Bladder control and enuresis. London: William Heinemann Medical Books, 1973. {4036}&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Rutter M, Yule W, Graham P</AU>
<TI>Enuresis and behavioural deviance. Some epidemiological considerations</TI>
<SO>Bladder control and enuresis</SO>
<YR>1973</YR>
<PG>137-50</PG>
<ED>Kolvin I, MacKeith RC, Meadow SR</ED>
<PB>William Heinemann Medical Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shaffer-1977" NAME="Shaffer 1977" NOTES="&lt;p&gt;Shaffer D. Enuresis. In: Rutter M, ????, eds. Child psychiatry: Modern approaches. Oxford: Blackwell Scientific Publications 1977. {9932}&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Shaffer D</AU>
<TI>Enuresis</TI>
<SO>Child psychiatry: Modern approaches</SO>
<YR>1977</YR>
<ED>Rutter M</ED>
<PB>Blackwell Scientific Publications</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warzak-1993" NAME="Warzak 1993" NOTES="&lt;p&gt;Warzak WJ. Psychosocial implications of nocturnal enuresis. Clin Pediatr 1992;Spec No:38-40. {6651}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Warzak WJ</AU>
<TI>Psychosocial implications of nocturnal enuresis</TI>
<SO>Clinical Pediatrics</SO>
<YR>1993</YR>
<VL>Spec No</VL>
<PG>38-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94313803"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-1992" NAME="WHO 1992" NOTES="&lt;p&gt;Nonorganic enuresis. In: WHO, ed. The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: WHO 1992.&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>World Health Organisation</AU>
<TI>Nonorganic enuresis</TI>
<SO>The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines</SO>
<YR>1992</YR>
<PB>WHO</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-10-28 17:21:20 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Glazener-2000" MODIFIED="2008-10-28 17:21:20 +0000" MODIFIED_BY="[Empty name]" NAME="Glazener 2000" NOTES="&lt;p&gt;this must be before Wiley as there is no doi available and not available at the moment online.&lt;/p&gt;&lt;p&gt;First desmo review&lt;/p&gt;" NOTES_MODIFIED="2008-10-28 17:21:20 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Glazener CMA, Evans JHC</AU>
<TI>Desmopression for nocturnal enuresis in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-10-28 17:14:23 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 17:14:23 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glazener-2002" MODIFIED="2008-10-28 17:20:05 +0000" MODIFIED_BY="[Empty name]" NAME="Glazener 2002" NOTES="&lt;p&gt;at 28 Oct 2008 this is still the correct citation for this review so it doesnt really make sense to put it in the public domain as a previous version!! Presumably every change since has been a minor update.&lt;/p&gt;&lt;p&gt;Glazener CMA, Evans JHC. Desmopressin for nocturnal enuresis in children. &lt;i&gt;Cochrane Database of Systematic Reviews&lt;/i&gt; 2002, Issue 3. Art. No.: CD002112. DOI: 10.1002/14651858.CD002112&lt;/p&gt;&lt;p&gt;First update of desmo review&lt;/p&gt;" NOTES_MODIFIED="2008-10-28 17:20:05 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Glazener CMA, Evans JHC</AU>
<TI>Desmopressin for nocturnal enuresis in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-10-28 17:20:05 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 17:20:05 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD002112. DOI: 10.1002/14651858.CD002112"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lister_x002d_Sharp-1997" NAME="Lister-Sharp 1997" NOTES="&lt;p&gt;Lister-Sharp D, O'Meara S, Bradley M, Sheldon TA. A Systematic Review of the Effectiveness of Interventions for Managing Childhood Nocturnal Enuresis. NHS Centre for Reviews and Dissemination, University of York. York Publishing Services Ltd., 1997. CRD Report 11, NHS Centre for Reviews and Dissemination, University of York {9946}&lt;br&gt;&lt;/p&gt;" TYPE="BOOK">
<AU>Lister-Sharp D, O'Meara S, Bradley M, Sheldon TA</AU>
<SO>A Systematic Review of the Effectiveness of Interventions for Managing Childhood Nocturnal Enuresis</SO>
<YR>1997</YR>
<VL>CRD Report 11</VL>
<PB>NHS Centre for Reviews and Dissemination, University of York. York Publishing Services Ltd</PB>
<CY>York</CY>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-10-10 13:38:46 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-10-10 13:38:40 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Aladjem-1982">
<CHAR_METHODS>
<P>RCT (double blind, method not specified)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned<BR/>Follow up after 30 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 32 (boys: A:7, B:8)<BR/>Previous treatment: 5/23 responded to chlorimipramine hydrochloride<BR/>Mean age (years): A:10.5, B:10.0 (range 7-15)<BR/>Baseline wetting: mean (SD) number of wet nights in 30: A:18.7 (6.5), B:21.3 (8.5)<BR/>No significant difference between groups in urine osmolalities</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (15): 10 µg DDAVP intranasally<BR/>B (17): placebo as above</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean (SD) number of wet nights out of 30: A:6.5 (9.2), B:18.8 (8.3)<BR/>Number totally dry: A:6, B:1<BR/>Number of wet nights at follow up: A:15.7 (8.9), B:16.9 (9.4)<BR/>Significant difference in response of children according to age Only those over 10 years became completely dry The only failures (n=3) were less than 10 years old<BR/>Side effects: none reported<BR/>Prompt response to DDAVP - as early as 1-3 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unclear about dropouts<BR/>Short follow up<BR/>Age effect suggested<BR/>Inclusion criteria: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Birkasova-1978_x0023_">
<CHAR_METHODS>
<P>RCT (double blind crossover)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned<BR/>Follow up after 4-6 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 22 (14 boys)<BR/>Previous treatment: all had failed to respond to psychotherapy and a regimen that included fluid deprivation after 5 pm<BR/>Some had previously been unsuccessfully treated with imipramine<BR/>Exclusion criteria: organic causes of enuresis<BR/>Mean age (years): 6.6 (range 4-12)<BR/>Baseline wetting: mean (SD) wet beds per fortnight: 10.6 (4.9)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A: 10 µg DDAVP drops intranasally at bedtime<BR/>B: 40 µg DDAVP drops intranasally at bedtime<BR/>C: placebo<BR/>Duration of treatment: 2 weeks in each arm</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean (SD) number of wet nights per fortnight<BR/>A+B:4.2 (4.5) C:11 (4.4)<BR/>Side effects: none reported<BR/>5 patients receiving a higher dosage were totally dry<BR/>9 continued DDAVP single blind for 4 to 6 weeks then given placebo<BR/>7 remained dry without drug<BR/>1 wet once monthly and 1 returned to daily wetting<BR/>4 who had wet nightly continued on DDAVP for 3 more months by which time they were dry <BR/>1 had 1 wet night per fortnight and 1 had 1 wet night in 3<BR/>2 patients who were indifferent to wetting showed no response to DDAVP or placebo</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No measure of comparability at baseline<BR/>No washout period<BR/>Not clear if intention to treat because no details of dropouts<BR/>Subjects were very young<BR/>High and low doses combined in analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bradbury-1995">
<CHAR_METHODS>
<P>RCT (quota allocation system based on age, baseline wetting, family or housing problems, gender, previous alarm use, daytime wetting and previous dry periods)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: No<BR/>6 month follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 71 (boys 48)<BR/>Dropouts A: 3, B: 8<BR/>Inclusion criteria: nocturnal enuresis at least 1 night per week (40/71 = severe, &gt;4 times per week) <BR/>Exclusion criteria: neuropathic bladder, urinary tract abnormalities, cystic fibrosis, allergic rhinitis, deafness/ learning difficulties, UTI<BR/>Previous treatment: 29 had used alarms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (36): desmopressin 40 µg intranasally and alarm (bell-and-pad or Mini Drinite)<BR/>B (35): alarm alone<BR/>Duration 6 weeks or until dry</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean DRY nights per week: A: n=33, mean = 6.1, 95% CI 5.6-6.7; B: 27, 4.8, 4.0-5.6<BR/>Number not achieving 4 dry nights: A: 6/33; B: 11/27<BR/>Number failing or relapsing: A: 10/33; B: 14/27<BR/>Side effects: none reported<BR/>Subgroup analysis in more severe group: A still better than B</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mini Drinite = body-worn alarm<BR/>Relapsing = 2 wet nights in 2 weeks after 4 weeks dry<BR/>Authors recommended using combined desmopressin and alarm only for children with severe wetting problems</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Burke-1995">
<CHAR_METHODS>
<P>RCT (multi-centre, double blind) <BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 45 (boys: A:11, B:10, C:9)<BR/>Dropouts: A:0, B:3, C:3<BR/>Inclusion criteria: age 6-17 years; at least 3 wet nights per week for preceding 3 month period and not dry for more than 6 months<BR/>Exclusion criteria: enuresis treatment in preceding 6 months; nocturnal enuresis of neurogenic origin; urinary tract infection; abnormal urinalysis haematology or blood biochemistry; concomitant medication known to interfere with study medication<BR/>Age, mean years (SD): A:8.6 (2.4), B:8.9 (2.5), C:8.9 (2.4) (range 6-14)<BR/>Baseline wetting: mean (SD) number of wet nights per week: A:5.8 (0.9), B:6.0 (0.9), C:6.3 (0.9)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (14): amitriptyline hydrochloride (25 mg or 50 mg)<BR/>B (17): desmopressin (20 µg) intranasally<BR/>C (14): DDAVP and amitriptyline<BR/>Duration of treatment: 16 weeks<BR/>Follow up 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean (SD) number of wet nights per week: A:3.3 (1.9), B:4.7 (1.7), C:3.3 (2.5)<BR/>Number attaining cure: A:3, B:1, C:5<BR/>7 out of 8 children who were cured relapsed. The exception was treated with amitriptyline and DDAVP<BR/>Follow up: mean (SD) number of wet nights per week: A:(n=10) 3.9 (2.9), B:(n=5) 3.8 (1.9), C:(n=8) 5.1 (3.2)<BR/>Side effects: none reported<BR/>Most parents said all the drugs were easy to use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No significant difference between groups in terms of number, age, height and weight<BR/>Trial prematurely halted due to one drug ceasing to be available<BR/>Not stated if intention to treat<BR/>Not full quota of subjects<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dimson-1986_x0023_">
<CHAR_METHODS>
<P>RCT (double blind crossover)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 17 (14 boys)<BR/>Inclusion criteria: 3 with encopresis<BR/>Exclusion criteria: UTI, organic disease (clinical or radiological)<BR/>Previous treatment: failure to respond to tricyclics and alarms<BR/>Age range 6-13 years<BR/>Baseline wetting &gt;50% wet nights in 2-week observation period</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (17): 20 µg desmopressin intranasally<BR/>B (17): matching placebo<BR/>Duration of treatment 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean wet nights per week: A: 117 in 2 weeks in 17 children (= mean 3.4/week); B: 169 in 2 weeks in 17 children (= mean 5.0/ week)<BR/>Number not achieving 14 dry nights: A: 2 cured, 10 improved, 5 failed; B: 5 improved slightly, 12 failed<BR/>Number failed or relapsed: A: 17/17; B: 17/17<BR/>Side effects: none reported (no overhydration, weight or BP change)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No washout period<BR/>All children relapsed after end of trial<BR/>No SDs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Faraj-1999">
<CHAR_METHODS>
<P>RCT (random number tables, details not given)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 135<BR/>Dropouts: 23 excluded for non-compliance, and 39 lost to follow up including 12 failed with alarms<BR/>Inclusion criteria: monosymptomatic nocturnal enuresis, age &gt;5 years<BR/>Exclusion criteria: previous treatment with DDAVP or alarm, urological pathology, diurnal enuresis, UTI<BR/>Age, mean years: 11.2 <BR/>Baseline wetting: A 21% dry nights, B 14% dry nights</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (62): desmopressin 20 µg intranasally increasing to 40 µg if response partial<BR/>B (73): alarm (pad-and-bell)<BR/>Duration of treatment 3 months. If failed at that time, changed to alternative arm</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>DRY nights at 3 months: A 85%; B: 90%<BR/>Number not achieving 14 dry nights: A 12/39; B: 6/37<BR/>Side effects: not mentioned</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No follow up<BR/>No mention of adverse events<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fera-2004">
<CHAR_METHODS>
<P>RCT (randomized in 2 groups)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: No<BR/>Daytime wetting excluded: Yes<BR/>Setting: Federal University of Sao Paulo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>No. of children (boys): 30 (21)<BR/>Dropouts: None<BR/>Inclusion: monosymptomatic nocturnal enuresis, age over 5 years, no daytime wetting<BR/>Exclusion: none mentioned<BR/>Previous treatment: none<BR/>Age, mean years (SD): 9.23 (1.85)<BR/>Baseline wetting, mean (SD) wet nights in 2 weeks: 9.40 (3.40)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (15): DDAVP (desmopressin), titrated to maximum 0.4 mg at bedtime<BR/>B (15): behavioural modification (dietary and fluid adjustment, voiding schedules, double voiding, bedtime toileting, alarm clock once at night, pelvic floor training, environmental modifications, changes in parents' attitudes, improvement of self-esteem, self care)<BR/>Duration of treatment: 30 days<BR/>Follow up: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Wet nights during last 2 weeks of treatment N, mean (SD): A: 15, 7.27 (4), B: 15, 3.93 (3.32)<BR/>50% improvement: A: 7/15, B: 8/15<BR/>Complete failure: A: 5/15, B: 1/15<BR/>Adverse effects: not mentioned</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Groups comparable at baseline on age, gender and baseline wetting <BR/>No data for children 'cured' (14 consecutive dry nights)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fjellestad-1987_x0023_">
<CHAR_METHODS>
<P>RCT (double blind, double dummy, cross over)<BR/>Periods of treatment preceded and followed by one week of observation<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>Follow up after 1 week</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 30 (20 boys), 1 dropout<BR/>Exclusion criteria: urinary tract infections; diurnal wetting; faecal soiling; neurological or urological abnormalities; 3+ wet nights a week during baseline<BR/>Previous treatment: 69% tried one or more other treatment<BR/>Age, mean (SD): 9.8 (2.5) (range 6-15)<BR/>Baseline wetting: mean number of dry nights in week: 2.2 (SD 0.2)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A: 200 µg oral desmopressin <BR/>B: 20 µg intranasal desmopressin <BR/>C: placebo tablets<BR/>D: placebo nasal pipette<BR/>Duration of treatment: 2 weeks placebo then 2 weeks each condition</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>During treatments mean number of dry nights: A:4, B:4.1, C:2.5<BR/>2 patients totally dry while taking tablets; 1 patient totally dry while using intranasal<BR/>9 children (31%) remained totally dry<BR/>Side effects: no significant adverse effects but 2 patients complained of occasional nasal discomfort and 3 of epistaxis but no difference between placebo and active arms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Not reported if comparable groups<BR/>Washout one week between each arm<BR/>Not intention to treat<BR/>Many results only given graphically<BR/>Short follow up<BR/>No SDs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Folwell-1997_x0023_">
<CHAR_METHODS>
<P>RCT (double-blind crossover)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 31 (22 boys), small number of adults<BR/>Dropouts/not included: 6<BR/>Inclusion criteria: primary monosymptomatic enuresis, age over 6 years<BR/>Exclusion criteria: diabetes, neurological or renal disease, steroids, diuretics, daytime wetting<BR/>Previous treatment: failed on alarms, anticholinergics<BR/>Age, mean years: 11.2 (SD 5.4)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A: desmopressin 20 µg intranasal<BR/>B: placebo<BR/>21 days each, then crossed over</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean wet nights/week during trial: A: 3.24 (SE 0.45); B: 4.86 (0.35)<BR/>Side effects: A: 1 nausea; B: 1 drowsy and vomiting</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No washout period<BR/>No follow up<BR/>Groups reported to be comparable but data not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gibb-2004">
<CHAR_METHODS>
<P>RCT (drug dispensed randomly by pharmacist)</P>
<P>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: No</P>
<P>Setting: Paediatric outpatients, Children's Hospital, Melbourne, Australia<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children (boys): 207/210 (A:64, B:78)<BR/>Dropouts: 10 eligible children declined, incomplete data on A:9/101, B:17/106 but dropouts counted as failures for analysis<BR/>Inclusion criteria: Non-responders to desmopressin treatment (&lt;50% reduction in wet nights), age 6-16 years, wetting at least twice per week, some daytime wetting (A:11, B:8)<BR/>Exclusion criteria: Neuropathic bladder, urinary tract abnormality, cystic fibrosis, allergic rhinitis, UTI in previous 2 weeks, imipramine or diuretics<BR/>Previous treatment: some had alarm (A:37, B:32) or desmopressin (A:31, B:28)<BR/>Age: mean 9.4 years (SD 2.08)<BR/>Baseline wet nights in 28 days: A: 23.9 (SD 5.05), B: 23.7 (5.83)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (84/101): desmopressin (40 µg nasal spray) + alarm (pad and bell)<BR/>B (85/106): placebo (nasal spray) + alarm (pad and bell)</P>
<P>Duration of treatment: 8 weeks</P>
<P>Follow up: 2 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Cure = 28 dry nights, relapse = 2 wet nights in 2 weeks<BR/>Wet nights during treatment (number, mean (SD)): A: 101, 1.8 (1.13), B: 106, 2.4 (1.53)<BR/>Cure during treatment: A: 52/101, B: 51/106 P=0.63 (failed: A: 49/101, B: 55/106)<BR/>Relapse after treatment stopped: A: 7, B: 3<BR/>Failed or relapsed: A: 56/101, B: 58/106<BR/>Adverse effects: A: 1 (headache), B: 1 (nose bleed)<BR/>Other: compliance same in both groups<BR/>Cure in daytime wetting: A: 6/11, B: 3/8<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Intention to treat analysis<BR/>Groups comparable at baseline on age, wetting, gender, family history, secondary enuresis, daytime wetting and previous treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hamano-2000">
<CHAR_METHODS>
<P>RCT (method not given)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>Follow up 2 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 114 (88 boys)<BR/>Dropouts: 18 (not wet or poor compliance)<BR/>Inclusion criteria: primary monosymptomatic nocturnal enuresis, at least 4 times per week<BR/>Exclusion criteria: neurological or physical abnormalities, UTI<BR/>Age: 5-15 years, A: 9.2; B: 9.4<BR/>Baseline wetting (SD): A: 6.8 (0.7); B: 6.7 (0.9)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (54): DDAVP intranasally, 5 µg increasing to 20 if no response, decreasing when strongly responding<BR/>B (60): retention control training; holding voiding once a day to increase bladder capacity<BR/>Duration of treatment: 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Wet nights per week (N, mean, SD): A: 54, 6.8 (SD 0.76); B: 60, 6.7 (0.87) <BR/>Number not achieving 14 dry nights A: 33/54; B: 46/60<BR/>Relapsing after cure: A 17; B: 5<BR/>Failed or relapsing after trial: A: 50/54; B: 51/60<BR/>Side effects: adverse events infrequent: A: 2/54 (nasal discomfort); B: 0/60</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Results presented according to functional bladder capacity but merged here Short follow up<BR/>Groups comparable at baseline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hoashi-1995">
<CHAR_METHODS>
<P>RCT (randomly allocated in blocks of 4)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>Setting: Day clinics at drug company</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>No. of children (boys): 231 (167)<BR/>Dropouts: 7 not wet at baseline, 1 moved, 2 daytime wetting, 4 delayed treatment, 2 non-compliance<BR/>Inclusion: wet 10/14 nights<BR/>Exclusion: daytime wetting, organic causes, family disruption<BR/>Previous treatment: no information<BR/>Age: at least 6 years<BR/>Baseline wetting: mean 12.8 wet nights in 2 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (112): desmopressin 10 µg nasal drops + placebo tablet<BR/>B (112): imipramine tablet (25 mg) + placebo nasal drops</P>
<P>Duration of treatment: 4 weeks<BR/>Follow up: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Wet nights during treatment (N, mean, SE) <BR/>At 2 weeks: A: 111, 9.5 (SE 0.5), B: 111, 9 (0.5)<BR/>At 4 weeks: A: 109, 8.7 (SE 0.5), B: 109, 8 (0.5)<BR/>Adverse effects causing stopping: A: 0, B: 1<BR/>Other adverse effects: Oedema, headache, sleepyness, insomnia, sleep disorder, dizziness, appetite loss, nausea, vomiting, diarrhoea, abdominal pain, eyelid swelling, rash, red eyelid, nose symptoms (itchy nose, bleeding nose, blocked nose, runny nose), fever, tiredness, shaking head, thirsty, dry lips<BR/>Total number of side effects: A: 29/120, B: 29/118<BR/>Total number of children with side effects: A: 16/120, B: 16/118<BR/>Other outcomes: wetting score, side effect score, satisfaction score, overall score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Japanese language<BR/>Data measured from graphs<BR/>No follow up</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Holt-1986">
<CHAR_METHODS>
<P>RCT (method not given, double-blind) <BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 36<BR/>Inclusion criteria: 2 or more wet nights per week; age 8-12;<BR/>Exclusion criteria: day time wetting; diabetes, insipidus or other chronic illness where need daily medication; other treatment for bed wetting<BR/>Mean age (years): A:9.8, B:9.5 (range 8-12)<BR/>Baseline wetting: wet bed 2 or more times per week</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (19): imipramine 50 mg and placebo nasal spray<BR/>B (17): intranasal desmopressin 20 µg and placebo tablets<BR/>Duration of treatment: 4 weeks<BR/>Follow up: 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Results first 2 weeks of treatment: % reduction in wet nights: A:48%, B:45%<BR/>Results final 2 weeks of treatment: A:54%, B:32%<BR/>Mean (SD) number of wet nights per first 14 days: A:4.9 (4.3), B:4.8 (4.0)<BR/>Mean (SD) number of wet nights per last 14 days: A:4.5 (3.7), B:6.0 (4.4)<BR/>Mean (SD) number of wet nights per 14 days at follow up: A:7.7 (3.9), B:7.3 (4.5)<BR/>Side effects: B: rash (1)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Norwegian translation<BR/>Direct comparison of imipramine and DDAVP<BR/>Children comparable in terms of sex, age and weight<BR/>No details of previous treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Janknegt-1990_x0023_">
<CHAR_METHODS>
<P>RCT (double-blind randomised crossover of dosages with placebo between)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned<BR/>Follow up after 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 22 (18 boys)<BR/>No dropouts<BR/>Inclusion criteria: maximum of 4 dry nights a week during baseline<BR/>Mean age: 10 years (range 6-16)<BR/>Previous treatment: all used imipramine or other medications, or enuresis alarm (8), acupuncture (1), and psychotherapy (1)<BR/>More than one method used with many patients<BR/>Baseline wetting: mean (SD) number of dry nights per week: 1.3 (1.3)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A: Placebo nasal pipette<BR/>B: 20 µg desmopressin intranasally<BR/>C: 40 µg desmopressin intranasally<BR/>Duration of treatment: 1 month each condition</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean (SD) number of dry nights per week: A:1.7 (1.8), B:3.6 (2.5), C:3.2 (2.2)<BR/>At follow up mean (SD) number of dry nights per week: 2.2 (1.8)<BR/>Morning urine osmolality not significantly different in pre-treatment or treatment periods<BR/>Significant increase in body weight<BR/>No significant changes in blood pressure, haematology or blood chemistry <BR/>Side effects: most common adverse reactions were headaches (3) and stomach ache (3) (though no different from placebo)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Janknegt-1997">
<CHAR_METHODS>
<P>RCT (double blind multi-centre trial, method not given) <BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>12 week open label follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 65 (boys: A:18, B:19)<BR/>3 dropouts<BR/>Exclusion criteria: diurnal wetting; other medical conditions; urological causes of wetting<BR/>Mean age: 19.4 years (range 12-45)<BR/>At least 6 wet nights in 2 weeks at baseline<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (34): desmopressin tablets 200 µg<BR/>B (31): desmopressin tablets 400 µg<BR/>Duration of treatment: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean change from baseline wetting (wet nights per week 95% CI) A:-3.2 (-2.4, -4.1), B:-3.4 (-2.7, -4.1)<BR/>Side effects: not mentioned</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Only DDAVP responders<BR/>Mixed age group (some adults)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kahan-1998">
<CHAR_METHODS>
<P>RCT (double-blind, method not specified)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned<BR/>Follow up for 2 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 228<BR/>Dropouts: A 6, B 1; due to difficulty complying with schedule of behavioural therapy<BR/>Inclusion criteria: primary nocturnal enuresis at least 2 times per week, age &gt;7 years<BR/>Exclusion criteria: previous treatment, other physical disorders, previous traumatic life events, psychiatric disorders, abnormal laboratory findings<BR/>Baseline differences in wetting between groups: A 5.1 (SD 2.1); B 5.5 (1.8); C 5.8 (1.6): P=0.044</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (70): desmopressin and behaviour therapy<BR/>B (75): placebo and behaviour therapy<BR/>C (76): desmopressin alone (20 µg intranasal)<BR/>Duration 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Wet nights at end of trial (N, mean, SD): A: 70, 3.0 (2.0); B: 75, 3.3 (2.2); C: 76, 4.5 (2.0)<BR/>Number not achieving 14 dry nights: A: 48/70; B: 63/75; C: 45/76<BR/>Number failing or relapsing: A: 66/70; B: 69/75; 73/76<BR/>Wet nights after end of trial (N, mean, SD): A: 70, 2.6 (1.7); B: 74, 3.0 (2.0); C: 76, 4.7 (1.8)<BR/>Side effects: nasal itch: A 5, B 1, C 4<BR/>7 dropouts due to problems with behavioural treatment schedule</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Power calculation given<BR/>Behaviour treatment = psychological (teaching self control, taking responsibility), bladder continence exercises, giving information about the mechanisms of wetting<BR/>Blinding of treatment not possible due to differences in interventions (but placebo and DDAVP blinded)<BR/>Group A had less wetting at baseline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kjoller-1984">
<CHAR_METHODS>
<P>RCT (double-blind)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned<BR/>Follow up after 3 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 37<BR/>Dropouts from follow up: A:3, B:2<BR/>Inclusion criteria: normal, healthy children who had failed with previous treatment, informed consent, more than 25% wet nights during baseline<BR/>Previous treatment: all failed treatment with tricyclic antidepressants and/or enuresis alarm<BR/>Mean age: 11.0 years (range 9-15)<BR/>Baseline wetting: mean (SD) number of wet nights per 100: A:56.6 (8.0), B:65.9 (7.5), C:64.7 (7.3)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (13): 10 µg DDAVP intranasally before bedtime<BR/>B (12): 20 µg DDAVP intranasally before bedtime<BR/>C (12): placebo<BR/>Duration of treatment: 1 month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of wet nights per 100 (mean, SD): A:35.5 (10), B:35.0 (7.6), C:54.8 (8.8)<BR/>Follow up: mean (SD) number of wet nights per 100: A:60.9 (11.4), B:60.0 (8.5), C:52.3 (8.9)<BR/>Side effects: none reported<BR/>DDAVP ineffective when participants had respiratory tract infections</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Not reported if the groups were comparable <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-10 13:38:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2005">
<CHAR_METHODS>
<P>RCT (randomly assigned to 1 of 3 groups)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: 53% also had daytime wetting but results available separately<BR/>Setting: 2 hospitals, 2003 to 2004<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children (boys): 145 (100)<BR/>Monosymptomatic enuresis (Trial 1): 68<BR/>Polysymptomatic (+ daytime wetting, Trial 2): 77<BR/>Dropouts: 13 (drug side effects or outcome unknown: A: 3, B: 3, C: 7)<BR/>Inclusion criteria: at least 3 wet nights/week<BR/>Exclusion criteria: drug treatment in 14 days prior to start of study<BR/>Age: 7.8 years (SD 2.5) (range 5 to 15)<BR/>Baseline wetting: 6.36x/week (SD 1.5)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-10 13:38:31 +0100" MODIFIED_BY="[Empty name]">
<P>Trial 1 (monosymptomatic enuresis)<BR/>A (22): desmopressin 0.1 or 0.2 mg, oxybutynin 5 mg<BR/>B (23): desmopressin0.2 mg increased to 0.4 mg if no response<BR/>C (23): imipramine 25 mg<BR/>Given orally before bedtime<BR/>Duration of treatment: 6 months<BR/>Follow up: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Trial 1<BR/>Wet nights at 6 months, N mean (SD): A: 22, 0.93 (1.35), B: 23, 0.7 (0.95), C: 23, 2.0 (2.05)<BR/>No. children cured (excellent response = 0-1 wet night per month): A: 14/22, B: 14/23, C: 3/23<BR/>No. children failed (not excellent): A: 8/22, B: 9/23, C: 20/23<BR/>Trial 2<BR/>Wet nights at 6 months, N mean (SD): A: 26, 1.2 (1.55), B: 26, 1.23 (0.88), C: 25, 2.63 (2)<BR/>No. children cured (excellent response = 0-1 wet night per month): A: 9/26, B: 7/26, C: 3/25<BR/>No. children failed (not excellent): A: 17/26, B: 19/26, C: 22/25<BR/>Adverse effects (both trials, including dropouts): A: 0/51, B: 2/52, C: 22/55</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data obtained from author enabling results to be given separately for nocturia and daytime wetting groups<BR/>Groups comparable at baseline on age, sex, disease type, baseline wetting<BR/>Higher side effect and drop out rate in imipramine group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-10 13:38:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leebeek-2001">
<CHAR_METHODS>
<P>RCT (double blind parallel group study)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>Follow up at 2 weeks and 6 months after end of trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children (boys): 93 (62)<BR/>Inclusion criteria: at least 6 wet nights per week<BR/>Exclusion criteria: treatment in previous 2 weeks; daytime wetting/ pollakisuria; urological or psychological disease; poor motivation to use alarm<BR/>Previous treatment: none in previous 2 weeks <BR/>Age: 6-14 years<BR/>Baseline wetting: mean number of wet nights: A: 6.14, B: 6.12 (NS)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (47): alarm and desmopressin 40 µg intranasal for 3 weeks, then alarm and desmopressin 20 µg for 3 weeks, then alarm alone for 3 weeks<BR/>B (46): alarm and placebo for 6 weeks, then alarm alone for 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-10 13:38:33 +0100" MODIFIED_BY="[Empty name]">
<P>Wet nights (number, mean):<BR/>First 3 weeks: A: 47, 2.93, B: 45, 3.86 (P=0.014)<BR/>Last 3 weeks, alarm only: A: 43, 2.77, B: 39, 2.21<BR/>Number cured 2 weeks after end of trial: A: 15/47, B: 17/46<BR/>Number cured 6 months after end of trial: A: 17/47, B: 17/46<BR/>i.e. failed at 6 months: A: 20/47, B: 21/46<BR/>Wet nights at 6 months (number, mean): A: 41, 2.72, B: 37, 1.90<BR/>Adverse events: none in either group<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Power calculation provided<BR/>Groups comparable for sex and age<BR/>SDs not given (authors contacted for more information)<BR/>Study supported by drug company (Ferring Pharmaceuticals A/S Ferring)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Longstaffe-2000">
<CHAR_METHODS>
<P>RCT (computer generated randomisation)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>Setting: Recruited from hospital clinic and advertising<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 182<BR/>At 6 months 17 withdrew due to failure (A 8; B 5; C 4)<BR/>Inclusion criteria: primary monosymptomatic nocturnal enuresis, age &gt;7 years, wet &gt;3 times per week, normal bladder capacity<BR/>Exclusion criteria: daytime wetting, CNS disorder, developmental delay, current alarm or DDAVP treatment, encopresis, other medical problems<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (61): alarm<BR/>B (60): desmopressin intranasally <BR/>C (61): placebo<BR/>Duration 6 months, then failures crossed over to alternative arm for 6 months (not randomised)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number not achieving 14 dry nights after 6 months: A: 26/61; B: 31/60; C: 38/61<BR/>All children improved psychologically, e.g. behaviour and self concept, regardless of outcome or treatment assignment<BR/>Side effects: not mentioned</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dose of DDAVP not given<BR/>No follow up as failures assigned to alternative treatment<BR/>Blinding to method not possible for alarm group<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Martin-1993">
<CHAR_METHODS>
<P>RCT (double-blind randomised placebo controlled)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: No<BR/>Only 7 DDAVP successes followed up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 44<BR/>Boys: A:54%, B:41%<BR/>Mean age (year): A:8.9, B:9.13<BR/>Previous treatment: all children had failed to improve during 1 month treatment with motivational therapy and bladder training<BR/>Baseline wetting: mean (SD) % of dry nights per month: A:24.45 (18.8), B:19.9 (20)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (22): placebo<BR/>B (22): 40 µg desmopressin drops 15 minutes before retiring<BR/>Duration of treatment: 2 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean (SD) % of dry nights per month after 2 months: A:47.4 (32.1), B:69.2 (33.5)<BR/>Number (%) of children becoming totally dry: A:1 (5), B:5 (27)<BR/>Side effects: anorexia (1)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Groups similar at baseline<BR/>No follow up<BR/>Very small sample<BR/>Unclear about dropouts<BR/>Inclusion/ exclusion criteria not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Miller-1990a">
<CHAR_METHODS>
<P>RCT (multi-centre, double-blind) Trial A = Centre 1<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned<BR/>No significant differences between groups except that more older children in group (A) in one centre<BR/>4 weeks open label phase then 2 week no treatment<BR/>Number at 2 week follow up: 1A:19, 1B:26, 1C:16</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 99 (70% boys) <BR/>4 dropouts<BR/>Inclusion criteria: children aged 7-14 with nocturnal enuresis; informed consent from parents; 10 or more wet nights per fortnight; no organic urologic disorders; no urinary tract infection; no abnormal urine osmolality<BR/>Previous treatment: 58% taken other drugs; 87% imipramine; 40% tried other measures of these, 76% tried enuresis alarm<BR/>Age range 7-14 (46% aged 7-8)<BR/>Baseline wetting: mean number of wet nights in 14: 1A:12.3, 1B:11.8, 1C:12.3</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1A (32): 20 µg desmopressin acetate intranasally at bedtime<BR/>1B (36): 40 µg desmopressin acetate intranasally at bedtime<BR/>1C (31): placebo<BR/>Duration of treatment: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean number of wet nights in final 14 days: 1A:8.7, 1B:7.0, 1C:10.7<BR/>Active treatment significantly different to placebo <BR/>2 week follow up: mean number of wet nights per 14: 1A:11.1, 1B:11.0, 1C:9.9<BR/>Side effects: no serious adverse events (6 minor)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No intention to treat<BR/>Short follow up<BR/>Statistics suggest sample size too small for conclusive findings<BR/>No SDs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Miller-1990b">
<CHAR_METHODS>
<P>RCT (multi-centre, double-blind) Trial B = Centre 2<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned<BR/>No significant differences between groups except that more older children in group (A) in one centre<BR/>4 weeks open label phase then 2 week no treatment<BR/>Number at 2 week follow up: 2A:19, 2B:20, 2C:20</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 77 (70% boys) <BR/>4 dropouts<BR/>Inclusion criteria: children aged 7-14 with nocturnal enuresis; informed consent from parents; 10 or more wet nights per fortnight; no organic urologic disorders; no urinary tract infection; no abnormal urine osmolality<BR/>Previous treatment: 58% taken other drugs; 87% imipramine; 40% tried other measures of these, 76% tried enuresis alarm<BR/>Age range 7-14 (46% aged 7-8)<BR/>Baseline wetting: mean number of wet nights in 14: 2A:12.6, 2B:12.3, 2C:12.4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2A (27): 20 µg desmopressin acetate intranasally at bedtime<BR/>2B (24): 40 µg desmopressin acetate intranasally at bedtime<BR/>2C (26): placebo<BR/>Duration of treatment: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean number of wet nights in final 14 days: 2A:10.0, 2B:8.1, 2C:10.5<BR/>Active treatment significantly better than placebo except A versus C not significant<BR/>2 week follow up: mean number of wet nights per 14: 2A:10.8, 2B:11.4, 2C:11.3<BR/>Side effects: no serious adverse events (11 minor)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No intention to treat<BR/>Short follow up<BR/>Statistics suggest sample size too small for conclusive findings<BR/>No SDs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Muller-2001_x0023_">
<CHAR_METHODS>
<P>RCT (double blind crossover, initial assignment of groups 'created at random')<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children (boys): 40 (29)<BR/>Inclusion criteria: at least 3 wet nights per week, primary nocturnal enuresis<BR/>Exclusion criteria: anatomical abnormalities, abnormal serum or urine analysis<BR/>Previous treatment: none<BR/>Baseline wetting: mean wet nights 5.35 (median 5.5, 95% CI 4.5-6)<BR/>Age (mean, median, range): A: 8.7, 8.9 (6-13); B: 8.6, 8 (6.3-11.9)<BR/>Recruited from Children's Hospital, University of Kiel, Germany</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (19): 20 µg desmopressin intranasally first 2 weeks<BR/>B (21): 0.9% saline first 2 weeks<BR/>Duration of treatment: crossed over after 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of wet nights during trial, mean (median, 95% CI): A: 3.27 (3, 2 to 4); B: 4.9 (5.25, 4.5 to 6): (P&lt;0.001)<BR/>Responders to desmopressin (undefined): 27/40 children (67.5%). Data not provided for placebo treatment<BR/>Reaction time: no difference between the groups<BR/>Short-term memory: better on desmopressin, more words remembered, P=0.012<BR/>Children slept more deeply on desmopressin (14/18) than placebo (4/18), P=0.03<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No useable data<BR/>Groups comparable at baseline on gender, age, weight and height<BR/>SDs not given (authors contacted for more infomation but not supplied)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Natochin-2000">
<CHAR_METHODS>
<P>CCT (randomisation using case record numbers)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>Setting: St Petersburg State Medical Academy, Russia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 62 (43 boys) plus 22 (15) on placebo<BR/>Inclusion criteria: primary nocturnal enuresis<BR/>Exclusion criteria: other medication, daytime wetting, other disease<BR/>Age: range 6-15 years (mean 9.8 +/- SD 7)<BR/>Baseline wetting: at least 6 wet nights per 2 weeks<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (32): desmopressin 10.5 - 24.5 µg intranasally<BR/>B (30): diclofenac tablet 1 mg/kg body mass<BR/>C (22): placebo (intranasally) for 2 weeks then given desmopressin<BR/>Duration of treatment: A and B 4 weeks each, C (placebo) 2 weeks only<BR/>Follow up: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number not achieving 14 dry nights: A: 11/32; B: 20/30; C: 21/22<BR/>Side effects: none reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Extra information supplied by authors (method of randomisation, results confirmed, no side effects)<BR/>Parallel groups<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Neveus-1999_x0023_">
<CHAR_METHODS>
<P>RCT (double blind crossover)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 33 (30 boys)<BR/>Dropouts: 2 extra withdrew<BR/>Inclusion criteria: primary monosymptomatic nocturnal enuresis<BR/>Previous treatment: resistant to 0.4 mg desmopressin<BR/>Age: range 6-16 years, mean 10.4<BR/>Baseline wetting: at least 6 wet nights without treatment, mean 11.4 in 2 weeks<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (33): 0.4 mg desmopressin orally<BR/>B (33): 0.8 mg desmopressin orally<BR/>C (33): placebo<BR/>Duration: 5 nights each</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number not achieving 14 dry nights: A: 30/33; B: 27/33; C: 32/33<BR/>Side effects: not mentioned</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Washout period of 48 hours between each phase<BR/>No follow up as all children treated after end of trial with high dose desmopressin or combined desmopressin and anticholinergics<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-10 13:38:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ng-2005">
<CHAR_METHODS>
<P>RCT 'randomly allocated' by consecutive sealed envelopes<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children 105<BR/>Dropouts: 12 (defaulted from treatment: A7, B2, C3; defaulted from follow up A2, B2, C5)<BR/>Inclusion: primary nocturnal enuresis<BR/>Exclusion: UTI in previous 3 months, daytime wetting, polyuric disorders, abnormal urinalysis, renal disease, previous diuretics, unwilling to be randomised<BR/>Previous treatment: none (excluded if had desmopressin, alarms or tricyclics)<BR/>Age: range 7-12 years<BR/>Baseline wetting: at least 3 wet nights in baseline 2 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (35): alarm only ('Wet-Stop' alarm) <BR/>B (38): oral desmopressing 200 µg, increased to 400 µg if &gt; 1 wet night<BR/>C (32): both treatments <BR/>Duration of treatment: 12 weeks<BR/>Follow up: 12 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Wet nights during trial (N, mean (SD)): A: 28, 2.8 (2.2), B: 36, 2.6 (2.4), C: 29, 1.3 (1.9)<BR/>Not achieving 14 dry nights: A: 27/35, B: 22/38, C: 12/32 (ITT, dropouts = failure)<BR/>Wet nights after trial (N, mean (SD)): A: 24, 2.5 (2.4), B: 34, 3.4 (2.5), C: 24, 2.6 (2.7)<BR/>Not achieving 14 dry nights or relapsing after: A: 35/35, B: 30/38, C: 19/32 (ITT, dropouts = failure)<BR/>Adverse effects: none<BR/>All children who responded completely to the alarm stayed dry afterwards <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-10 13:38:38 +0100" MODIFIED_BY="[Empty name]">
<P>All children had star charts and kept wetting diaries<BR/>Comparable at baseline on wetting frequency, age, gender, urine osmolality<BR/>More children failed to comply in Group A (alarm only), these were included as failures in the dry night analyses<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Post-1983a_x0023_">
<CHAR_METHODS>
<P>RCT (Trial 1 = multi-centre double-blind randomised crossover trial)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned<BR/>Follow up after 1-3 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Trial 1: Number of children: 52<BR/>(40 boys)<BR/>Inclusion criteria: healthy children age 6-16; history of severe primary or secondary enuresis<BR/>Exclusion criteria: organic causes<BR/>Previous treatment: 18 had previous pharmacologic treatment; 3 had undergone urethral dilation procedures and 16 subjects had been involved in an identical study of lower dose (20 µg) of desmopressin<BR/>Mean age (years): 9.0 <BR/>Baseline wetting: mean (SEM) number of dry nights: 2.52 (0.28)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1A: 40 µg desmopressin intranasally at bedtime<BR/>1B: placebo<BR/>Drinking prohibited until the next morning<BR/>Duration of treatment: 2 weeks each arm<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Trial 1<BR/>Mean (SEM) number of dry nights per 14: A:6.23 (0.65), B:4.00 (0.53)<BR/>No significant order effects<BR/>Post treatment results: mean number of dry nights per 14: 3.44 (0.50)<BR/>Only 4 of 21 responders reported persistent effect<BR/>During longer term study of 9 patients at Syracuse, the mean number of dry nights while taking desmopressin: 5.11 (1.31) was the same as that during the 2 week period: 5.11 (1.59)<BR/>Side effects: not mentioned</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Not stated if comparable groups<BR/>No washout<BR/>No details of dropouts - unclear if intention to treat<BR/>Results from 3 centres combined because no significant difference in mean number of wet nights during active treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Post-1983b_x0023_">
<CHAR_METHODS>
<P>RCT (Trial 2 = multi-centre double-blind randomised crossover trial)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned<BR/>Follow up after 1-3 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Trial 2: Number of children: 20 (15 boys)<BR/>Inclusion criteria: healthy children age 6-16; history of severe primary or secondary enuresis<BR/>Exclusion criteria: organic causes<BR/>Previous treatment: 18 had previous pharmacologic treatment; 3 had undergone urethral dilation procedures and 16 children had been involved in an identical study of lower dose (20 µg) of desmopressin<BR/>Mean age: 8.9 years<BR/>Baseline wetting: mean (SEM) number of dry nights: 1.90 (0.43)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2A: 20 µg desmopressin intranasally at 8 pm each night<BR/>2B: placebo<BR/>Drinking prohibited until the next morning<BR/>Duration of treatment: 2 weeks each arm</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Trial 2<BR/>Mean (SEM) number of dry nights per 14: A:4.25 (0.88), B:2.35 (0.51)<BR/>Post treatment mean (SEM) number of dry nights per 14: 4.00 (0.66)<BR/>Comparing the results of 16 children who had both low and high dose (Trial 1), they did better on high dose - mean paired increase (SEM): 2.18 (0.90), t=2.44 P=0.05. 6 children had increase of 3 or more dry nights while on higher dose<BR/>Side effects: not mentioned</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Not stated if comparable groups<BR/>No washout<BR/>No details of dropouts - unclear if intention to treat<BR/>Results from 3 centres combined because no significant difference in mean number of wet nights during active treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Radmayr-2001">
<CHAR_METHODS>
<P>RCT (details not given)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: No apart from UTI<BR/>Daytime wetting excluded: Yes<BR/>Setting: Recruitment from Department of Urology and Anaesthesiology, Austria<BR/>Follow up 6 months after end of trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children (boys): 40 (31)<BR/>Inclusion criteria: primary monosymptomatic nocturnal enuresis, high night-time urine production (polyuria), age &gt;5 years<BR/>Exclusion criteria: UTI<BR/>Previous treatment: none<BR/>Age mean (range): A: 8.6 (5-16), B: 8 (5-14)<BR/>Baseline wetting 5.5 wet nights per week; mean (range): A: 5.5 (2-7), B: 6 (4-7)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (20): desmopressin, intranasal, 20 µg increasing to 40 µg if no response (12/20 children)<BR/>B (20): laser acupuncture, see Notes<BR/>Duration of treatment: 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response = decrease of 90% wet nights; partial response = decrease of 50%; failed = less than 50% decrease<BR/>Non-response at end of trial: A: 3/20, B: 2/20<BR/>Partial response: A: 1/20, B: 4/20<BR/>Non-response at 6 months after end of trial: A: 3/20, B: 5/20 (counting 1 who did not finish acupuncture course as a failure) <BR/>Partial response at 6 months: A:2/20, B:2/20<BR/>Adverse events: none in either group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Laser acupuncture described and illustrated, soft laser stimulation for 30 of several pre-defined acupuncture areas, 3 visits per week, minimum 10, maximum 15 visits</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rittig-1988_x0023_">
<CHAR_METHODS>
<P>RCT (double-blind randomised crossover) Placebo period of 3 weeks randomly and blindly placed throughout treatment period<BR/>Only patients who responded in dose titration period entered into randomised trial<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>6 non-responders were not entered into crossover trial (all children, 4 girls and 2 boys)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 34 (12 boys, 11 girls, 8 women and 3 men)<BR/>Previous treatment: all failed previous treatments including alarms and/or tricyclics<BR/>Age (years): children mean: 13 (range 8-17); adults mean: 25 (range 18-45)<BR/>Baseline wetting: at least 3 wet nights per week</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dose titration period then:<BR/>A: optimum dose of desmopressin intranasally<BR/>B: placebo (3 weeks blindly inserted into 24 week period)<BR/>Duration of treatment: 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean number of dry nights per week: A:7, B:4<BR/>Side effects: headache (2); sight disturbance (1)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Some adults<BR/>Only patients who responded to desmopressin included<BR/>Children and adults analysed together<BR/>Placebo period not equal to active drug period<BR/>No washout period<BR/>No SDs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rodriguez-2001">
<CHAR_METHODS>
<P>RCT (method not specified)<BR/>Systematic baseline measure of wetting: No<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 84 (80% boys)<BR/>3 dropouts after 3 months<BR/>Inclusion criteria: wetting at least 1 time per week, age &gt;7 years<BR/>Exclusion criteria: diurnal enuresis, encopresis, neurological abnormalities<BR/>Previous treatment: 38% of children <BR/>Age range 7-14 years<BR/>Hospital clinic, Spain</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (30): bed alarm<BR/>B (29): alarm and desmopressin 20 µg or 40 µg for more frequent wetters (&gt;2 times per week)<BR/>Duration 4-6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response: A: 73.3%; B: 58.6%<BR/>[=number not achieving 14 dry nights: A: 8/30; B: 12/29]<BR/>All children treated with desmopressin if not cured at 6 months, therefore follow up not possible<BR/>Side effects: not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Spanish language<BR/>No follow up possible<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rushton-1995">
<CHAR_METHODS>
<P>RCT (double-blind multi-institutional) Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>Follow up after 5 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 96 (71 boys)<BR/>No dropouts reported<BR/>Inclusion criteria: confirmed monosymptomatic nocturnal enuresis; wet 6+ nights during 14 day baseline; no organic urological disease; no daytime wetting; no central diabetes insipidus; no urinary tract infection in previous 18 months; no use of any drug that could affect urine concentration; no medical treatment for hyperactivity or attention deficit disorder; no history of acute or perennial rhinitis, rhinorrhoea or nasal polyps; no clinically significant medical disease that may interfere with the study<BR/>Mean age: 9.7 years (range 7-14)<BR/>Severity: mean number of wet nights during 2 week baseline: A:11.16 (2.44), B:10.96 (2.53)<BR/>No significant difference between the groups in demographics<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (49): 20 µg desmopressin spray, dose doubled if not completely dry after 14 days<BR/>B (47): placebo as above<BR/>Duration of treatment: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean number of wet nights (SD)<BR/>Period 1 (20 µg): A:7.91 (4.74), B:9.79 (3.28)<BR/>Period 2 (40 µg): A:7.54 (5.04), B:9.79 (3.63)<BR/>Side effects: none reported<BR/>No meaningful differences between responders and non-responders with regard to demographic variables of age, gender, race or family history</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No follow up results<BR/>No details of previous treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schulman-2001a">
<CHAR_METHODS>
<P>RCT (double-blind placebo controlled multi-centre parallel group design)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>Follow up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children (boys): 193 (133)<BR/>Dropouts: 6, due to non-compliance, consent withdrawn, failure to keep diary<BR/>Inclusion criteria: at least 3 wet nights per week, informed consent<BR/>Exclusion criteria: organic urological disease; daytime wetting; diabetes insipidus; UTI; known hypersensitivity to desmopressin; antibiotics, diuretics; hyperactivity<BR/>Previous treatment: none in previous 30 days<BR/>Age range 6-16 years<BR/>Baseline wetting (mean in 2 weeks, range): A: 11 (5-14), B: 10 (4-14), C: 10 (6-14), D: 10 (6-14)<BR/>Multicentre trial in 16 centres in USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (46): desmopressin 0.2 mg oral<BR/>B (49): desmopressin 0.4 mg<BR/>C (50): desmopressin 0.6 mg<BR/>D (48): matching placebo<BR/>Treatment for 2 weeks, then 2-week placebo washout before being randomly assigned to second trial</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean wet nights during 2 weeks treatment: A: 4 (SD 1.33), B: 3.5 (1.73), C: 3 (1.73), D: 4.5 (1.37)<BR/>Number not achieving 14 dry nights during trial: A: 42/44, B: 42/48, C: 46/49, D: 47/47<BR/>Number improved during trial: A: 4, B: 9, C: 9, D: 3<BR/>Adverse events (1 or more per child): 43/143 on desmopressin, 13/48 on placebo. <BR/>Headache, increased cough, and abdominal pain, all mild (81% desmopressin, 62% placebo) or otherwise moderate, all resolved before end of study and were mostly unrelated to treatment (79% desmopressin, 77% placebo)<BR/>No child stopped trial because of side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>First trial, dose ranging phase<BR/>Fluid restriction 2 hours before bedtime<BR/>Groups comparable at baseline<BR/>Dropouts comparable from all groups<BR/>No SDs - authors contacted for more information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schulman-2001b">
<CHAR_METHODS>
<P>RCT (double-blind placebo controlled multi-centre parallel group design)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>Follow up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children from Trial 1 were eligible to be randomised again if they continued to have at least 3 wet nights per week during the placebo washout phase (31 children withdrew at this stage, 1 due to UTI)<BR/>Dropouts: 11</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>E (110): desmopressin 0.2 mg increased every 2 weeks if no response to max 0.6 mg<BR/>F (38): matching placebo, tablets changed every 2 weeks if no response</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of children requiring maximum increase in dose by 8 weeks: E: 86/99, F: 38/38<BR/>Improvement (50% reduction from baseline level of wetting): E: 51/99 [28 at 0.2 mg; 16 at 0.4 mg; 8 at 6 mg]: F: 7/35<BR/>First 2 weeks, desmopressin dose = 0.2 mg, mean wet nights in 1 week: E: n=109, mean=4 (SD 1.57), F: 38, 5 (1.54)<BR/>Last 2 weeks, dose increased up to 0.6 mg: E: 99, 3.2 (1.69), F: 36, 4.5 (1.5)<BR/>Adverse events (1 or more per child): 43/143 on desmopressin, 13/48 on placebo.<BR/>Rhinitis, pharyngitis, infection, headache and fever, all mild (79% desmopressin, 92% placebo) or otherwise moderate, all resolved before end of study and were mostly unrelated to treatment (80% desmopressin, 83% placebo)<BR/>1 child on desmopressin and 1 on placebo stopped trial because of nervousness</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Second trial, dose titration phase<BR/>Fluid restriction 2 hours before bedtime<BR/>Authors contacted for more information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Segni-1982">
<CHAR_METHODS>
<P>RCT<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned<BR/>Dropouts included in analysis<BR/>Followed up after 1 week</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 40 (boys: A:14, B:10)<BR/>Dropouts: A:0, B:12<BR/>Inclusion criteria: age 4-15 years; constant enuresis; no physical deformity or neurological damage<BR/>Age 4-15 years with persistent enuresis, mean = 8.59 years<BR/>Baseline wetting: A:5.2, B:4.6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (20): 20 to 30 µg desmopressin intranasally<BR/>B (20): placebo<BR/>Duration of treatment: 1 week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>From graph: mean number of wet nights per week (SEM): A:2.2 (0.3), B:4.2 (0.4)<BR/>No cases of total dryness<BR/>Side effects: none reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Italian language<BR/>Not reported if comparable groups<BR/>Comparison with placebo for 1 week only<BR/>Results taken from graph<BR/>Follow up for 1 week only<BR/>No details of previous treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sener-1998">
<CHAR_METHODS>
<P>RCT (method not specified)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 85<BR/>Inclusion criteria: primary enuresis, age &gt;5 years<BR/>Exclusion criteria: enuresis treatment, other disease symptoms<BR/>Age: mean 8 years, range 6-15 <BR/>Baseline wetting at least 3 wet nights/week<BR/>Dry nights in 2 weeks: A: 1.5 (SE 0.3); B: 1.5 (0.4); C: 1.1 (0.3)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (31): desmopressin 20 µg, intranasally<BR/>B (29): indomethacin 100 mg/day, suppository<BR/>C (25): placebo<BR/>Duration of treatment: 4 weeks<BR/>Follow up: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>DRY nights/2 weeks (number, mean, SE) on treatment: A: 31, 11.8 (0.5); B: 29, 8.9 (0.8); C: 25, 3.8 (0.8)<BR/>[= WET nights per week, number, mean, SD: A: 31, 1.1 (SD 1.39); B: 29, 2.55 (2.15); C: 25, 5.1 (2)]<BR/>Side effects: none reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Parallel groups<BR/>Blinding not possible due to different routes of administration<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Skoog-1997">
<CHAR_METHODS>
<P>RCT (parallel group trial)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 147 (112 boys)<BR/>6 extra had no outcome data, 12/147 discontinued trial<BR/>Inclusion criteria: Primary nocturnal enuresis<BR/>Exclusion criteria: Organic urological disease, daytime wetting, diabetes insipidus, UTI, previous non-response to desmopressin<BR/>Age: means 9.1 to 9.5 years, range 5-17 <BR/>Baseline wetting at least 3 wet nights/week for 2 weeks<BR/>14 centres in USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (37): 200 µg desmopressin orally <BR/>B (35): 400 µg desmopressin<BR/>C (37): 600 µg desmopressin<BR/>D (38): placebo (double blind)<BR/>Duration 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Wet nights during last 2 weeks of trial (number, mean, SD): A: 33, 4 (SD 1.15), B: 33, 3.5 (1.44), C: 33, 3.5 (1.15), D: 36, 5 (1.2) <BR/>Number not achieving 14 dry nights: A: 32/33, B: 29/33, C: 31/33, D: 36/36 <BR/>Side effects: 66 children on desmopressin and 21 on placebo had at least one adverse event (rhinitis, headache, pharyngitis, infection, cough) 92% were mild, 87% were unrelated to treatment, 89% resolved spontaneously. 3 serious events with desmopressin (2 vomiting, 1 atopic dermatitis) required treatment to stop</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dropouts and reasons clearly described<BR/>No follow up<BR/>Parallel group study (not crossover)<BR/>Number of wet nights calculated from decrease from baseline, using SE at baseline as proxy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stenberg-1994_x0023_">
<CHAR_METHODS>
<P>RCT (double blind crossover)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 10<BR/>Inclusion criteria: adolescents (puberty stage at least 2, at least 12 years) <BR/>Exclusion criteria: treatment in previous 2 weeks, daytime wetting, UTI, urinary tract abnormalities <BR/>Previous treatment: failed using alarms, desmopressin, other drugs<BR/>Age range 11-21, median 13 years<BR/>Baseline wetting 4.7 (SD 1.1) wet nights/week<BR/>Department of Paediatric Surgery, Sweden</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A : desmopressin orally (dosage based on titration period)<BR/>B : placebo<BR/>Duration 4 weeks each<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Wet nights during trial (number, mean, SD): A: 10, 1.8 (SD 1.4); B: 10, 4.1 (1.5)<BR/>Side effects: headache (5); abdominal pain (6); nausea and vertigo (1)<BR/>All resolved while treatment continued</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No washout period<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sukhai-1989_x0023_">
<CHAR_METHODS>
<P>RCT (double blind randomised crossover with 2 weeks washout)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>Follow up: 4 weeks to 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 28 (21 boys)<BR/>Inclusion criteria: Normal urine concentration capacity of 800 milliosmol/kg or higher; 3 or more wet nights per week during observation period; informed parental consent; no urological or renal disorder; no history of daytime wetting; no chronic urinary tract infection; no neurological or cardiovascular disease<BR/>Previous treatment: 19 had previous attempts at treatment, including alarm (n=9) and tricyclic antidepressants (n=10)<BR/>Age: mean 11 years (range 7 to 16) xx Severity at baseline: mean (SEM) number of dry nights per week = 1.4 (0.3)<BR/>No dropouts</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A: enuresis alarm and bedtime dose of 20 µg DDAVP intranasally<BR/>B: enuresis alarm and bedtime dose of placebo<BR/>Duration of treatment: 2 weeks in each condition<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean (SE) dry nights during treatment: A: 5.1 (0.4) B: 4.1 (0.4) <BR/>6 week follow up: 14 dry, 5 relapsed<BR/>4.5 month follow up: 9 remained dry<BR/>Side effects: none reported<BR/>Mean urine osmolality significantly increased from baseline<BR/>Significantly higher urine osmolality with DDAVP than placebo<BR/>Steady significant increase in body weight</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Very good study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-10 13:38:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Terho-1984_x0023_">
<CHAR_METHODS>
<P>RCT (double-blind, randomised crossover 2 periods of DDAVP and 2 periods on placebo, each period lasting 3 weeks and mutual order of all 4 periods being selected randomly)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>Follow up after 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-10 13:38:40 +0100" MODIFIED_BY="[Empty name]">
<P>Number of children: 54 but 5 children excluded<BR/>Exclusion criteria: faecal soiling; voiding difficulties; obvious neurological abnormalities; diurnal wetting<BR/>Previous treatment: 49 had awakening protocol: 46 had water deprivation; 43 had tricyclic antidepressants; 13 had psychological counselling; 2 had alarm device and 1 had no previous treatment<BR/>Age range: 7-16 years<BR/>Baseline wetting: no details</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A: 20 µg DDAVP intranasal drops<BR/>B: placebo<BR/>Duration of treatment: 2 periods of 3 weeks in each condition</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean % (SD) number of wet nights during combined periods: A:30.9 (28.7), B:57.5 (26.1)<BR/>Only 1 child remained dry during follow up period<BR/>Side effects: none reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Not reported if comparable groups<BR/>No washout<BR/>Unclear if intention to treat<BR/>Baseline and follow up results lumped together<BR/>5 children excluded because of error in medication<BR/>Short follow up</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Terho-1991_x0023_">
<CHAR_METHODS>
<P>RCT (double-blind randomised crossover) Children allocated to 2 periods of desmopressin and 2 periods of placebo. Each period lasted for 3 weeks and mutual order of all 4 periods selected at random. Closed by 3 week observation period<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>Follow up after 3 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 52 (35 boys), no dropouts<BR/>Inclusion criteria: lifelong nocturnal enuresis; no diurnal wetting; no soiling; no urological or renal pathological conditions<BR/>Previous treatment: 52 had night awakening; 52 had fluid restriction; 29 had used tricyclic antidepressants; 25 had used enuresis alarms<BR/>Age range: 5-13 years <BR/>Baseline wetting: mean (SD) number of dry nights per week: 0.6 (0.2)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A: intranasal desmopressin (20 µg) at bedtime rising to 40 µg if no response<BR/>B: placebo<BR/>Duration of treatment: 2 periods of 3 weeks in each condition</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean (SD) number of dry nights per week:<BR/>Period 1: A:4.4, B:2.1<BR/>Period 2: A:4.6, B:2.5<BR/>15 children became totally dry during desmopressin treatment. 5 children remained dry after treatment.<BR/>47 patients relapsed after treatment<BR/>Side effects: none reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Not reported if comparable groups<BR/>No washout reported<BR/>Short follow up<BR/>No SDs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tuvemo-1978_x0023_">
<CHAR_METHODS>
<P>RCT (double-blind randomised crossover)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned<BR/>No follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 18<BR/>Inclusion criteria: age at least 6 years<BR/>Age: range 6-12 years<BR/>Previous treatment: children had not responded satisfactorily to previous treatment with imipramine or amitriptyline<BR/>Baseline wetting: mean (SEM) number of dry nights out of 28: 7.5 (2.98)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A: 20 µg intranasal DDAVP (Minerin) just before bedtime after emptying bladder<BR/>B: identical placebo as above<BR/>Duration of treatment: 28 days in each condition</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean (SE) number of dry nights out of 28: A:21.7 (1.72), B:12.1 (2.07)<BR/>Side effects: none reported (no physical or subjective side effects observed)<BR/>Number of children whose results were said to be excellent: 8; relatively good: 8;<BR/>unsatisfactory: 2<BR/>Follow up after 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Not stated if comparable groups<BR/>No washout<BR/>No details of dropouts: unclear if intention to treat<BR/>No follow up<BR/>Active and placebo results combined so cannot see any order or carryover effects</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Uygur-1997_x0023_">
<CHAR_METHODS>
<P>RCT (double-blind randomised crossover)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>65 children but 11 excluded before RCT because they did not respond to trial of desmopressin<BR/>Dropouts: 1 (UTI); 3 (found no longer to respond to desmopressin during 6 month open treatment)<BR/>Inclusion criteria: primary nocturnal enuresis<BR/>Exclusion criteria: urological disease, non-response to 2 week trial of desmopressin<BR/>Age: 7-17 years<BR/>Baseline wetting: '3 or more wet nights / week'</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (54): desmopressin spray, 20 mcg or 40 mcg if no response<BR/>B (54): placebo spray<BR/>Duration of treatment: 2 weeks each arm<BR/>Follow up: 6 months open desmopressin treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Wet nights in 2 weeks: A: 1, B: 9.6 (no SDs)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No useable data<BR/>Population selected on the basis of all initially responding to desmopressin<BR/>No SDs<BR/>Baseline comparability of groups not stated<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Vertucci-1997">
<CHAR_METHODS>
<P>RCT (double blind crossover)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Not mentioned<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 57<BR/>Dropouts: 5<BR/>Inclusion criteria: primary nocturnal enuresis, age &gt; 5 years, baseline wetting at least 3 nights/week, <BR/>Previous treatment: not mentioned<BR/>Age range 6-15<BR/>6 Child Neuropsychiatry Clinics, Italy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (29): desmopressin 30 µg intranasal then imipramine<BR/>B (28): imipramine 0.9 mg/kg then desmopressin<BR/>Duration of treatment: 3 weeks each<BR/>Follow up: 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean wet nights during first arm of trial: A: n=29, 1; B: 28, 2.5<BR/>Number not achieving 14 dry nights: A: 4/29; B: 9/28<BR/>Mean wet nights after both drugs: A: 29, 3.5; B: 28, 2.8<BR/>Side effects: desmopressin: 1 back pain, 1 inflamed nasal mucosa; imipramine: 1 pallor, restlessness and cold extremities</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data estimated from graphs<BR/>Data only given from first arm of trial here<BR/>No washout<BR/>SDs not available<BR/>Blinding not possible due to different routes of administration</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wille-1986">
<CHAR_METHODS>
<P>RCT<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: Yes<BR/>Daytime wetting excluded: Yes<BR/>Distribution of social class of parents in 2 groups was similar<BR/>Dropouts not included in analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 50 (boys and girls)<BR/>Inclusion criteria: age over 6 years; not dry for more than 6 months; at least 3 wet nights per week at baseline; written informed parental consent; no treatment for enuresis during previous year; no daytime wetting; no cardiovascular disease; no renal disorder; no neurological disease; no urinary tract infection<BR/>Age: over 6 years<BR/>Baseline wetting: mean number of dry nights per week: A:2.1, B:1.9<BR/>Number completing treatment: A:24, B:22</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A (25): intranasal desmopressin (20 µg)<BR/>B (25): enuresis alarm<BR/>Duration of treatment: 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean (SEM) number of dry nights per week in first week: A:4.2 (0.5), B:2.5 (0.4)<BR/>In last week of treatment: A:4.9 (0.5), B:6.3 (0.4)<BR/>A:10 relapses given 3 months more treatment. Successful for 7/10 but 4/7 relapsed immediately and 1/7 after 2 months. B: 1 relapsed and further treatment unsuccessful.<BR/>Side effects: A: nasal discomfort (5); bad taste in throat (2); B:false alarms (21); alarm did not go off (5); alarm did not wake child (15); other family members woken (15); child frightened by alarm (1).<BR/>Lab tests: urine osmolality and density higher during treatment with desmopressin and urine osmolality in alarm group lower during treatment than before</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Direct comparison of desmopressin and alarm<BR/>Not intention to treat analysis<BR/>Results taken from graph</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yap-1998_x0023_">
<CHAR_METHODS>
<P>RCT (double blind crossover)<BR/>Systematic baseline measure of wetting: Yes<BR/>Organic causes excluded: No<BR/>Daytime wetting excluded: Yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of children: 37 (22 boys)<BR/>3 excluded because data incomplete<BR/>Inclusion criteria: Primary monosymptomatic nocturnal enuresis<BR/>Exclusion criteria: No current enuresis treatment<BR/>Hospital clinic, Singapore</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A: (34) DDAVP 400 mg oral<BR/>B (34) Placebo<BR/>Duration of treatment 5 weeks, 2 week washout</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Wet nights during trial (number, mean, SD): A: 34, 2.5 (2.7); B: 34, 4.5 (2.1)<BR/>Number not achieving 14 dry nights: A: 11/34; B: 27/34<BR/>Wet nights after trial (number, mean, SD): 34, 4.5 (2.1)<BR/>Side effects: None reported (looked at body weight, BP, serum sodium and osmolality, urine osmolality, water retention or intoxication)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Groups comparable at baseline (same children)<BR/>Follow up data unusable as all had had both treatments</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P># = crossover trial; BP = blood pressure; CCT = controlled clinical trial; CI = confidence interval; CNS = central nervous system; DDAVP = 'brand name' for desmopressin; ITT = intention to treat; kg = kilograms; mg = milligrams; NS = not significant; RCT = randomised controlled trial; SD = standard deviation; SE = standard error; SEM = standard error of the mean; µg = micrograms; UTI = urinary tract infection; wt = weight</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-10-10 13:38:46 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bernasconi-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Interventions: Desmopressin 5 µg, 10 µg rising to 40 µg</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bogaert-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: Yes, of different doses of desmopressin<BR/>Excluded as not actually used to treat enuresis (was a dose-response study for one day only)<BR/>Intervention: single dose oral lyophilisate desmopressin: 30, 60, 120, 240, 360, 480 mg, placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Butler-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No <BR/>Comparison group: No <BR/>Intervention: Withdrawal from desmopressin or imipramine treatment, use of alarms optional</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Caione-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No mention of method of allocation to groups<BR/>Organic causes excluded: Yes<BR/>Systematic baseline measures of wetting: Yes<BR/>Interventions: Desmopressin, acupuncture</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-10 13:38:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caione-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-10 13:38:46 +0100" MODIFIED_BY="[Empty name]">
<P>RCT: Yes<BR/>Participants all had daytime wetting as well as bedwetting; some adults were included<BR/>Interventions: Desmopressin, oxybutynin<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Capozza-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Comparison group: Yes<BR/>Organic causes excluded: Yes<BR/>Systematic baseline measures of wetting: Yes<BR/>Interventions: Desmopressin, acupuncture</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chiozza-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No (open multicentre trial)<BR/>Comparison groups: Yes<BR/>Interventions: desmopressin, 20, 30, 40 µg per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eckford-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: Yes<BR/>Comparison group: Yes<BR/>Organic causes excluded: No<BR/>Systematic baseline: No<BR/>Systematic outcome measures: No<BR/>Intervention: Desmopressin in adults with multiple sclerosis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Evans-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Comparison group: Yes<BR/>Organic causes excluded: Yes<BR/>Systematic baseline measures of wetting: Yes<BR/>Intervention: Intranasal desmopressin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ferrie-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Comparison group: crossover trial<BR/>Organic causes excluded: Yes<BR/>Systematic baseline measures of wetting: Yes<BR/>Intervention: Intranasal desmopressin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Comparison group: Yes<BR/>Organic causes excluded: No<BR/>Systematic baseline measurement of wetting: No<BR/>Systematic outcome measures: Yes<BR/>Interventions: Pituitary snuff and propantheline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Key-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Comparison group: No<BR/>Organic causes excluded: Yes<BR/>Systematic baseline: No<BR/>Systematic outcome measures: Yes<BR/>Intervention: Desmopressin (DDAVP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kim-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: Yes<BR/>Comparison group: Yes<BR/>Organic causes excluded: No<BR/>Systematic baseline measurement of wetting: Yes<BR/>Systematic outcome measures: Yes (but improvement rates only)<BR/>Interventions: Imipramine, desmopressin<BR/>2 children switched from imipramine to desmopressin due to side effects but data not given according to allocated groups therefore excluded as not intention to treat</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Knudsen-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Participants included adults (mean age 15.8 years)<BR/>Intervention: Desmopressin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marson-1955">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: Unclear<BR/>Participants: 4<BR/>Intervention: pituitrin snuff, placebo snuff</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matthieson-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Comparison group: No<BR/>Organic causes excluded: Yes<BR/>Systematic baseline: Yes<BR/>Systematic outcome measures: Yes<BR/>Intervention: Desmopressin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miller-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Comparison group: No<BR/>Organic causes excluded: Yes<BR/>Systematic baseline: No<BR/>Systematic outcome measures: Yes<BR/>Intervention: Desmopressin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miller-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Comparison group: No<BR/>Organic causes excluded: Yes<BR/>Systematic baseline: Yes<BR/>Systematic outcome measures: Yes<BR/>Intervention: Desmopressin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Monda-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Comparison group: Yes<BR/>Organic causes excluded: Yes<BR/>Systematic baseline: No<BR/>Systematic outcome measures: Yes<BR/>Intervention: Desmopressin, imipramine, alarms</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petersen-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: Yes<BR/>Design: Randomized placebo-controlled, double blind, crossover study<BR/>Participants were adults with multiple sclerosis, urinary frequency and incontinence<BR/>Intervention: Desmopressin<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ramsden-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Comparison group: Yes<BR/>Organic causes excluded: Yes<BR/>Systematic baseline: No<BR/>Systematic outcome measures: Yes<BR/>Intervention: Desmopressin (DDAVP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robinson-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: Yes (double-blind randomised placebo controlled trial)<BR/>Intervention: Desmopressin<BR/>Excluded because participants were adult women with severe daytime incontinence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Snajderova-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Intervention: Desmopressin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Steffens-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Comparison group: No<BR/>Organic causes excluded: Yes<BR/>Systematic baseline: No<BR/>Systematic outcome measures: No<BR/>Intervention: Desmopressin (vasopressin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stenberg-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Comparison group: No<BR/>Organic causes excluded: No<BR/>Systematic baseline: Yes<BR/>Systematic outcome measures: Yes<BR/>Intervention: Desmopressin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stenberg-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Comparison group: No<BR/>Organic causes excluded: No<BR/>Systematic baseline: Yes<BR/>Systematic outcome measures: Yes<BR/>Intervention: Desmopressin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taylor-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: Yes, crossover<BR/>Participants: Adults with detrusor instability<BR/>Intervention: Desmopressin (DDAVP)<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wood-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT: No<BR/>Comparison group: Yes<BR/>Organic causes excluded: No<BR/>Systematic baseline: Yes<BR/>Systematic outcome measures: Yes<BR/>Intervention: Desmopressin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>DDAVP = 'brand name' for desmopressin; µg = microgram; RCT = randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Hjalmas-2001">
<CHAR_STUDY_NAME>
<P>Cessation of desmopressin treatment after response</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>77 responders to the SWEET trial</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Abrupt or tapered cessation of treatment after response to desmopressin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Relapse</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>See references</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>SWEET (Swedish Enuresis Trial)</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Aladjem-1982">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Birkasova-1978_x0023_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bradbury-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Burke-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Dimson-1986_x0023_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Faraj-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fera-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fjellestad-1987_x0023_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Folwell-1997_x0023_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gibb-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hamano-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hoashi-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Holt-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Janknegt-1990_x0023_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Janknegt-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kahan-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kjoller-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lee-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Leebeek-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Longstaffe-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Martin-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Miller-1990a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Miller-1990b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Muller-2001_x0023_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Natochin-2000">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Neveus-1999_x0023_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Ng-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Post-1983a_x0023_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Post-1983b_x0023_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Radmayr-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rittig-1988_x0023_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rodriguez-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rushton-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Schulman-2001a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Schulman-2001b">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Segni-1982">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sener-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Skoog-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Stenberg-1994_x0023_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sukhai-1989_x0023_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Terho-1984_x0023_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Terho-1991_x0023_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tuvemo-1978_x0023_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Uygur-1997_x0023_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vertucci-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wille-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Yap-1998_x0023_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-10-10 13:43:54 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" NO="1">
<NAME>DESMOPRESSIN VS PLACEBO</NAME>
<CONT_OUTCOME CHI2="70.78666220611397" CI_END="-1.2775030435741093" CI_START="-1.6001565798300106" CI_STUDY="95" CI_TOTAL="95" DF="24.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.43882981170206" ESTIMABLE="YES" I2="66.095307714725" I2_Q="59.330931265572566" ID="CMP-001.01" NO="1" P_CHI2="1.6608467545697891E-6" P_Q="0.030969693579510404" P_Z="2.0211667399415253E-68" Q="12.29435577354976" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="933" TOTAL_2="800" UNITS="" WEIGHT="600.0" Z="17.480388676614147">
<NAME>Number of wet nights per week during treatment</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.6767156799129128" CI_END="-1.1759837472591417" CI_START="-3.4233456547115897" DF="1.0" EFFECT_SIZE="-2.2996647009853657" ESTIMABLE="YES" I2="40.35959632393137" ID="CMP-001.01.01" NO="1" P_CHI2="0.19536151123282575" P_Z="6.042207856963463E-5" STUDIES="2" TAU2="0.0" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0" Z="4.011156347807554">
<NAME>10 mcg vs placebo</NAME>
<CONT_DATA CI_END="-1.453723957580768" CI_START="-4.306276042419233" EFFECT_SIZE="-2.8800000000000003" ESTIMABLE="YES" MEAN_1="1.52" MEAN_2="4.4" ORDER="103937" SD_1="2.15" SD_2="1.94" SE="0.7277052301315309" STUDY_ID="STD-Aladjem-1982" TOTAL_1="15" TOTAL_2="17" WEIGHT="62.06958829969707"/>
<CONT_DATA CI_END="0.47452257532204234" CI_START="-3.1745225753220416" EFFECT_SIZE="-1.3499999999999996" ESTIMABLE="YES" MEAN_1="2.49" MEAN_2="3.84" ORDER="103938" SD_1="2.52" SD_2="2.13" SE="0.9308959703921312" STUDY_ID="STD-Kjoller-1984" TOTAL_1="13" TOTAL_2="12" WEIGHT="37.93041170030293"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="52.18418391249605" CI_END="-1.1098182299069885" CI_START="-1.5733537413982" DF="11.0" EFFECT_SIZE="-1.3415859856525942" ESTIMABLE="YES" I2="78.92081627942076" ID="CMP-001.01.02" NO="2" P_CHI2="2.524770285061706E-7" P_Z="7.831340298837866E-30" STUDIES="12" TAU2="0.0" TOTAL_1="443" TOTAL_2="370" WEIGHT="100.0" Z="11.345237414858168">
<NAME>20 mcg vs placebo</NAME>
<CONT_DATA CI_END="-0.5011191956887129" CI_START="-2.7388808043112873" EFFECT_SIZE="-1.62" ESTIMABLE="YES" MEAN_1="3.24" MEAN_2="4.86" ORDER="103939" SD_1="2.51" SD_2="1.95" SE="0.5708680430542991" STUDY_ID="STD-Folwell-1997_x0023_" TOTAL_1="31" TOTAL_2="31" WEIGHT="4.290801113650494"/>
<CONT_DATA CI_END="-0.6127293812737802" CI_START="-3.1872706187262194" EFFECT_SIZE="-1.9" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="5.3" ORDER="103940" SD_1="2.5" SD_2="1.8" SE="0.6567827923778427" STUDY_ID="STD-Janknegt-1990_x0023_" TOTAL_1="22" TOTAL_2="22" WEIGHT="3.241651454083553"/>
<CONT_DATA CI_END="0.20253355555828145" CI_START="-2.982533555558281" EFFECT_SIZE="-1.3899999999999997" ESTIMABLE="YES" MEAN_1="2.45" MEAN_2="3.84" ORDER="103941" SD_1="1.84" SD_2="2.13" SE="0.812532050649901" STUDY_ID="STD-Kjoller-1984" TOTAL_1="12" TOTAL_2="12" WEIGHT="2.1180141001809294"/>
<CONT_DATA CI_END="0.07860905575160426" CI_START="-1.8786090557516033" EFFECT_SIZE="-0.8999999999999995" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="5.8" ORDER="103942" SD_1="1.92" SD_2="1.14" SE="0.4992995093127971" STUDY_ID="STD-Post-1983b_x0023_" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.609027513264946"/>
<CONT_DATA CI_END="-0.1274864303452452" CI_START="-1.7525135696547556" EFFECT_SIZE="-0.9400000000000004" ESTIMABLE="YES" MEAN_1="3.96" MEAN_2="4.9" ORDER="103943" SD_1="2.37" SD_2="1.64" SE="0.4145553571717432" STUDY_ID="STD-Rushton-1995" TOTAL_1="49" TOTAL_2="47" WEIGHT="8.136634077841205"/>
<CONT_DATA CI_END="0.05483362838968653" CI_START="-1.0548336283896864" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="4.5" ORDER="103944" SD_1="1.33" SD_2="1.37" SE="0.28308358355875074" STUDY_ID="STD-Schulman-2001a" TOTAL_1="44" TOTAL_2="47" WEIGHT="17.44939924131798"/>
<CONT_DATA CI_END="-0.42849558157451584" CI_START="-1.571504418425484" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="5.0" ORDER="103945" SD_1="1.57" SD_2="1.54" SE="0.29158924497258015" STUDY_ID="STD-Schulman-2001b" TOTAL_1="109" TOTAL_2="38" WEIGHT="16.44624842509253"/>
<CONT_DATA CI_END="-1.020047407630746" CI_START="-2.979952592369254" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="4.2" ORDER="103946" SD_1="1.34" SD_2="1.79" SE="0.4999849997749933" STUDY_ID="STD-Segni-1982" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.593657855699145"/>
<CONT_DATA CI_END="-3.0758488055185538" CI_START="-4.924151194481445" EFFECT_SIZE="-3.9999999999999996" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="5.1" ORDER="103947" SD_1="1.39" SD_2="2.0" SE="0.4715143756574267" STUDY_ID="STD-Sener-1998" TOTAL_1="31" TOTAL_2="25" WEIGHT="6.289555771211312"/>
<CONT_DATA CI_END="-0.44537605058638297" CI_START="-1.554623949413617" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="5.0" ORDER="103948" SD_1="1.15" SD_2="1.2" SE="0.2829766025235259" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="36" WEIGHT="17.46259543950024"/>
<CONT_DATA CI_END="-1.1369599067594405" CI_START="-2.5830400932405584" EFFECT_SIZE="-1.8599999999999994" ESTIMABLE="YES" MEAN_1="2.16" MEAN_2="4.02" ORDER="103949" SD_1="2.0" SD_2="1.83" SE="0.3689047854673896" STUDY_ID="STD-Terho-1984_x0023_" TOTAL_1="54" TOTAL_2="54" WEIGHT="10.274986758436686"/>
<CONT_DATA CI_END="-1.0509702873823672" CI_START="-3.689029712617633" EFFECT_SIZE="-2.37" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="3.97" ORDER="103950" SD_1="1.82" SD_2="2.2" SE="0.6729867094609753" STUDY_ID="STD-Tuvemo-1978_x0023_" TOTAL_1="18" TOTAL_2="18" WEIGHT="3.087428249720955"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.108699548942393" CI_END="-0.9869659449776496" CI_START="-1.6693200300792408" DF="5.0" EFFECT_SIZE="-1.3281429875284452" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" NO="3" P_CHI2="0.683231939649847" P_Z="2.351191306425477E-14" STUDIES="6" TAU2="0.0" TOTAL_1="211" TOTAL_2="213" WEIGHT="100.00000000000001" Z="7.629799480097266">
<NAME>40 mcg vs placebo</NAME>
<CONT_DATA CI_END="-0.3122024340056062" CI_START="-2.687797565994394" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="5.3" ORDER="103951" SD_1="2.2" SD_2="1.8" SE="0.6060303022726894" STUDY_ID="STD-Janknegt-1990_x0023_" TOTAL_1="22" TOTAL_2="22" WEIGHT="8.250394942418021"/>
<CONT_DATA CI_END="-0.19035940331900858" CI_START="-2.8496405966809917" EFFECT_SIZE="-1.52" ESTIMABLE="YES" MEAN_1="2.16" MEAN_2="3.68" ORDER="103952" SD_1="2.25" SD_2="2.25" SE="0.6784005252999681" STUDY_ID="STD-Martin-1993" TOTAL_1="22" TOTAL_2="22" WEIGHT="6.584018877504949"/>
<CONT_DATA CI_END="-0.2790212473192675" CI_START="-1.9209787526807327" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="5.0" ORDER="103953" SD_1="2.34" SD_2="1.91" SE="0.41887440746692706" STUDY_ID="STD-Post-1983a_x0023_" TOTAL_1="52" TOTAL_2="52" WEIGHT="17.27013631334953"/>
<CONT_DATA CI_END="-0.373160355017792" CI_START="-1.626839644982208" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="4.5" ORDER="103954" SD_1="1.73" SD_2="1.37" SE="0.31982202220379513" STUDY_ID="STD-Schulman-2001a" TOTAL_1="48" TOTAL_2="47" WEIGHT="29.624203921268798"/>
<CONT_DATA CI_END="-0.8714766064982006" CI_START="-2.1285233935017995" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="5.0" ORDER="103955" SD_1="1.44" SD_2="1.2" SE="0.32068109335656764" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="36" WEIGHT="29.465696222921505"/>
<CONT_DATA CI_END="-0.8502549105777291" CI_START="-3.1497450894222707" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="4.5" ORDER="103956" SD_1="2.7" SD_2="2.1" SE="0.5866154166562821" STUDY_ID="STD-Yap-1998_x0023_" TOTAL_1="34" TOTAL_2="34" WEIGHT="8.805549722537213"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.0846253871376945" CI_START="-1.9153746128623055" DF="1.0" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.04" NO="4" P_CHI2="1.0" P_Z="1.4644170560742787E-12" STUDIES="2" TAU2="0.0" TOTAL_1="81" TOTAL_2="83" WEIGHT="100.00000000000001" Z="7.0778181568469085">
<NAME>60 mcg vs placebo</NAME>
<CONT_DATA CI_END="-0.873160355017792" CI_START="-2.126839644982208" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="4.5" ORDER="103957" SD_1="1.73" SD_2="1.37" SE="0.31982202220379513" STUDY_ID="STD-Schulman-2001a" TOTAL_1="48" TOTAL_2="47" WEIGHT="43.91035892778521"/>
<CONT_DATA CI_END="-0.945376050586383" CI_START="-2.054623949413617" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="5.0" ORDER="103958" SD_1="1.15" SD_2="1.2" SE="0.2829766025235259" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="36" WEIGHT="56.0896410722148"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.0850501915571833" CI_START="-4.7149498084428165" DF="0.0" EFFECT_SIZE="-3.4" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.05" NO="5" P_CHI2="1.0" P_Z="4.024802579342908E-7" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="5.067780918062302">
<NAME>combined dose vs placebo</NAME>
<CONT_DATA CI_END="-2.0850501915571833" CI_START="-4.7149498084428165" EFFECT_SIZE="-3.4" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="5.5" ORDER="103959" SD_1="2.25" SD_2="2.2" SE="0.6709050874480208" STUDY_ID="STD-Birkasova-1978_x0023_" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5227072912128552" CI_END="-1.087758455546379" CI_START="-2.081668682189361" DF="1.0" EFFECT_SIZE="-1.58471356886787" ESTIMABLE="YES" I2="34.32749644197949" ID="CMP-001.01.06" NO="6" P_CHI2="0.21721067764963642" P_Z="4.1038890065824363E-10" STUDIES="2" TAU2="0.0" TOTAL_1="148" TOTAL_2="83" WEIGHT="100.0" Z="6.2500242728836435">
<NAME>dose titration vs placebo</NAME>
<CONT_DATA CI_END="-0.2533096307487708" CI_START="-2.00669036925123" EFFECT_SIZE="-1.1300000000000003" ESTIMABLE="YES" MEAN_1="3.77" MEAN_2="4.9" ORDER="103960" SD_1="2.52" SD_2="1.82" SE="0.44729922394822114" STUDY_ID="STD-Rushton-1995" TOTAL_1="49" TOTAL_2="47" WEIGHT="32.13230315404924"/>
<CONT_DATA CI_END="-1.1967662829561994" CI_START="-2.4032337170438005" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="5.0" ORDER="103961" SD_1="1.69" SD_2="1.54" SE="0.30777796010642594" STUDY_ID="STD-Schulman-2001b" TOTAL_1="99" TOTAL_2="36" WEIGHT="67.86769684595076"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-001.02" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES">
<NAME>Number of wet nights per week during treatment (no SDs)</NAME>
<TR>
<TH>
<P>Desmopressin</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.02.01" NO="1" STUDIES="5">
<NAME>20 mcg vs placebo</NAME>
<OTHER_DATA ORDER="283" STUDY_ID="STD-Dimson-1986_x0023_">
<TR>
<TD>
<P>3.4 wet nights, n=17</P>
</TD>
<TD>
<P>5.0 wet nights, n=17</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="284" STUDY_ID="STD-Fjellestad-1987_x0023_">
<TR>
<TD>
<P>2.9 wet nights, n=19</P>
</TD>
<TD>
<P>4.5 wet nights, n=19</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="285" STUDY_ID="STD-Miller-1990a">
<TR>
<TD>
<P>4.4 wet nights, n=19</P>
</TD>
<TD>
<P>5.4 wet nights, n=31</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="286" STUDY_ID="STD-Miller-1990b">
<TR>
<TD>
<P>5 wet nights, n=27</P>
</TD>
<TD>
<P>5.3 wet nights, n=26</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="287" STUDY_ID="STD-Muller-2001_x0023_">
<TR>
<TD>
<P>3.27 wet nights, n=19</P>
</TD>
<TD>
<P>4.9 wet nights, n=21</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.02.02" NO="2" STUDIES="3">
<NAME>dose titration vs placebo</NAME>
<OTHER_DATA ORDER="288" STUDY_ID="STD-Rittig-1988_x0023_">
<TR>
<TD>
<P>0 wet nights, n=34</P>
</TD>
<TD>
<P>3 wet nights, n=34</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="289" STUDY_ID="STD-Terho-1991_x0023_">
<TR>
<TD>
<P>2.3 wet nights, n=52</P>
</TD>
<TD>
<P>4.7 wet nights, n=52</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="290" STUDY_ID="STD-Uygur-1997_x0023_">
<TR>
<TD>
<P>0.5 wet nights, n=54</P>
</TD>
<TD>
<P>4.8 wet nights, n=54</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="61.95166759206374" CI_END="0.8811480509390375" CI_START="0.7990879636070736" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8391154876780772" ESTIMABLE="YES" EVENTS_1="391" EVENTS_2="472" I2="77.40173825152455" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.05495111507955758" LOG_CI_START="-0.097405410915747" LOG_EFFECT_SIZE="-0.0761782629976523" METHOD="MH" NO="3" P_CHI2="5.319532014880224E-8" P_Q="0.0" P_Z="2.0104163500358557E-12" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="506" TOTAL_2="508" WEIGHT="500.0" Z="7.033759431852112">
<NAME>Number failing to achieve 14 consecutive dry nights during treatment</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9799498359166873" CI_START="0.4147214837990458" DF="0.0" EFFECT_SIZE="0.6375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.008796155472995172" LOG_CI_START="-0.38224346631501926" LOG_EFFECT_SIZE="-0.19551981089400725" NO="1" P_CHI2="1.0" P_Z="0.040141124811310165" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="2.0522937318910985">
<NAME>10 mcg vs placebo</NAME>
<DICH_DATA CI_END="0.9799498359166872" CI_START="0.4147214837990458" EFFECT_SIZE="0.6375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="-0.008796155472995221" LOG_CI_START="-0.38224346631501926" LOG_EFFECT_SIZE="-0.19551981089400725" ORDER="103970" O_E="0.0" SE="0.21936479898260736" STUDY_ID="STD-Aladjem-1982" TOTAL_1="15" TOTAL_2="17" VAR="0.048120915032679734" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="34.26166955191026" CI_END="0.9097973463710965" CI_START="0.784184993340062" DF="4.0" EFFECT_SIZE="0.8446593550093578" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="140" I2="88.32514570272312" ID="CMP-001.03.02" LOG_CI_END="-0.0410553342219028" LOG_CI_START="-0.10558147289013771" LOG_EFFECT_SIZE="-0.07331840355602025" NO="2" P_CHI2="6.585561268535045E-7" P_Z="8.426416808267639E-6" STUDIES="5" TAU2="0.0" TOTAL_1="146" TOTAL_2="142" WEIGHT="100.0" Z="4.454053298078873">
<NAME>20 mcg vs placebo</NAME>
<DICH_DATA CI_END="1.0832145190299334" CI_START="0.7242238560658444" EFFECT_SIZE="0.8857142857142857" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.0347144725119737" LOG_CI_START="-0.14012717354397963" LOG_EFFECT_SIZE="-0.052706350516002975" ORDER="103971" O_E="0.0" SE="0.10270284837337323" STUDY_ID="STD-Dimson-1986_x0023_" TOTAL_1="17" TOTAL_2="17" VAR="0.010547875064004092" WEIGHT="12.296719650967301"/>
<DICH_DATA CI_END="1.1311963391113777" CI_START="0.7934139230973833" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.053537990948669116" LOG_CI_START="-0.1005001826477149" LOG_EFFECT_SIZE="-0.023481095849522914" ORDER="103972" O_E="0.0" SE="0.09048278567177276" STUDY_ID="STD-Fjellestad-1987_x0023_" TOTAL_1="20" TOTAL_2="20" VAR="0.008187134502923965" WEIGHT="13.350724192478783"/>
<DICH_DATA CI_END="0.5862621129855436" CI_START="0.22120775943992774" EFFECT_SIZE="0.3601190476190476" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" LOG_CI_END="-0.2319081710599137" LOG_CI_START="-0.6551996430868743" LOG_EFFECT_SIZE="-0.443553907073394" ORDER="103973" O_E="0.0" SE="0.24864350599521612" STUDY_ID="STD-Natochin-2000" TOTAL_1="32" TOTAL_2="22" VAR="0.06182359307359307" WEIGHT="17.488667948042384"/>
<DICH_DATA CI_END="1.0303404205211222" CI_START="0.8840307066288412" EFFECT_SIZE="0.9543859649122807" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="47" LOG_CI_END="0.012980737644803743" LOG_CI_START="-0.053532649593426754" LOG_EFFECT_SIZE="-0.020275955974311508" ORDER="103974" O_E="0.0" SE="0.03907029291031347" STUDY_ID="STD-Schulman-2001a" TOTAL_1="44" TOTAL_2="47" VAR="0.0015264877880976913" WEIGHT="32.300139175351894"/>
<DICH_DATA CI_END="1.0512209526239107" CI_START="0.8931668556750625" EFFECT_SIZE="0.9689766317485898" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="36" LOG_CI_END="0.021694008530640727" LOG_CI_START="-0.04906740143636171" LOG_EFFECT_SIZE="-0.013686696452860461" ORDER="103975" O_E="0.0" SE="0.041565602489245734" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="36" VAR="0.001727699310293991" WEIGHT="24.56374903315963"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.870144602067334" CI_END="0.8857562499221487" CI_START="0.7366400481641542" DF="5.0" EFFECT_SIZE="0.8077645242298972" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="201" I2="68.4943009318978" ID="CMP-001.03.03" LOG_CI_END="-0.052685774589337354" LOG_CI_START="-0.1327446739905976" LOG_EFFECT_SIZE="-0.0927152242899675" NO="3" P_CHI2="0.0072247767567928944" P_Z="5.635563362823913E-6" STUDIES="6" TAU2="0.0" TOTAL_1="230" TOTAL_2="233" WEIGHT="99.99999999999999" Z="4.5396202492393725">
<NAME>40 mcg vs placebo</NAME>
<DICH_DATA CI_END="1.134277443408422" CI_START="0.6064486980596578" EFFECT_SIZE="0.8293859649122807" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="38" LOG_CI_END="0.054719295653865685" LOG_CI_START="-0.21720593196469393" LOG_EFFECT_SIZE="-0.0812433181554141" ORDER="103976" O_E="0.0" SE="0.15973022475472748" STUDY_ID="STD-Longstaffe-2000" TOTAL_1="60" TOTAL_2="61" VAR="0.025513744700195757" WEIGHT="18.783489060043756"/>
<DICH_DATA CI_END="1.0335173578160304" CI_START="0.6340762380331418" EFFECT_SIZE="0.8095238095238095" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="21" LOG_CI_END="0.014317774955001474" LOG_CI_START="-0.1978585216662921" LOG_EFFECT_SIZE="-0.09177037335564533" ORDER="103977" O_E="0.0" SE="0.12463340692495496" STUDY_ID="STD-Martin-1993" TOTAL_1="22" TOTAL_2="22" VAR="0.01553348612172141" WEIGHT="10.46685212753754"/>
<DICH_DATA CI_END="1.0608471928141359" CI_START="0.8284946747782811" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.025652831500813964" LOG_CI_START="-0.08171027870130106" LOG_EFFECT_SIZE="-0.02802872360024354" ORDER="103978" O_E="0.0" SE="0.06306562238868905" STUDY_ID="STD-Neveus-1999_x0023_" TOTAL_1="33" TOTAL_2="33" VAR="0.003977272727272718" WEIGHT="15.94948895624768"/>
<DICH_DATA CI_END="0.9816072731114327" CI_START="0.7826060266282493" EFFECT_SIZE="0.8764769065520945" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="47" LOG_CI_END="-0.008062232411798362" LOG_CI_START="-0.10645681204316457" LOG_EFFECT_SIZE="-0.05725952222748147" ORDER="103979" O_E="0.0" SE="0.057797463136488904" STUDY_ID="STD-Schulman-2001a" TOTAL_1="48" TOTAL_2="47" VAR="0.0033405467450137935" WEIGHT="23.91909506808407"/>
<DICH_DATA CI_END="1.008260300598346" CI_START="0.7672400227613416" EFFECT_SIZE="0.8795326349717969" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" LOG_CI_END="0.0035726675456823156" LOG_CI_START="-0.11506875045282607" LOG_EFFECT_SIZE="-0.05574804145357185" ORDER="103980" O_E="0.0" SE="0.0696905562168145" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="36" VAR="0.004856773625808983" WEIGHT="17.42369348125297"/>
<DICH_DATA CI_END="0.682055672048026" CI_START="0.24335373549791098" EFFECT_SIZE="0.4074074074074074" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" LOG_CI_END="-0.16618017508476285" LOG_CI_START="-0.6137619829167618" LOG_EFFECT_SIZE="-0.3899710790007623" ORDER="103981" O_E="0.0" SE="0.2629117694861971" STUDY_ID="STD-Yap-1998_x0023_" TOTAL_1="34" TOTAL_2="34" VAR="0.06912259853436323" WEIGHT="13.45738130683398"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0109648363272199E-4" CI_END="1.0013422764761801" CI_START="0.8815268565719175" DF="1.0" EFFECT_SIZE="0.9395265346623346" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="83" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="5.82552381022008E-4" LOG_CI_START="-0.05476445195988046" LOG_EFFECT_SIZE="-0.027090949789429226" NO="4" P_CHI2="0.9919776654580081" P_Z="0.05502168336072004" STUDIES="2" TAU2="0.0" TOTAL_1="82" TOTAL_2="83" WEIGHT="100.0" Z="1.9187049606955662">
<NAME>60 mcg vs placebo</NAME>
<DICH_DATA CI_END="1.0194837243640797" CI_START="0.8663250170065825" EFFECT_SIZE="0.9397894736842105" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="47" LOG_CI_END="0.008380296837757116" LOG_CI_START="-0.06231914422844558" LOG_EFFECT_SIZE="-0.026969423695344243" ORDER="103982" O_E="0.0" SE="0.04152920165016494" STUDY_ID="STD-Schulman-2001a" TOTAL_1="49" TOTAL_2="47" VAR="0.001724674589700062" WEIGHT="58.0978697160655"/>
<DICH_DATA CI_END="1.0399370977022802" CI_START="0.8481524513582906" EFFECT_SIZE="0.9391619661563255" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.01700707108053734" LOG_CI_START="-0.07152607836480601" LOG_EFFECT_SIZE="-0.027259503642134333" ORDER="103983" O_E="0.0" SE="0.05200481023035239" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="36" VAR="0.0027045002870949644" WEIGHT="41.9021302839345"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0018762775681607" CI_START="0.7105808156552208" DF="0.0" EFFECT_SIZE="0.84375" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="32" I2="0.0" ID="CMP-001.03.05" LOG_CI_END="8.140935002898361E-4" LOG_CI_START="-0.14838652182212717" LOG_EFFECT_SIZE="-0.07378621416091866" NO="5" P_CHI2="1.0" P_Z="0.052553059699269454" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="1.9385754140282212">
<NAME>80 mcg vs placebo</NAME>
<DICH_DATA CI_END="1.0018762775681607" CI_START="0.7105808156552209" EFFECT_SIZE="0.84375" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="32" LOG_CI_END="8.140935002898361E-4" LOG_CI_START="-0.14838652182212708" LOG_EFFECT_SIZE="-0.07378621416091866" ORDER="103984" O_E="0.0" SE="0.0876411799953448" STUDY_ID="STD-Neveus-1999_x0023_" TOTAL_1="33" TOTAL_2="33" VAR="0.007680976430976427" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.5871003802600608" CI_END="1.206947346045562" CI_START="-0.7344956686746432" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.23622583868545943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.7456118284138026" P_Q="0.6665257471940687" P_Z="0.6333914829690147" Q="0.18569299480689788" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="35" TOTAL_2="41" UNITS="" WEIGHT="200.0" Z="0.47695876987457647">
<NAME>Number of wet nights per week at follow-up</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.40140738545316296" CI_END="1.2726313540898264" CI_START="-1.100073697895744" DF="1.0" EFFECT_SIZE="0.08627882809704125" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="0.5263633312832061" P_Z="0.8866530160654124" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="100.0" Z="0.1425405956437874">
<NAME>10 mcg vs placebo</NAME>
<CONT_DATA CI_END="1.2804543503175823" CI_START="-1.6804543503175817" EFFECT_SIZE="-0.19999999999999973" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="3.9" ORDER="103985" SD_1="2.08" SD_2="2.19" SE="0.7553477318946761" STUDY_ID="STD-Aladjem-1982" TOTAL_1="15" TOTAL_2="17" WEIGHT="64.21514648786984"/>
<CONT_DATA CI_END="2.583189148563362" CI_START="-1.3831891485633627" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" MEAN_1="4.26" MEAN_2="3.66" ORDER="103986" SD_1="2.52" SD_2="2.16" SE="1.0118497912239741" STUDY_ID="STD-Kjoller-1984" TOTAL_1="10" TOTAL_2="12" WEIGHT="35.784853512130155"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.228574663754022" CI_START="-1.148574663754022" DF="0.0" EFFECT_SIZE="0.54" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="1.0" P_Z="0.5307973540483174" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="12" WEIGHT="100.0" Z="0.6267893119387735">
<NAME>20 mcg vs placebo</NAME>
<CONT_DATA CI_END="2.228574663754022" CI_START="-1.148574663754022" EFFECT_SIZE="0.54" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="3.66" ORDER="103987" SD_1="1.88" SD_2="2.16" SE="0.8615335164693246" STUDY_ID="STD-Kjoller-1984" TOTAL_1="10" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-001.05" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Number of wet nights per week at followup (no SDs)</NAME>
<TR>
<TH>
<P>Desmopressin</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.05.01" NO="1" STUDIES="2">
<NAME>20 mcg vs placebo</NAME>
<OTHER_DATA ORDER="309" STUDY_ID="STD-Miller-1990a">
<TR>
<TD>
<P>5.6 wet nights, n=19</P>
</TD>
<TD>
<P>4.9 wet nights, n=16</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="310" STUDY_ID="STD-Miller-1990b">
<TR>
<TD>
<P>5.4 wet nights, n=19</P>
</TD>
<TD>
<P>5.7 wet nights, n=20</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.05.02" NO="2" STUDIES="2">
<NAME>40 mcg vs placebo</NAME>
<OTHER_DATA ORDER="311" STUDY_ID="STD-Miller-1990a">
<TR>
<TD>
<P>5.5 wet nights, n=26</P>
</TD>
<TD>
<P>4.9 wet nights, n=16</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="312" STUDY_ID="STD-Miller-1990b">
<TR>
<TD>
<P>5.7 wet nights, n=20</P>
</TD>
<TD>
<P>5.7 wet nights, n=20</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Number failing to achieve 14 consecutive dry nights or relapsing after cure</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="17" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>20 mcg vs placebo</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="103992" O_E="0.0" SE="0.0" STUDY_ID="STD-Dimson-1986_x0023_" TOTAL_1="17" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>DESMOPRESSIN VS PLACEBO excluding crossover trials</NAME>
<CONT_OUTCOME CHI2="55.00724508352511" CI_END="-1.179352534587228" CI_START="-1.5447365728203355" CI_STUDY="95" CI_TOTAL="95" DF="15.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3620445537037817" ESTIMABLE="YES" I2="72.73086485748664" I2_Q="21.69037027090247" ID="CMP-002.01" NO="1" P_CHI2="1.7808590451195982E-6" P_Q="0.2764016272876215" P_Z="2.3432220420916342E-48" Q="5.107928633857043" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="658" TOTAL_2="525" UNITS="" WEIGHT="500.0" Z="14.612342036108434">
<NAME>Number of wet nights per week during treatment</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.6767156799129128" CI_END="-1.1759837472591417" CI_START="-3.4233456547115897" DF="1.0" EFFECT_SIZE="-2.2996647009853657" ESTIMABLE="YES" I2="40.35959632393137" ID="CMP-002.01.01" NO="1" P_CHI2="0.19536151123282575" P_Z="6.042207856963463E-5" STUDIES="2" TAU2="0.0" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0" Z="4.011156347807554">
<NAME>10 mcg vs placebo</NAME>
<CONT_DATA CI_END="-1.453723957580768" CI_START="-4.306276042419233" EFFECT_SIZE="-2.8800000000000003" ESTIMABLE="YES" MEAN_1="1.52" MEAN_2="4.4" ORDER="103993" SD_1="2.15" SD_2="1.94" SE="0.7277052301315309" STUDY_ID="STD-Aladjem-1982" TOTAL_1="15" TOTAL_2="17" WEIGHT="62.06958829969707"/>
<CONT_DATA CI_END="0.47452257532204234" CI_START="-3.1745225753220416" EFFECT_SIZE="-1.3499999999999996" ESTIMABLE="YES" MEAN_1="2.49" MEAN_2="3.84" ORDER="103994" SD_1="2.52" SD_2="2.13" SE="0.9308959703921312" STUDY_ID="STD-Kjoller-1984" TOTAL_1="13" TOTAL_2="12" WEIGHT="37.93041170030293"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="45.337880766004616" CI_END="-0.948378673798355" CI_START="-1.48907180123226" DF="6.0" EFFECT_SIZE="-1.2187252375153075" ESTIMABLE="YES" I2="86.76603339497302" ID="CMP-002.01.02" NO="2" P_CHI2="4.0096831521729825E-8" P_Z="9.961688712869293E-19" STUDIES="7" TAU2="0.0" TOTAL_1="298" TOTAL_2="225" WEIGHT="100.0" Z="8.835538871804948">
<NAME>20 mcg vs placebo</NAME>
<CONT_DATA CI_END="0.20253355555828145" CI_START="-2.982533555558281" EFFECT_SIZE="-1.3899999999999997" ESTIMABLE="YES" MEAN_1="2.45" MEAN_2="3.84" ORDER="103995" SD_1="1.84" SD_2="2.13" SE="0.812532050649901" STUDY_ID="STD-Kjoller-1984" TOTAL_1="12" TOTAL_2="12" WEIGHT="2.8818045565139134"/>
<CONT_DATA CI_END="-0.1274864303452452" CI_START="-1.7525135696547556" EFFECT_SIZE="-0.9400000000000004" ESTIMABLE="YES" MEAN_1="3.96" MEAN_2="4.9" ORDER="103996" SD_1="2.37" SD_2="1.64" SE="0.4145553571717432" STUDY_ID="STD-Rushton-1995" TOTAL_1="49" TOTAL_2="47" WEIGHT="11.07083713852808"/>
<CONT_DATA CI_END="0.05483362838968653" CI_START="-1.0548336283896864" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="4.5" ORDER="103997" SD_1="1.33" SD_2="1.37" SE="0.28308358355875074" STUDY_ID="STD-Schulman-2001a" TOTAL_1="44" TOTAL_2="47" WEIGHT="23.741937429861757"/>
<CONT_DATA CI_END="-0.42849558157451584" CI_START="-1.571504418425484" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="5.0" ORDER="103998" SD_1="1.57" SD_2="1.54" SE="0.29158924497258015" STUDY_ID="STD-Schulman-2001b" TOTAL_1="109" TOTAL_2="38" WEIGHT="22.377034055128696"/>
<CONT_DATA CI_END="-1.020047407630746" CI_START="-2.979952592369254" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="4.2" ORDER="103999" SD_1="1.34" SD_2="1.79" SE="0.4999849997749933" STUDY_ID="STD-Segni-1982" TOTAL_1="20" TOTAL_2="20" WEIGHT="7.610822182324763"/>
<CONT_DATA CI_END="-3.0758488055185538" CI_START="-4.924151194481445" EFFECT_SIZE="-3.9999999999999996" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="5.1" ORDER="104000" SD_1="1.39" SD_2="2.0" SE="0.4715143756574267" STUDY_ID="STD-Sener-1998" TOTAL_1="31" TOTAL_2="25" WEIGHT="8.557672245136047"/>
<CONT_DATA CI_END="-0.44537605058638297" CI_START="-1.554623949413617" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="5.0" ORDER="104001" SD_1="1.15" SD_2="1.2" SE="0.2829766025235259" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="36" WEIGHT="23.75989239250674"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.3620127125376933" CI_END="-0.8554637681422548" CI_START="-1.6974661680707908" DF="2.0" EFFECT_SIZE="-1.2764649681065228" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.03" NO="3" P_CHI2="0.5061074587588372" P_Z="2.8060296588320216E-9" STUDIES="3" TAU2="0.0" TOTAL_1="103" TOTAL_2="105" WEIGHT="100.0" Z="5.942561126258532">
<NAME>40 mcg vs placebo</NAME>
<CONT_DATA CI_END="-0.19035940331900858" CI_START="-2.8496405966809917" EFFECT_SIZE="-1.52" ESTIMABLE="YES" MEAN_1="2.16" MEAN_2="3.68" ORDER="104002" SD_1="2.25" SD_2="2.25" SE="0.6784005252999681" STUDY_ID="STD-Martin-1993" TOTAL_1="22" TOTAL_2="22" WEIGHT="10.025317470897285"/>
<CONT_DATA CI_END="-0.373160355017792" CI_START="-1.626839644982208" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="4.5" ORDER="104003" SD_1="1.73" SD_2="1.37" SE="0.31982202220379513" STUDY_ID="STD-Schulman-2001a" TOTAL_1="48" TOTAL_2="47" WEIGHT="45.108019077531374"/>
<CONT_DATA CI_END="-0.8714766064982006" CI_START="-2.1285233935017995" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="5.0" ORDER="104004" SD_1="1.44" SD_2="1.2" SE="0.32068109335656764" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="36" WEIGHT="44.86666345157135"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.0846253871376945" CI_START="-1.9153746128623055" DF="1.0" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.04" NO="4" P_CHI2="1.0" P_Z="1.4644170560742787E-12" STUDIES="2" TAU2="0.0" TOTAL_1="81" TOTAL_2="83" WEIGHT="100.00000000000001" Z="7.0778181568469085">
<NAME>60 mcg vs placebo</NAME>
<CONT_DATA CI_END="-0.873160355017792" CI_START="-2.126839644982208" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="4.5" ORDER="104005" SD_1="1.73" SD_2="1.37" SE="0.31982202220379513" STUDY_ID="STD-Schulman-2001a" TOTAL_1="48" TOTAL_2="47" WEIGHT="43.91035892778521"/>
<CONT_DATA CI_END="-0.945376050586383" CI_START="-2.054623949413617" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="5.0" ORDER="104006" SD_1="1.15" SD_2="1.2" SE="0.2829766025235259" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="36" WEIGHT="56.0896410722148"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.05" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>combined dose vs placebo</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5227072912128552" CI_END="-1.087758455546379" CI_START="-2.081668682189361" DF="1.0" EFFECT_SIZE="-1.58471356886787" ESTIMABLE="YES" I2="34.32749644197949" ID="CMP-002.01.06" NO="6" P_CHI2="0.21721067764963642" P_Z="4.1038890065824363E-10" STUDIES="2" TAU2="0.0" TOTAL_1="148" TOTAL_2="83" WEIGHT="100.0" Z="6.2500242728836435">
<NAME>dose titration vs placebo</NAME>
<CONT_DATA CI_END="-0.2533096307487708" CI_START="-2.00669036925123" EFFECT_SIZE="-1.1300000000000003" ESTIMABLE="YES" MEAN_1="3.77" MEAN_2="4.9" ORDER="104007" SD_1="2.52" SD_2="1.82" SE="0.44729922394822114" STUDY_ID="STD-Rushton-1995" TOTAL_1="49" TOTAL_2="47" WEIGHT="32.13230315404924"/>
<CONT_DATA CI_END="-1.1967662829561994" CI_START="-2.4032337170438005" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="5.0" ORDER="104008" SD_1="1.69" SD_2="1.54" SE="0.30777796010642594" STUDY_ID="STD-Schulman-2001b" TOTAL_1="99" TOTAL_2="36" WEIGHT="67.86769684595076"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-002.02" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Number of wet nights per week during treatment (no SDs)</NAME>
<TR>
<TH>
<P>Desmopressin</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.02.01" NO="1" STUDIES="2">
<NAME>20 mcg vs placebo</NAME>
<OTHER_DATA ORDER="330" STUDY_ID="STD-Miller-1990a">
<TR>
<TD>
<P>4.4 wet nights, n=19</P>
</TD>
<TD>
<P>5.4 wet nights, n=31</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="331" STUDY_ID="STD-Miller-1990b">
<TR>
<TD>
<P>5 wet nights, n=27</P>
</TD>
<TD>
<P>5.3 wet nights, n=26</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.02.02" NO="2" STUDIES="0">
<NAME>dose titration vs placebo</NAME>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="39.900820561386254" CI_END="0.9032440184841104" CI_START="0.8092954073257838" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8549802546571914" ESTIMABLE="YES" EVENTS_1="290" EVENTS_2="345" I2="77.44407289530861" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.044194905760987155" LOG_CI_START="-0.09189292418020056" LOG_EFFECT_SIZE="-0.06804391497059387" METHOD="MH" NO="3" P_CHI2="7.919446602833169E-6" P_Q="0.0" P_Z="2.244708152213803E-8" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="369" TOTAL_2="371" WEIGHT="400.0" Z="5.591998457350972">
<NAME>Number failing to achieve 14 consecutive dry nights during treatment</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9799498359166873" CI_START="0.4147214837990458" DF="0.0" EFFECT_SIZE="0.6375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-0.008796155472995172" LOG_CI_START="-0.38224346631501926" LOG_EFFECT_SIZE="-0.19551981089400725" NO="1" P_CHI2="1.0" P_Z="0.040141124811310165" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="2.0522937318910985">
<NAME>10 mcg vs placebo</NAME>
<DICH_DATA CI_END="0.9799498359166872" CI_START="0.4147214837990458" EFFECT_SIZE="0.6375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="-0.008796155472995221" LOG_CI_START="-0.38224346631501926" LOG_EFFECT_SIZE="-0.19551981089400725" ORDER="104011" O_E="0.0" SE="0.21936479898260736" STUDY_ID="STD-Aladjem-1982" TOTAL_1="15" TOTAL_2="17" VAR="0.048120915032679734" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="42.426729745265845" CI_END="0.8956943440288128" CI_START="0.749653946927372" DF="2.0" EFFECT_SIZE="0.8194271171017731" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="104" I2="95.28599066671367" ID="CMP-002.03.02" LOG_CI_END="-0.04784016818235765" LOG_CI_START="-0.12513916810499753" LOG_EFFECT_SIZE="-0.08648966814367758" NO="2" P_CHI2="6.125843166060463E-10" P_Z="1.1545511218051151E-5" STUDIES="3" TAU2="0.0" TOTAL_1="109" TOTAL_2="105" WEIGHT="100.0" Z="4.385998131051633">
<NAME>20 mcg vs placebo</NAME>
<DICH_DATA CI_END="0.5862621129855436" CI_START="0.22120775943992774" EFFECT_SIZE="0.3601190476190476" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" LOG_CI_END="-0.2319081710599137" LOG_CI_START="-0.6551996430868743" LOG_EFFECT_SIZE="-0.443553907073394" ORDER="104012" O_E="0.0" SE="0.24864350599521612" STUDY_ID="STD-Natochin-2000" TOTAL_1="32" TOTAL_2="22" VAR="0.06182359307359307" WEIGHT="23.52127331200142"/>
<DICH_DATA CI_END="1.0303404205211222" CI_START="0.8840307066288412" EFFECT_SIZE="0.9543859649122807" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="47" LOG_CI_END="0.012980737644803743" LOG_CI_START="-0.053532649593426754" LOG_EFFECT_SIZE="-0.020275955974311508" ORDER="104013" O_E="0.0" SE="0.03907029291031347" STUDY_ID="STD-Schulman-2001a" TOTAL_1="44" TOTAL_2="47" VAR="0.0015264877880976913" WEIGHT="43.44186783214548"/>
<DICH_DATA CI_END="1.0512209526239107" CI_START="0.8931668556750625" EFFECT_SIZE="0.9689766317485898" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="36" LOG_CI_END="0.021694008530640727" LOG_CI_START="-0.04906740143636171" LOG_EFFECT_SIZE="-0.013686696452860461" ORDER="104014" O_E="0.0" SE="0.041565602489245734" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="36" VAR="0.001727699310293991" WEIGHT="33.036858855853104"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5821471265731877" CI_END="0.9477230519059334" CI_START="0.7709409798727969" DF="3.0" EFFECT_SIZE="0.8547739691195549" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="142" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="-0.023318555701253477" LOG_CI_START="-0.1129788685076502" LOG_EFFECT_SIZE="-0.06814871210445182" NO="3" P_CHI2="0.9005069450261136" P_Z="0.002887703095151025" STUDIES="4" TAU2="0.0" TOTAL_1="163" TOTAL_2="166" WEIGHT="100.0" Z="2.9794458024238595">
<NAME>40 mcg vs placebo</NAME>
<DICH_DATA CI_END="1.134277443408422" CI_START="0.6064486980596578" EFFECT_SIZE="0.8293859649122807" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="38" LOG_CI_END="0.054719295653865685" LOG_CI_START="-0.21720593196469393" LOG_EFFECT_SIZE="-0.0812433181554141" ORDER="104015" O_E="0.0" SE="0.15973022475472748" STUDY_ID="STD-Longstaffe-2000" TOTAL_1="60" TOTAL_2="61" VAR="0.025513744700195757" WEIGHT="26.608097884375976"/>
<DICH_DATA CI_END="1.0335173578160304" CI_START="0.6340762380331418" EFFECT_SIZE="0.8095238095238095" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="21" LOG_CI_END="0.014317774955001474" LOG_CI_START="-0.1978585216662921" LOG_EFFECT_SIZE="-0.09177037335564533" ORDER="104016" O_E="0.0" SE="0.12463340692495496" STUDY_ID="STD-Martin-1993" TOTAL_1="22" TOTAL_2="22" VAR="0.01553348612172141" WEIGHT="14.827012439517402"/>
<DICH_DATA CI_END="0.9816072731114327" CI_START="0.7826060266282493" EFFECT_SIZE="0.8764769065520945" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="47" LOG_CI_END="-0.008062232411798362" LOG_CI_START="-0.10645681204316457" LOG_EFFECT_SIZE="-0.05725952222748147" ORDER="104017" O_E="0.0" SE="0.057797463136488904" STUDY_ID="STD-Schulman-2001a" TOTAL_1="48" TOTAL_2="47" VAR="0.0033405467450137935" WEIGHT="33.88303529992808"/>
<DICH_DATA CI_END="1.008260300598346" CI_START="0.7672400227613416" EFFECT_SIZE="0.8795326349717969" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" LOG_CI_END="0.0035726675456823156" LOG_CI_START="-0.11506875045282607" LOG_EFFECT_SIZE="-0.05574804145357185" ORDER="104018" O_E="0.0" SE="0.0696905562168145" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="36" VAR="0.004856773625808983" WEIGHT="24.681854376178535"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0109648363272199E-4" CI_END="1.0013422764761801" CI_START="0.8815268565719175" DF="1.0" EFFECT_SIZE="0.9395265346623346" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="83" I2="0.0" ID="CMP-002.03.04" LOG_CI_END="5.82552381022008E-4" LOG_CI_START="-0.05476445195988046" LOG_EFFECT_SIZE="-0.027090949789429226" NO="4" P_CHI2="0.9919776654580081" P_Z="0.05502168336072004" STUDIES="2" TAU2="0.0" TOTAL_1="82" TOTAL_2="83" WEIGHT="100.0" Z="1.9187049606955662">
<NAME>60 mcg vs placebo</NAME>
<DICH_DATA CI_END="1.0194837243640797" CI_START="0.8663250170065825" EFFECT_SIZE="0.9397894736842105" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="47" LOG_CI_END="0.008380296837757116" LOG_CI_START="-0.06231914422844558" LOG_EFFECT_SIZE="-0.026969423695344243" ORDER="104019" O_E="0.0" SE="0.04152920165016494" STUDY_ID="STD-Schulman-2001a" TOTAL_1="49" TOTAL_2="47" VAR="0.001724674589700062" WEIGHT="58.0978697160655"/>
<DICH_DATA CI_END="1.0399370977022802" CI_START="0.8481524513582906" EFFECT_SIZE="0.9391619661563255" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.01700707108053734" LOG_CI_START="-0.07152607836480601" LOG_EFFECT_SIZE="-0.027259503642134333" ORDER="104020" O_E="0.0" SE="0.05200481023035239" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="36" VAR="0.0027045002870949644" WEIGHT="41.9021302839345"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.5871003802600608" CI_END="1.206947346045562" CI_START="-0.7344956686746432" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.23622583868545943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="0.7456118284138026" P_Q="0.6665257471940687" P_Z="0.6333914829690147" Q="0.18569299480689788" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="35" TOTAL_2="41" UNITS="" WEIGHT="200.0" Z="0.47695876987457647">
<NAME>Number of wet nights per week at follow-up</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.40140738545316296" CI_END="1.2726313540898264" CI_START="-1.100073697895744" DF="1.0" EFFECT_SIZE="0.08627882809704125" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" NO="1" P_CHI2="0.5263633312832061" P_Z="0.8866530160654124" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="100.0" Z="0.1425405956437874">
<NAME>10 mcg vs placebo</NAME>
<CONT_DATA CI_END="1.2804543503175823" CI_START="-1.6804543503175817" EFFECT_SIZE="-0.19999999999999973" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="3.9" ORDER="104021" SD_1="2.08" SD_2="2.19" SE="0.7553477318946761" STUDY_ID="STD-Aladjem-1982" TOTAL_1="15" TOTAL_2="17" WEIGHT="64.21514648786984"/>
<CONT_DATA CI_END="2.583189148563362" CI_START="-1.3831891485633627" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" MEAN_1="4.26" MEAN_2="3.66" ORDER="104022" SD_1="2.52" SD_2="2.16" SE="1.0118497912239741" STUDY_ID="STD-Kjoller-1984" TOTAL_1="10" TOTAL_2="12" WEIGHT="35.784853512130155"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.228574663754022" CI_START="-1.148574663754022" DF="0.0" EFFECT_SIZE="0.54" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.02" NO="2" P_CHI2="1.0" P_Z="0.5307973540483174" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="12" WEIGHT="100.0" Z="0.6267893119387735">
<NAME>20 mcg vs placebo</NAME>
<CONT_DATA CI_END="2.228574663754022" CI_START="-1.148574663754022" EFFECT_SIZE="0.54" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="3.66" ORDER="104023" SD_1="1.88" SD_2="2.16" SE="0.8615335164693246" STUDY_ID="STD-Kjoller-1984" TOTAL_1="10" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-002.05" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Number of wet nights per week at followup (no SDs)</NAME>
<TR>
<TH>
<P>Desmopressin</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.05.01" NO="1" STUDIES="2">
<NAME>20 mcg vs placebo</NAME>
<OTHER_DATA ORDER="345" STUDY_ID="STD-Miller-1990a">
<TR>
<TD>
<P>5.6 wet nights, n=19</P>
</TD>
<TD>
<P>4.9 wet nights, n=16</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="346" STUDY_ID="STD-Miller-1990b">
<TR>
<TD>
<P>5.4 wet nights, n=19</P>
</TD>
<TD>
<P>5.7 wet nights, n=20</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.05.02" NO="2" STUDIES="2">
<NAME>40 mcg vs placebo</NAME>
<OTHER_DATA ORDER="347" STUDY_ID="STD-Miller-1990a">
<TR>
<TD>
<P>5.5 wet nights, n=26</P>
</TD>
<TD>
<P>4.9 wet nights, n=16</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="348" STUDY_ID="STD-Miller-1990b">
<TR>
<TD>
<P>5.7 wet nights, n=20</P>
</TD>
<TD>
<P>5.7 wet nights, n=20</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Number failing to achieve 14 consecutive dry nights or relapsing after cure</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>10 mcg vs placebo</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>20 mcg vs placebo</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.06.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>40 mcg vs placebo</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.06.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>60 mcg vs placebo</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.06.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>80 mcg vs placebo</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>DESMOPRESSIN: COMPARING DOSES</NAME>
<CONT_OUTCOME CHI2="6.705079704682434" CI_END="0.7089521749028093" CI_START="0.2139576167649109" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.46145489583386007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.4602192421823038" P_Q="0.4267759754214794" P_Z="2.57861573337555E-4" Q="2.7801628461742354" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="270" TOTAL_2="277" UNITS="" WEIGHT="400.0" Z="3.654322907008952">
<NAME>Number of wet nights per week during treatment</NAME>
<GROUP_LABEL_1>Low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>High dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>low dose better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>high dose better</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7205599862169916" CI_START="-1.7205599862169916" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="99.99999999999999" Z="0.0">
<NAME>10 vs 20 mcg</NAME>
<CONT_DATA CI_END="1.7205599862169916" CI_START="-1.7205599862169916" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="2.5" ORDER="104028" SD_1="2.52" SD_2="1.84" SE="0.8778528584140062" STUDY_ID="STD-Kjoller-1984" TOTAL_1="13" TOTAL_2="12" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.458257716708536" CI_END="0.8399436837593892" CI_START="-0.006400443527302013" DF="2.0" EFFECT_SIZE="0.4167716201160436" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" NO="2" P_CHI2="0.4823290674480345" P_Z="0.05356723927283919" STUDIES="3" TAU2="0.0" TOTAL_1="99" TOTAL_2="103" WEIGHT="100.0" Z="1.9303196864486585">
<NAME>20 vs 40 mcg</NAME>
<CONT_DATA CI_END="0.9915618811820743" CI_START="-1.7915618811820742" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="3.8" ORDER="104029" SD_1="2.5" SD_2="2.2" SE="0.7099935979224806" STUDY_ID="STD-Janknegt-1990_x0023_" TOTAL_1="22" TOTAL_2="22" WEIGHT="9.24759776488404"/>
<CONT_DATA CI_END="1.1276610037987236" CI_START="-0.12766100379872358" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="3.5" ORDER="104030" SD_1="1.33" SD_2="1.73" SE="0.3202410905249451" STUDY_ID="STD-Schulman-2001a" TOTAL_1="44" TOTAL_2="48" WEIGHT="45.45521168747424"/>
<CONT_DATA CI_END="1.1287548614417595" CI_START="-0.1287548614417594" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="3.5" ORDER="104031" SD_1="1.15" SD_2="1.44" SE="0.32079919141438185" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="33" WEIGHT="45.29719054764171"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.3683194652773387" CI_END="1.1350694371788483" CI_START="0.3036220762343104" DF="1.0" EFFECT_SIZE="0.7193457567065794" ESTIMABLE="YES" I2="26.917651515151515" ID="CMP-003.01.03" NO="3" P_CHI2="0.24210101361666714" P_Z="6.953257495875473E-4" STUDIES="2" TAU2="0.0" TOTAL_1="77" TOTAL_2="81" WEIGHT="100.0" Z="3.3914156008023104">
<NAME>20 vs 60 mcg</NAME>
<CONT_DATA CI_END="1.6276610037987236" CI_START="0.3723389962012764" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="3.0" ORDER="104032" SD_1="1.33" SD_2="1.73" SE="0.3202410905249451" STUDY_ID="STD-Schulman-2001a" TOTAL_1="44" TOTAL_2="48" WEIGHT="43.869151341315884"/>
<CONT_DATA CI_END="1.054886244982507" CI_START="-0.05488624498250694" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="3.5" ORDER="104033" SD_1="1.15" SD_2="1.15" SE="0.28311042925246527" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="33" WEIGHT="56.130848658684116"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.0983396765223237" CI_END="0.6914582783498507" CI_START="-0.2393284146604612" DF="1.0" EFFECT_SIZE="0.22606493184469476" ESTIMABLE="YES" I2="8.953484848484841" ID="CMP-003.01.04" NO="4" P_CHI2="0.2946312556141384" P_Z="0.34107012296294537" STUDIES="2" TAU2="0.0" TOTAL_1="81" TOTAL_2="81" WEIGHT="100.0" Z="0.9520529846642211">
<NAME>40 vs 60 mcg</NAME>
<CONT_DATA CI_END="1.192131433341224" CI_START="-0.19213143334122396" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.0" ORDER="104034" SD_1="1.73" SD_2="1.73" SE="0.35313477125124154" STUDY_ID="STD-Schulman-2001a" TOTAL_1="48" TOTAL_2="48" WEIGHT="45.21298636893895"/>
<CONT_DATA CI_END="0.6287548614417594" CI_START="-0.6287548614417594" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.5" ORDER="104035" SD_1="1.44" SD_2="1.15" SE="0.32079919141438185" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="33" WEIGHT="54.78701363106104"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-003.02" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Number of wet nights per week during treatment (no SDs)</NAME>
<TR>
<TH>
<P>lower dose</P>
</TH>
<TH>
<P>higher dose</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-003.02.01" NO="1" STUDIES="2">
<NAME>20 mcg vs 40 mcg</NAME>
<OTHER_DATA ORDER="357" STUDY_ID="STD-Miller-1990a">
<TR>
<TD>
<P>4.4 wet nights, n=19</P>
</TD>
<TD>
<P>3.5 wet nights, n=26</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="358" STUDY_ID="STD-Miller-1990b">
<TR>
<TD>
<P>5 wet nights, n=27</P>
</TD>
<TD>
<P>4 wet nights, n=24</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="249" EVENTS_2="252" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="268" TOTAL_2="278" WEIGHT="0.0" Z="0.0">
<NAME>Number failing to achieve 14 consecutive dry nights during treatment</NAME>
<GROUP_LABEL_1>lower dose</GROUP_LABEL_1>
<GROUP_LABEL_2>higher dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours higher dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="74" EVENTS_2="71" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="77" TOTAL_2="81" WEIGHT="0.0" Z="0.0">
<NAME>20 mcg vs 40 mcg</NAME>
<DICH_DATA CI_END="1.2359904648642244" CI_START="0.9628574640815142" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" LOG_CI_END="0.09201512037025274" LOG_CI_START="-0.01643799859145325" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="104038" O_E="0.0" SE="0.06370589892970317" STUDY_ID="STD-Schulman-2001a" TOTAL_1="44" TOTAL_2="48" VAR="0.004058441558441556" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2696933099585896" CI_START="0.9589702394688399" EFFECT_SIZE="1.103448275862069" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="29" LOG_CI_END="0.10369883128855933" LOG_CI_START="-0.018194870446659572" LOG_EFFECT_SIZE="0.04275198042094988" ORDER="104039" O_E="0.0" SE="0.07160096378282241" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="33" VAR="0.005126698014629047" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="74" EVENTS_2="77" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="77" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>20 mcg vs 60 mcg</NAME>
<DICH_DATA CI_END="1.1195660688262448" CI_START="0.9234640577385084" EFFECT_SIZE="1.016798418972332" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="46" LOG_CI_END="0.049049727642614276" LOG_CI_START="-0.034580003125309" LOG_EFFECT_SIZE="0.007234862258652624" ORDER="104040" O_E="0.0" SE="0.0491245178269219" STUDY_ID="STD-Schulman-2001a" TOTAL_1="44" TOTAL_2="49" VAR="0.0024132182517275676" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1472094743669943" CI_START="0.9288248881892613" EFFECT_SIZE="1.032258064516129" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="31" LOG_CI_END="0.059642725011586094" LOG_CI_START="-0.03206615604031953" LOG_EFFECT_SIZE="0.013788284485633283" ORDER="104041" O_E="0.0" SE="0.05387025069617204" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="33" VAR="0.0029020039100684236" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="71" EVENTS_2="77" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="81" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>40 mcg vs 60 mcg</NAME>
<DICH_DATA CI_END="1.0600094953389945" CI_START="0.8195639504086439" EFFECT_SIZE="0.9320652173913043" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="46" LOG_CI_END="0.025309755599542978" LOG_CI_START="-0.08641715286103736" LOG_EFFECT_SIZE="-0.030553698630747177" ORDER="104042" O_E="0.0" SE="0.06562893908686139" STUDY_ID="STD-Schulman-2001a" TOTAL_1="48" TOTAL_2="49" VAR="0.004307157645666963" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.090702806868792" CI_START="0.8023542869144427" EFFECT_SIZE="0.9354838709677419" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="31" LOG_CI_END="0.03770643077197171" LOG_CI_START="-0.09563382264260495" LOG_EFFECT_SIZE="-0.02896369593531662" ORDER="104043" O_E="0.0" SE="0.07832472490062176" STUDY_ID="STD-Skoog-1997" TOTAL_1="33" TOTAL_2="33" VAR="0.006134762530758078" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="27" I2="0.0" ID="CMP-003.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="0.0" Z="0.0">
<NAME>40 mcg vs 80 mcg</NAME>
<DICH_DATA CI_END="1.348554691402863" CI_START="0.9154748480762631" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="27" LOG_CI_END="0.12986856420590887" LOG_CI_START="-0.03835358308455862" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="104044" O_E="0.0" SE="0.09881452203147953" STUDY_ID="STD-Neveus-1999_x0023_" TOTAL_1="33" TOTAL_2="33" VAR="0.009764309764309753" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.048641889901715" CI_START="-1.8486418899017159" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9198830602508146" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.10058102490236946">
<NAME>Number of wet nights per week at follow-up</NAME>
<GROUP_LABEL_1>Low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>High dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>low dose better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>high dose better</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.048641889901715" CI_START="-1.8486418899017159" DF="0.0" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" NO="1" P_CHI2="1.0" P_Z="0.9198830602508146" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.10058102490236946">
<NAME>10 vs 20 mcg</NAME>
<CONT_DATA CI_END="2.048641889901715" CI_START="-1.8486418899017159" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="4.2" ORDER="104045" SD_1="2.52" SD_2="1.88" SE="0.9942233149549451" STUDY_ID="STD-Kjoller-1984" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-003.05" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Number of wet nights per week at followup (no SDs)</NAME>
<TR>
<TH>
<P>lower dose</P>
</TH>
<TH>
<P>higher dose</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-003.05.01" NO="1" STUDIES="2">
<NAME>20 mcg vs 40 mcg</NAME>
<OTHER_DATA ORDER="367" STUDY_ID="STD-Miller-1990a">
<TR>
<TD>
<P>5.6 wet nights, n=19</P>
</TD>
<TD>
<P>5.5 wet nights, n=26</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="368" STUDY_ID="STD-Miller-1990b">
<TR>
<TD>
<P>5.4 wet nights, n=19</P>
</TD>
<TD>
<P>5.7 wet nights, n=20</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>DESMOPRESSIN: ORAL VS NOSE DROPS</NAME>
<OTHER_OUTCOME COLS="2" ID="CMP-004.01" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Number of wet nights per week during treatment (no SDs)</NAME>
<TR>
<TH>
<P>oral</P>
</TH>
<TH>
<P>nose drops</P>
</TH>
</TR>
<OTHER_DATA ORDER="369" STUDY_ID="STD-Fjellestad-1987_x0023_">
<TR>
<TD>
<P>3 wet nights, n=19</P>
</TD>
<TD>
<P>2.9 wet nights, n=19</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1311963391113777" CI_START="0.7934139230973832" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.053537990948669116" LOG_CI_START="-0.10050018264771496" LOG_EFFECT_SIZE="-0.023481095849522914" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.5501458981451032" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.5975415198467164">
<NAME>Number failing to achieve 14 consecutive dry nights during treatment</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Nose drops</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours nose drops</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1311963391113777" CI_START="0.7934139230973833" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.053537990948669116" LOG_CI_START="-0.1005001826477149" LOG_EFFECT_SIZE="-0.023481095849522914" ORDER="104049" O_E="0.0" SE="0.09048278567177276" STUDY_ID="STD-Fjellestad-1987_x0023_" TOTAL_1="20" TOTAL_2="20" VAR="0.008187134502923965" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-10-10 13:43:54 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>DESMOPRESSIN: COMPARISON WITH OTHER DRUGS</NAME>
<CONT_OUTCOME CHI2="27.50006857257085" CI_END="0.30348233233322136" CI_START="-0.29093883377409163" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.006271749279564847" ESTIMABLE="YES" I2="70.90916344848911" I2_Q="71.96181327693681" ID="CMP-005.01" MODIFIED="2008-10-10 13:42:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.792686040244632E-4" P_Q="0.0031634017731744235" P_Z="0.9670095097629102" Q="17.832822248405893" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="365" TOTAL_2="360" UNITS="" WEIGHT="600.0" Z="0.041359236207927835">
<NAME>Number of wet nights per week during treatment</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopres</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours other</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.6820279230288078" CI_START="0.11797207697119272" DF="0.0" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.01" NO="1" P_CHI2="1.0" P_Z="0.03232894159019939" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0" Z="2.1403196678224137">
<NAME>desmopressin vs amitriptyline</NAME>
<CONT_DATA CI_END="2.6820279230288078" CI_START="0.11797207697119294" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="3.3" ORDER="104050" SD_1="1.7" SD_2="1.9" SE="0.654107898482462" STUDY_ID="STD-Burke-1995" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.938825842336346" CI_START="-0.13882584233634554" DF="0.0" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.02" NO="2" P_CHI2="1.0" P_Z="0.07456270579953495" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0" Z="1.783144981624453">
<NAME>desmopressin vs desmopressin + amitriptyline</NAME>
<CONT_DATA CI_END="2.938825842336346" CI_START="-0.13882584233634554" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="3.3" ORDER="104051" SD_1="1.7" SD_2="2.5" SE="0.7851296526234195" STUDY_ID="STD-Burke-1995" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.1992972409709325" CI_END="0.7968391756960437" CI_START="-0.43877164273046765" DF="1.0" EFFECT_SIZE="0.17903376648278804" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.03" NO="3" P_CHI2="0.6552887016840446" P_Z="0.5700500700893162" STUDIES="2" TAU2="0.0" TOTAL_1="128" TOTAL_2="130" WEIGHT="100.0" Z="0.5679777630462514">
<NAME>desmopressin vs imipramine (first fortnight)</NAME>
<CONT_DATA CI_END="0.9419223322145939" CI_START="-0.44192233221459387" EFFECT_SIZE="0.25" ESTIMABLE="YES" MEAN_1="4.75" MEAN_2="4.5" ORDER="104052" SD_1="2.63" SD_2="2.63" SE="0.35302808504257677" STUDY_ID="STD-Hoashi-1995" TOTAL_1="111" TOTAL_2="111" WEIGHT="79.72393328079659"/>
<CONT_DATA CI_END="1.272018131350226" CI_START="-1.472018131350226" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="2.5" ORDER="104053" SD_1="2.0" SD_2="2.2" SE="0.7000221137595026" STUDY_ID="STD-Holt-1986" TOTAL_1="17" TOTAL_2="19" WEIGHT="20.276066719203417"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.467949083194025" CI_END="0.405294680299761" CI_START="-0.6180043853634454" DF="2.0" EFFECT_SIZE="-0.1063548525318422" ESTIMABLE="YES" I2="78.87610101801162" ID="CMP-005.01.04" NO="4" P_CHI2="0.00879149254993672" P_Z="0.683706103274009" STUDIES="3" TAU2="0.0" TOTAL_1="149" TOTAL_2="151" WEIGHT="100.0" Z="0.4074110639559326">
<NAME>desmopressin vs imipramine (at end of treatment)</NAME>
<CONT_DATA CI_END="1.040276658110332" CI_START="-0.3402766581103327" EFFECT_SIZE="0.34999999999999964" ESTIMABLE="YES" MEAN_1="4.35" MEAN_2="4.0" ORDER="104054" SD_1="2.6" SD_2="2.6" SE="0.3521884399688701" STUDY_ID="STD-Hoashi-1995" TOTAL_1="109" TOTAL_2="109" WEIGHT="54.94128188783379"/>
<CONT_DATA CI_END="2.05039368296808" CI_START="-0.6503936829680794" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="2.3" ORDER="104055" SD_1="2.2" SD_2="1.9" SE="0.688989029196359" STUDY_ID="STD-Holt-1986" TOTAL_1="17" TOTAL_2="19" WEIGHT="14.355699815945021"/>
<CONT_DATA CI_END="-0.37661663527797395" CI_START="-2.223383364722026" EFFECT_SIZE="-1.3" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="2.0" ORDER="104056" SD_1="0.95" SD_2="2.05" SE="0.4711226185815434" STUDY_ID="STD-Lee-2005" TOTAL_1="23" TOTAL_2="23" WEIGHT="30.703018296221185"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5271038473591187" CI_START="-2.3728961526408807" DF="0.0" EFFECT_SIZE="-1.4499999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.05" NO="5" P_CHI2="1.0" P_Z="0.0020743204972564966" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0" Z="3.079379808281574">
<NAME>desmopressin vs indomethacin</NAME>
<CONT_DATA CI_END="-0.5271038473591187" CI_START="-2.3728961526408807" EFFECT_SIZE="-1.4499999999999997" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="2.55" ORDER="104057" SD_1="1.39" SD_2="2.15" SE="0.47087403642136694" STUDY_ID="STD-Sener-1998" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7113078323671648" CI_START="-0.5113078323671648" DF="0.0" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.06" MODIFIED="2008-10-10 13:42:48 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.7484997669136562" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0" Z="0.320618169891672">
<NAME>desmopressin vs desmopressin + oxybutynin</NAME>
<CONT_DATA CI_END="0.7113078323671648" CI_START="-0.5113078323671648" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.6" ORDER="104058" SD_1="0.95" SD_2="1.13" SE="0.31189748239716797" STUDY_ID="STD-Lee-2005" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="26.189119977232924" CI_END="0.9388328692509142" CI_START="0.6094154549272031" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7563988763312365" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="78" I2="80.90810227931802" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.02741171382801971" LOG_CI_START="-0.21508653615782677" LOG_EFFECT_SIZE="-0.12124912499292327" METHOD="MH" MODIFIED="2008-10-10 13:43:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="8.200668787616827E-5" P_Q="0.0" P_Z="0.011325004828630159" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="141" TOTAL_2="131" WEIGHT="500.0" Z="2.532507186558094">
<NAME>Number failing to achieve 14 consecutive dry nights during treatment</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours other drug</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6141256311495455" CI_START="0.8889462244767675" DF="0.0" EFFECT_SIZE="1.1978609625668448" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.20793733385051646" LOG_CI_START="-0.05112451025518888" LOG_EFFECT_SIZE="0.0784064117976638" NO="1" P_CHI2="1.0" P_Z="0.23546970338737405" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0" Z="1.1863865465092094">
<NAME>desmopressin vs amitriptyline</NAME>
<DICH_DATA CI_END="1.6141256311495458" CI_START="0.8889462244767675" EFFECT_SIZE="1.1978609625668448" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.20793733385051655" LOG_CI_START="-0.05112451025518888" LOG_EFFECT_SIZE="0.0784064117976638" ORDER="104059" O_E="0.0" SE="0.1521742096045016" STUDY_ID="STD-Burke-1995" TOTAL_1="17" TOTAL_2="14" VAR="0.023156990068754782" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8735069867885585" CI_START="0.9267079246938736" DF="0.0" EFFECT_SIZE="1.3176470588235294" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.27265531702846063" LOG_CI_START="-0.033057123116682866" LOG_EFFECT_SIZE="0.11979909695588888" NO="2" P_CHI2="1.0" P_Z="0.1245146973176475" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0" Z="1.5360965703750034">
<NAME>desmopressin vs desmopressin + amitriptyline</NAME>
<DICH_DATA CI_END="1.8735069867885585" CI_START="0.9267079246938736" EFFECT_SIZE="1.3176470588235294" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.27265531702846063" LOG_CI_START="-0.033057123116682866" LOG_EFFECT_SIZE="0.11979909695588888" ORDER="104060" O_E="0.0" SE="0.17957700064224225" STUDY_ID="STD-Burke-1995" TOTAL_1="17" TOTAL_2="14" VAR="0.032247899159663876" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8861278973718807" CI_START="0.30003472570215545" DF="0.0" EFFECT_SIZE="0.515625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="20" I2="0.0" ID="CMP-005.02.03" LOG_CI_END="-0.05250359062517082" LOG_CI_START="-0.5228284775868286" LOG_EFFECT_SIZE="-0.28766603410599967" NO="3" P_CHI2="1.0" P_Z="0.016504869540190925" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0" Z="2.397555740949741">
<NAME>desmopressin vs diclofenac</NAME>
<DICH_DATA CI_END="0.8861278973718808" CI_START="0.30003472570215545" EFFECT_SIZE="0.515625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="20" LOG_CI_END="-0.052503590625170765" LOG_CI_START="-0.5228284775868286" LOG_EFFECT_SIZE="-0.28766603410599967" ORDER="104061" O_E="0.0" SE="0.27627116674701613" STUDY_ID="STD-Natochin-2000" TOTAL_1="32" TOTAL_2="30" VAR="0.0763257575757576" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0066121311005662995" CI_END="0.7257440016442385" CI_START="0.2709502036660281" DF="1.0" EFFECT_SIZE="0.44344163658243085" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="29" I2="0.0" ID="CMP-005.02.04" LOG_CI_END="-0.13921654497417116" LOG_CI_START="-0.5671105182039102" LOG_EFFECT_SIZE="-0.3531635315890407" NO="4" P_CHI2="0.9351914362253152" P_Z="0.0012150480345410315" STUDIES="2" TAU2="0.0" TOTAL_1="52" TOTAL_2="51" WEIGHT="100.0" Z="3.2353239160760676">
<NAME>desmopressin vs imipramine</NAME>
<DICH_DATA CI_END="0.7673722720719753" CI_START="0.2638875645757065" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.11499389748028142" LOG_CI_START="-0.5785810749690312" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="104062" O_E="0.0" SE="0.27231340285043015" STUDY_ID="STD-Lee-2005" TOTAL_1="23" TOTAL_2="23" VAR="0.07415458937198066" WEIGHT="68.59205776173286"/>
<DICH_DATA CI_END="1.2350524808714047" CI_START="0.14909724485821307" EFFECT_SIZE="0.42911877394636017" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.09168541238807172" LOG_CI_START="-0.8265303817242704" LOG_EFFECT_SIZE="-0.36742248466809935" ORDER="104063" O_E="0.0" SE="0.5393645027030753" STUDY_ID="STD-Vertucci-1997" TOTAL_1="29" TOTAL_2="28" VAR="0.29091406677613574" WEIGHT="31.407942238267147"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.282447702560775" CI_START="0.5073339190628776" DF="0.0" EFFECT_SIZE="1.076086956521739" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-005.02.05" LOG_CI_END="0.3584008353850987" LOG_CI_START="-0.29470610088110943" LOG_EFFECT_SIZE="0.0318473672519946" MODIFIED="2008-10-10 13:43:54 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.8484104809372701" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0" Z="0.19114692969938799">
<NAME>desmopressin vs desmopressin + oxybutynin</NAME>
<DICH_DATA CI_END="2.282447702560775" CI_START="0.5073339190628776" EFFECT_SIZE="1.076086956521739" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3584008353850987" LOG_CI_START="-0.29470610088110943" LOG_EFFECT_SIZE="0.0318473672519946" ORDER="104064" O_E="0.0" SE="0.3836382472942452" STUDY_ID="STD-Lee-2005" TOTAL_1="23" TOTAL_2="22" VAR="0.14717830478700045" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.6047831406274982" CI_START="-1.2047831406274987" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.7802129758699756" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="17" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="0.2790415015465748">
<NAME>Number of wet nights at followup</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopres</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours other</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6047831406274982" CI_START="-1.2047831406274987" DF="0.0" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.01" NO="1" P_CHI2="1.0" P_Z="0.7802129758699756" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="19" WEIGHT="100.0" Z="0.2790415015465748">
<NAME>desmopressin vs imipramine</NAME>
<CONT_DATA CI_END="1.6047831406274982" CI_START="-1.2047831406274987" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="3.7" ORDER="104065" SD_1="2.0" SD_2="2.3" SE="0.7167392624090282" STUDY_ID="STD-Holt-1986" TOTAL_1="17" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="34" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Number failing to achieve 14 consecutive dry nights or relapsing after cure</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours other drug</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="14" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>desmopressin vs amitriptyline</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="104066" O_E="0.0" SE="0.0" STUDY_ID="STD-Burke-1995" TOTAL_1="17" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="13" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>desmopressin vs desmopressin + amitriptyline</NAME>
<DICH_DATA CI_END="1.30092231332612" CI_START="0.8970046730277874" EFFECT_SIZE="1.0802469135802468" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.11425136274056423" LOG_CI_START="-0.04720529445323735" LOG_EFFECT_SIZE="0.033523034143663456" ORDER="104067" O_E="0.0" SE="0.0948404396589819" STUDY_ID="STD-Burke-1995" TOTAL_1="17" TOTAL_2="14" VAR="0.008994708994708986" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-005.05" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Number of wet nights per week during treatment (no SDs)</NAME>
<TR>
<TH>
<P>Desmopressin</P>
</TH>
<TH>
<P>Alarm</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-005.05.01" NO="1" STUDIES="1">
<NAME>desmopressin vs imipramine (first arm)</NAME>
<OTHER_DATA ORDER="389" STUDY_ID="STD-Vertucci-1997">
<TR>
<TD>
<P>1 wet night, n=29</P>
</TD>
<TD>
<P>2.5 wet nights, n=28</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>DESMOPRESSIN ALONE VS ALARM ALONE</NAME>
<CONT_OUTCOME CHI2="11.713062590152571" CI_END="0.5283497662251987" CI_START="-0.8682585783499973" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1699544060623993" ESTIMABLE="YES" I2="82.92504642055405" I2_Q="87.9087227430748" ID="CMP-006.01" NO="1" P_CHI2="0.0028611668873818052" P_Q="0.004029646432569867" P_Z="0.6333484336498785" Q="8.270424858773758" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="85" TOTAL_2="75" UNITS="" WEIGHT="200.0" Z="0.47701922473836905">
<NAME>Number of wet nights per week during treatment</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Alarm</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours alarm</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.44501071060961195" CI_START="-2.9549892893903884" DF="0.0" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.01" NO="1" P_CHI2="1.0" P_Z="0.007931923532483624" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="2.6549539521063035">
<NAME>desmopressin vs alarm, in first week</NAME>
<CONT_DATA CI_END="-0.44501071060961195" CI_START="-2.9549892893903884" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="4.5" ORDER="104069" SD_1="2.5" SD_2="2.0" SE="0.6403124237432849" STUDY_ID="STD-Wille-1986" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.442637731378812" CI_END="1.3566110648991265" CI_START="-0.3242278659504415" DF="1.0" EFFECT_SIZE="0.5161915994743425" ESTIMABLE="YES" I2="70.952505664908" ID="CMP-006.01.02" NO="2" P_CHI2="0.06353428974387176" P_Z="0.2286577154855629" STUDIES="2" TAU2="0.0" TOTAL_1="60" TOTAL_2="50" WEIGHT="100.0" Z="1.2038237876611664">
<NAME>desmopressin vs alarm, in last week</NAME>
<CONT_DATA CI_END="0.9307771696756248" CI_START="-1.3307771696756243" EFFECT_SIZE="-0.19999999999999973" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="2.8" ORDER="104070" SD_1="2.4" SD_2="2.2" SE="0.5769377287516764" STUDY_ID="STD-Ng-2005" TOTAL_1="36" TOTAL_2="28" WEIGHT="55.23802503285361"/>
<CONT_DATA CI_END="2.6561499424252624" CI_START="0.1438500575747379" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="0.7" ORDER="104071" SD_1="2.45" SD_2="1.88" SE="0.640904604540498" STUDY_ID="STD-Wille-1986" TOTAL_1="24" TOTAL_2="22" WEIGHT="44.76197496714639"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="6.589020190028582" CI_END="1.3646736619423763" CI_START="0.8332204096605966" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.06633669525936" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="59" I2="69.64647334019894" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.13502880979284324" LOG_CI_START="-0.07924010058889243" LOG_EFFECT_SIZE="0.0278943546019754" METHOD="MH" NO="2" P_CHI2="0.03708629009337949" P_Q="0.0" P_Z="0.6098333417103887" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="137" TOTAL_2="133" WEIGHT="100.0" Z="0.5103113680324305">
<NAME>Number failing to achieve 14 consecutive dry nights during treatment</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Alarm</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours alarm</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.589020190028582" CI_END="1.3646736619423763" CI_START="0.8332204096605966" DF="2.0" EFFECT_SIZE="1.06633669525936" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="59" I2="69.64647334019894" ID="CMP-006.02.01" LOG_CI_END="0.13502880979284324" LOG_CI_START="-0.07924010058889243" LOG_EFFECT_SIZE="0.0278943546019754" NO="1" P_CHI2="0.03708629009337949" P_Z="0.6098333417103887" STUDIES="3" TAU2="0.0" TOTAL_1="137" TOTAL_2="133" WEIGHT="100.0" Z="0.5103113680324305">
<NAME>desmopressin vs alarm</NAME>
<DICH_DATA CI_END="4.531984111034575" CI_START="0.7944120933946722" EFFECT_SIZE="1.8974358974358974" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.6562883785739493" LOG_CI_START="-0.09995415316499534" LOG_EFFECT_SIZE="0.27816711270447697" ORDER="104072" O_E="0.0" SE="0.44422060660436197" STUDY_ID="STD-Faraj-1999" TOTAL_1="39" TOTAL_2="37" VAR="0.19733194733194734" WEIGHT="10.254167084637725"/>
<DICH_DATA CI_END="1.7731748496173836" CI_START="0.8286713007776912" EFFECT_SIZE="1.212179487179487" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" LOG_CI_END="0.24875156271874155" LOG_CI_START="-0.0816177017375854" LOG_EFFECT_SIZE="0.08356693049057808" ORDER="104073" O_E="0.0" SE="0.19406054129588016" STUDY_ID="STD-Longstaffe-2000" TOTAL_1="60" TOTAL_2="61" VAR="0.03765949368805001" WEIGHT="42.93755914228469"/>
<DICH_DATA CI_END="1.0393618355809597" CI_START="0.5419010130646197" EFFECT_SIZE="0.7504873294346979" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" LOG_CI_END="0.0167667658821721" LOG_CI_START="-0.2660800370888033" LOG_EFFECT_SIZE="-0.1246566356033156" ORDER="104074" O_E="0.0" SE="0.16614561217940638" STUDY_ID="STD-Ng-2005" TOTAL_1="38" TOTAL_2="35" VAR="0.02760436444646971" WEIGHT="46.80827377307758"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.771678406974653" CI_END="1.906777753136429" CI_START="1.0515404864897122" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4159992959605738" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="26" I2="85.23261236136042" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.28030007625980247" LOG_CI_START="0.021825998582565464" LOG_EFFECT_SIZE="0.15106303742118393" METHOD="MH" NO="3" P_CHI2="0.009261620753646893" P_Q="0.0" P_Z="0.02196517841733728" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="62" TOTAL_2="57" WEIGHT="99.99999999999999" Z="2.290969488324992">
<NAME>Number failing to achieve 14 consecutive dry nights or relapsing after cure</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Alarm</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours alarm</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.771678406974653" CI_END="1.906777753136429" CI_START="1.0515404864897122" DF="1.0" EFFECT_SIZE="1.4159992959605738" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="26" I2="85.23261236136042" ID="CMP-006.03.01" LOG_CI_END="0.28030007625980247" LOG_CI_START="0.021825998582565464" LOG_EFFECT_SIZE="0.15106303742118393" NO="1" P_CHI2="0.009261620753646893" P_Z="0.02196517841733728" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="57" WEIGHT="99.99999999999999" Z="2.290969488324992">
<NAME>desmopressin vs alarm</NAME>
<DICH_DATA CI_END="1.4423574038054836" CI_START="0.8469514178499632" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="25" LOG_CI_END="0.1590728881698436" LOG_CI_START="-0.0721415006076629" LOG_EFFECT_SIZE="0.043465693781090345" ORDER="104075" O_E="0.0" SE="0.13581647649759052" STUDY_ID="STD-Ng-2005" TOTAL_1="38" TOTAL_2="35" VAR="0.018446115288220554" WEIGHT="96.14538414151191"/>
<DICH_DATA CI_END="65.89867299098015" CI_START="1.2751057641066463" EFFECT_SIZE="9.166666666666666" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.8188766692450362" LOG_CI_START="0.10554620897616399" LOG_EFFECT_SIZE="0.9622114391106001" ORDER="104076" O_E="0.0" SE="1.0064187934844957" STUDY_ID="STD-Wille-1986" TOTAL_1="24" TOTAL_2="22" VAR="1.012878787878788" WEIGHT="3.8546158584880748"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.1759704681051755" CI_START="-0.3759704681051754" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.1668330407003973" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="34" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="1.382451733938288">
<NAME>Number of wet nights per week after end of treatment</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Alarm</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours alarm</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.1759704681051755" CI_START="-0.3759704681051754" DF="0.0" EFFECT_SIZE="0.8999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.02" NO="2" P_CHI2="1.0" P_Z="0.1668330407003973" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="24" WEIGHT="100.0" Z="1.382451733938288">
<NAME>desmopressin vs alarm</NAME>
<CONT_DATA CI_END="2.1759704681051755" CI_START="-0.3759704681051754" EFFECT_SIZE="0.8999999999999999" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="2.5" ORDER="104077" SD_1="2.5" SD_2="2.4" SE="0.6510173034657103" STUDY_ID="STD-Ng-2005" TOTAL_1="34" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>DESMOPRESSIN ALONE VS DESMOPRESSIN + ALARM</NAME>
<CONT_OUTCOME CHI2="1.7331035038946471E-31" CI_END="2.3453845237226574" CI_START="0.2546154762773434" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.3000000000000003" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-007.01" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.014795930052361192" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="2.4373358530588396">
<NAME>Number of wet nights per week during treatment</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Desmo + Alarm</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours desmo+alarm</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.7331035038946471E-31" CI_END="2.3453845237226574" CI_START="0.2546154762773434" DF="0.0" EFFECT_SIZE="1.3000000000000003" ESTIMABLE="YES" I2="100.0" ID="CMP-007.01.01" NO="1" P_CHI2="0.0" P_Z="0.014795930052361192" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="29" WEIGHT="100.0" Z="2.4373358530588396">
<NAME>desmopressin alone vs desmopressin + alarm</NAME>
<CONT_DATA CI_END="2.345384523722657" CI_START="0.25461547627734316" EFFECT_SIZE="1.3" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="1.3" ORDER="104078" SD_1="2.4" SD_2="1.9" SE="0.5333692516640697" STUDY_ID="STD-Ng-2005" TOTAL_1="36" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.604785389110326" CI_START="0.9150475989899847" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.543859649122807" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.4157719471500786" LOG_CI_START="-0.03855631419472418" LOG_EFFECT_SIZE="0.1886078164776772" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.10367308238078932" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="38" TOTAL_2="32" WEIGHT="100.0" Z="1.6273014863957078">
<NAME>Number failing to achieve 14 consecutive dry nights during treatment</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Desmo + Alarm</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours desmo+alarm</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.604785389110326" CI_START="0.9150475989899847" DF="0.0" EFFECT_SIZE="1.543859649122807" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="0.4157719471500786" LOG_CI_START="-0.03855631419472418" LOG_EFFECT_SIZE="0.1886078164776772" NO="1" P_CHI2="1.0" P_Z="0.10367308238078932" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="32" WEIGHT="100.0" Z="1.6273014863957078">
<NAME>desmopressin alone vs desmopressin + alarm</NAME>
<DICH_DATA CI_END="2.604785389110326" CI_START="0.9150475989899847" EFFECT_SIZE="1.543859649122807" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" LOG_CI_END="0.4157719471500786" LOG_CI_START="-0.03855631419472418" LOG_EFFECT_SIZE="0.1886078164776772" ORDER="104079" O_E="0.0" SE="0.26687466967510154" STUDY_ID="STD-Ng-2005" TOTAL_1="38" TOTAL_2="32" VAR="0.07122208931419458" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8500303534384503" CI_START="0.9556287720669373" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3296398891966759" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.26717885392878893" LOG_CI_START="-0.01971078298893039" LOG_EFFECT_SIZE="0.12373403546992927" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.09090464049437752" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="38" TOTAL_2="32" WEIGHT="100.0" Z="1.6906449168982476">
<NAME>Number failing to achieve 14 consecutive dry nights or relapsing after cure</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Desmo + Alarm</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours desmo+alarm</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8500303534384503" CI_START="0.9556287720669373" DF="0.0" EFFECT_SIZE="1.3296398891966759" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="19" I2="0.0" ID="CMP-007.03.01" LOG_CI_END="0.26717885392878893" LOG_CI_START="-0.01971078298893039" LOG_EFFECT_SIZE="0.12373403546992927" NO="1" P_CHI2="1.0" P_Z="0.09090464049437752" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="32" WEIGHT="100.0" Z="1.6906449168982476">
<NAME>desmopressin alone vs desmopressin + alarm</NAME>
<DICH_DATA CI_END="1.8500303534384503" CI_START="0.9556287720669373" EFFECT_SIZE="1.3296398891966759" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="19" LOG_CI_END="0.26717885392878893" LOG_CI_START="-0.01971078298893039" LOG_EFFECT_SIZE="0.12373403546992927" ORDER="104080" O_E="0.0" SE="0.16852039285207454" STUDY_ID="STD-Ng-2005" TOTAL_1="38" TOTAL_2="32" VAR="0.028399122807017535" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.168573576865997" CI_START="-0.5685735768659976" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.2519203996774857" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="34" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="1.1456973992020667">
<NAME>Number of wet nights per week after end of treatment</NAME>
<GROUP_LABEL_1>Desmopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Desmo + Alarm</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours desmo+alarm</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.168573576865997" CI_START="-0.5685735768659976" DF="0.0" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-007.04.01" NO="1" P_CHI2="1.0" P_Z="0.2519203996774857" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="24" WEIGHT="100.0" Z="1.1456973992020667">
<NAME>desmopressin alone vs desmopressin + alarm</NAME>
<CONT_DATA CI_END="2.168573576865997" CI_START="-0.5685735768659976" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="2.6" ORDER="104081" SD_1="2.5" SD_2="2.7" SE="0.6982646557085391" STUDY_ID="STD-Ng-2005" TOTAL_1="34" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>DESMOPRESSIN + ALARM VS ALARM ALONE</NAME>
<CONT_OUTCOME CHI2="4.496438645078847" CI_END="-0.5464922594671162" CI_START="-1.1081981943596246" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8273452269133704" ESTIMABLE="YES" I2="33.28053073106274" I2_Q="0.0" ID="CMP-008.01" NO="1" P_CHI2="0.21260847570412977" P_Q="1.0" P_Z="7.753950814919822E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="191" TOTAL_2="189" UNITS="" WEIGHT="100.0" Z="5.773721610549256">
<NAME>Number of wet nights per week during treatment</NAME>
<GROUP_LABEL_1>Desmo + Alarm</GROUP_LABEL_1>
<GROUP_LABEL_2>Alarm</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmo+alarm</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours alarm</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.496438645078847" CI_END="-0.5464922594671162" CI_START="-1.1081981943596246" DF="3.0" EFFECT_SIZE="-0.8273452269133704" ESTIMABLE="YES" I2="33.28053073106274" ID="CMP-008.01.01" NO="1" P_CHI2="0.21260847570412977" P_Z="7.753950814919822E-9" STUDIES="4" TAU2="0.0" TOTAL_1="191" TOTAL_2="189" WEIGHT="100.0" Z="5.773721610549256">
<NAME>desmopressin + alarm vs alarm (+/- placebo)</NAME>
<CONT_DATA CI_END="-0.37985199080704046" CI_START="-2.32014800919296" EFFECT_SIZE="-1.35" ESTIMABLE="YES" MEAN_1="0.85" MEAN_2="2.2" ORDER="104082" SD_1="1.61" SD_2="2.12" SE="0.49498256949891084" STUDY_ID="STD-Bradbury-1995" TOTAL_1="33" TOTAL_2="27" WEIGHT="8.380733683730616"/>
<CONT_DATA CI_END="-0.23475958598073027" CI_START="-0.9652404140192694" EFFECT_SIZE="-0.5999999999999999" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="2.4" ORDER="104083" SD_1="1.13" SD_2="1.53" SE="0.18635057424536336" STUDY_ID="STD-Gibb-2004" TOTAL_1="101" TOTAL_2="106" WEIGHT="59.12897914661935"/>
<CONT_DATA CI_END="-0.43125354397016014" CI_START="-2.5687464560298396" EFFECT_SIZE="-1.4999999999999998" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="2.8" ORDER="104084" SD_1="1.9" SD_2="2.2" SE="0.5452888239069571" STUDY_ID="STD-Ng-2005" TOTAL_1="29" TOTAL_2="28" WEIGHT="6.905715121358192"/>
<CONT_DATA CI_END="-0.4447482468714934" CI_START="-1.5552517531285066" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="2.9" ORDER="104085" SD_1="1.06" SD_2="1.06" SE="0.28329691642716986" STUDY_ID="STD-Sukhai-1989_x0023_" TOTAL_1="28" TOTAL_2="28" WEIGHT="25.584572048291843"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="13.153747767911943" CI_END="1.0481773495928632" CI_START="0.7332891448665038" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8767080884487088" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="129" I2="69.59041582234195" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.020434770656484424" LOG_CI_START="-0.13472474396862164" LOG_EFFECT_SIZE="-0.05714498665606858" METHOD="MH" NO="2" P_CHI2="0.010548517134373214" P_Q="0.0" P_Z="0.14882258301033283" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="242" TOTAL_2="244" WEIGHT="100.0" Z="1.4437028372192857">
<NAME>Number failing to achieve 14 consecutive dry nights during treatment</NAME>
<GROUP_LABEL_1>Desmo + Alarm</GROUP_LABEL_1>
<GROUP_LABEL_2>Alarm</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmo+alarm</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours alarm</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="13.153747767911943" CI_END="1.0481773495928632" CI_START="0.7332891448665038" DF="4.0" EFFECT_SIZE="0.8767080884487088" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="129" I2="69.59041582234195" ID="CMP-008.02.01" LOG_CI_END="0.020434770656484424" LOG_CI_START="-0.13472474396862164" LOG_EFFECT_SIZE="-0.05714498665606858" NO="1" P_CHI2="0.010548517134373214" P_Z="0.14882258301033283" STUDIES="5" TAU2="0.0" TOTAL_1="242" TOTAL_2="244" WEIGHT="100.0" Z="1.4437028372192857">
<NAME>desmopressin + alarm vs alarm (+/- placebo)</NAME>
<DICH_DATA CI_END="1.0492249171457093" CI_START="0.18982271611149285" EFFECT_SIZE="0.4462809917355372" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.020868595729211372" LOG_CI_START="-0.7216518167161746" LOG_EFFECT_SIZE="-0.35039161049348155" ORDER="104086" O_E="0.0" SE="0.4361601658057396" STUDY_ID="STD-Bradbury-1995" TOTAL_1="33" TOTAL_2="27" VAR="0.19023569023569023" WEIGHT="9.473253857932738"/>
<DICH_DATA CI_END="1.2272491190765844" CI_START="0.7123657569743042" EFFECT_SIZE="0.9350135013501351" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="55" LOG_CI_END="0.08893272903402503" LOG_CI_START="-0.14729696500123005" LOG_EFFECT_SIZE="-0.029182117983602495" ORDER="104087" O_E="0.0" SE="0.13876249163215346" STUDY_ID="STD-Gibb-2004" TOTAL_1="101" TOTAL_2="106" VAR="0.01925502908396346" WEIGHT="42.020142277172006"/>
<DICH_DATA CI_END="1.514879545449621" CI_START="0.825896717158271" EFFECT_SIZE="1.1185410334346504" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="28" LOG_CI_END="0.18037810159984213" LOG_CI_START="-0.08307426015275547" LOG_EFFECT_SIZE="0.04865192072354334" ORDER="104088" O_E="0.0" SE="0.1547532214036989" STUDY_ID="STD-Leebeek-2001" TOTAL_1="47" TOTAL_2="46" VAR="0.02394855953482225" WEIGHT="22.157295080493174"/>
<DICH_DATA CI_END="0.7873867674087744" CI_START="0.30011173939757224" EFFECT_SIZE="0.4861111111111111" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="27" LOG_CI_END="-0.10381188811022936" LOG_CI_START="-0.5227170160517565" LOG_EFFECT_SIZE="-0.31326445208099285" ORDER="104089" O_E="0.0" SE="0.24606694576667912" STUDY_ID="STD-Ng-2005" TOTAL_1="32" TOTAL_2="35" VAR="0.0605489417989418" WEIGHT="20.192158216982573"/>
<DICH_DATA CI_END="3.235137710556347" CI_START="0.7442798470003104" EFFECT_SIZE="1.5517241379310345" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5098927720717357" LOG_CI_START="-0.12826374031896043" LOG_EFFECT_SIZE="0.19081451587638756" ORDER="104090" O_E="0.0" SE="0.37485629430397766" STUDY_ID="STD-Rodriguez-2001" TOTAL_1="29" TOTAL_2="30" VAR="0.14051724137931032" WEIGHT="6.157150567419514"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8841589680181765" CI_END="1.0829997151794057" CI_START="0.7563691304800921" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9050677062410495" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="118" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.03462834240922739" LOG_CI_START="-0.1212662042264277" LOG_EFFECT_SIZE="-0.043318930908600124" METHOD="MH" NO="3" P_CHI2="0.4098326963178026" P_Q="0.0" P_Z="0.27604663036737354" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="213" TOTAL_2="214" WEIGHT="99.99999999999999" Z="1.0892432899280993">
<NAME>Number failing to achieve 14 consecutive dry nights or relapsing after cure</NAME>
<GROUP_LABEL_1>Desmo + Alarm</GROUP_LABEL_1>
<GROUP_LABEL_2>Alarm</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmo+alarm</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours alarm</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.8841589680181765" CI_END="1.0829997151794057" CI_START="0.7563691304800921" DF="3.0" EFFECT_SIZE="0.9050677062410495" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="118" I2="0.0" ID="CMP-008.03.01" LOG_CI_END="0.03462834240922739" LOG_CI_START="-0.1212662042264277" LOG_EFFECT_SIZE="-0.043318930908600124" NO="1" P_CHI2="0.4098326963178026" P_Z="0.27604663036737354" STUDIES="4" TAU2="0.0" TOTAL_1="213" TOTAL_2="214" WEIGHT="99.99999999999999" Z="1.0892432899280993">
<NAME>desmopressin + alarm vs alarm (+/- placebo)</NAME>
<DICH_DATA CI_END="1.099873693750144" CI_START="0.3105279972132839" EFFECT_SIZE="0.5844155844155844" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.041342814924712604" LOG_CI_START="-0.507899237718989" LOG_EFFECT_SIZE="-0.23327821139713822" ORDER="104091" O_E="0.0" SE="0.32262750051491906" STUDY_ID="STD-Bradbury-1995" TOTAL_1="33" TOTAL_2="27" VAR="0.10408850408850409" WEIGHT="13.150542244070852"/>
<DICH_DATA CI_END="1.2960312688635394" CI_START="0.7922706546083114" EFFECT_SIZE="1.0133151246159098" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="58" LOG_CI_END="0.11261547972212906" LOG_CI_START="-0.10112642987134757" LOG_EFFECT_SIZE="0.005744524925390762" ORDER="104092" O_E="0.0" SE="0.1255530557347245" STUDY_ID="STD-Gibb-2004" TOTAL_1="101" TOTAL_2="106" VAR="0.01576356980432684" WEIGHT="48.33168734912294"/>
<DICH_DATA CI_END="1.4735807826788214" CI_START="0.589613474850348" EFFECT_SIZE="0.9321175278622087" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" LOG_CI_END="0.16837394915097842" LOG_CI_START="-0.22943259979914135" LOG_EFFECT_SIZE="-0.030529325324081473" ORDER="104093" O_E="0.0" SE="0.23367353602747606" STUDY_ID="STD-Leebeek-2001" TOTAL_1="47" TOTAL_2="46" VAR="0.05460332143958416" WEIGHT="18.125380805610853"/>
<DICH_DATA CI_END="1.1855357802319584" CI_START="0.5828390623223584" EFFECT_SIZE="0.83125" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.07391466579865023" LOG_CI_START="-0.23445134917632812" LOG_EFFECT_SIZE="-0.08026834168883897" ORDER="104094" O_E="0.0" SE="0.18113572363269445" STUDY_ID="STD-Ng-2005" TOTAL_1="32" TOTAL_2="35" VAR="0.03281015037593986" WEIGHT="20.39238960119535"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.5452658003815183" CI_START="-1.345265800381518" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.8921274645198529" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="0.1356127007241622">
<NAME>Number of wet nights per week after end of treatment</NAME>
<GROUP_LABEL_1>Desmo + Alarm</GROUP_LABEL_1>
<GROUP_LABEL_2>Alarm</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours desmo+alarm</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours alarm</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5452658003815183" CI_START="-1.345265800381518" DF="0.0" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-008.04.01" NO="1" P_CHI2="1.0" P_Z="0.8921274645198529" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.1356127007241622">
<NAME>desmopressin + alarm vs alarm alone</NAME>
<CONT_DATA CI_END="1.5452658003815183" CI_START="-1.345265800381518" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="2.5" ORDER="104095" SD_1="2.7" SD_2="2.4" SE="0.7373940601876312" STUDY_ID="STD-Ng-2005" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-008.05" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Number of wet nights per week during treatment (no SDs)</NAME>
<TR>
<TH>
<P>Desmopressin + Alarm</P>
</TH>
<TH>
<P>Alarm alone</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-008.05.01" NO="1" STUDIES="1">
<NAME>desmopressin + alarm vs alarm (+/- placebo)</NAME>
<OTHER_DATA ORDER="417" STUDY_ID="STD-Leebeek-2001">
<TR>
<TD>
<P>2.93 wet nights, n=47</P>
</TD>
<TD>
<P>3.86 wet nights, n=45</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-008.06" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Number of wet nights per week after treatment stops (no SDs)</NAME>
<TR>
<TH>
<P>Desmopressin + Alarm</P>
</TH>
<TH>
<P>Alarm alone</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-008.06.01" NO="1" STUDIES="1">
<NAME>desmopressin + alarm vs alarm (+/- placebo)</NAME>
<OTHER_DATA ORDER="418" STUDY_ID="STD-Leebeek-2001">
<TR>
<TD>
<P>2.72 wet nights, n=41</P>
</TD>
<TD>
<P>1.90 wet nights, n=37</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>DESMOPRESSIN VS BEHAVIOURAL METHODS</NAME>
<CONT_OUTCOME CHI2="19.356164640342396" CI_END="0.04810723376283574" CI_START="-0.4479424917523879" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.19991762899477608" ESTIMABLE="YES" I2="84.50106177673568" I2_Q="84.50106177673568" ID="CMP-009.01" NO="1" P_CHI2="2.30741953189173E-4" P_Q="2.30741953189173E-4" P_Z="0.11415112900796913" Q="19.356164640342396" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="209" TOTAL_2="226" UNITS="" WEIGHT="400.0" Z="1.5798067514196272">
<NAME>Number of wet nights per week during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.261788275983727E-33" CI_END="0.3992480322060974" CI_START="-0.1992480322060981" DF="0.0" EFFECT_SIZE="0.09999999999999963" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-009.01.01" NO="1" P_CHI2="0.0" P_Z="0.5124915600126414" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="60" WEIGHT="100.00000000000001" Z="0.654963031867218">
<NAME>desmopressin vs retention control training</NAME>
<CONT_DATA CI_END="0.3992480322060974" CI_START="-0.1992480322060981" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="6.7" ORDER="104098" SD_1="0.76" SD_2="0.87" SE="0.1526803729897733" STUDY_ID="STD-Hamano-2000" TOTAL_1="54" TOTAL_2="60" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8506203146036052" CI_START="-2.149379685396395" DF="0.0" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.02" NO="2" P_CHI2="1.0" P_Z="5.973803922991214E-6" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="76" WEIGHT="100.0" Z="4.5273143631148205">
<NAME>desmopressin + psychology + retention control training vs desmopressin alone</NAME>
<CONT_DATA CI_END="-0.8506203146036052" CI_START="-2.149379685396395" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="4.5" ORDER="104099" SD_1="2.0" SD_2="2.0" SE="0.33132225414273875" STUDY_ID="STD-Kahan-1998" TOTAL_1="70" TOTAL_2="76" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.38367687921504323" CI_START="-0.9836768792150429" DF="0.0" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.03" NO="3" P_CHI2="1.0" P_Z="0.3897672182092231" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="75" WEIGHT="100.0" Z="0.8600396082387779">
<NAME>desmopressin + psychology + retention control training vs placebo + psychology + retention control training</NAME>
<CONT_DATA CI_END="0.38367687921504323" CI_START="-0.9836768792150429" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.3" ORDER="104100" SD_1="2.0" SD_2="2.2" SE="0.3488211439637662" STUDY_ID="STD-Kahan-1998" TOTAL_1="70" TOTAL_2="75" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0253290895964968" CI_START="-1.605329089596497" DF="0.0" EFFECT_SIZE="-0.29000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.04" NO="4" P_CHI2="1.0" P_Z="0.6656489242879366" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.4321272600235585">
<NAME>desmopressin vs toileting, alarm clock, pelvic floor training, dietary and fluid adjustment etc</NAME>
<CONT_DATA CI_END="1.0253290895964968" CI_START="-1.605329089596497" EFFECT_SIZE="-0.29000000000000004" ESTIMABLE="YES" MEAN_1="3.64" MEAN_2="3.93" ORDER="104101" SD_1="2.0" SD_2="1.66" SE="0.6710986017965864" STUDY_ID="STD-Fera-2004" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="9.169609593523585" CI_END="1.0690285984277577" CI_START="0.823243310895061" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.938120803953933" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="155" I2="67.28323087911099" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.02898932351863237" LOG_CI_START="-0.08447178937787184" LOG_EFFECT_SIZE="-0.027741232929619757" METHOD="MH" NO="2" P_CHI2="0.027118838242154664" P_Q="0.0" P_Z="0.3378499818869596" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="209" TOTAL_2="226" WEIGHT="400.0" Z="0.9584220715054615">
<NAME>Number failing to achieve 14 consecutive dry nights during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0280846004012847" CI_START="0.6180140429969319" DF="0.0" EFFECT_SIZE="0.7971014492753623" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="46" I2="0.0" ID="CMP-009.02.01" LOG_CI_END="0.012028853935216978" LOG_CI_START="-0.20900165642123988" LOG_EFFECT_SIZE="-0.09848640124301147" NO="1" P_CHI2="1.0" P_Z="0.08070069291205453" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="60" WEIGHT="100.0" Z="1.746634879428757">
<NAME>desmopressin vs retention control training</NAME>
<DICH_DATA CI_END="1.0280846004012847" CI_START="0.6180140429969319" EFFECT_SIZE="0.7971014492753623" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="46" LOG_CI_END="0.012028853935216978" LOG_CI_START="-0.20900165642123988" LOG_EFFECT_SIZE="-0.09848640124301147" ORDER="104102" O_E="0.0" SE="0.12983441590205475" STUDY_ID="STD-Hamano-2000" TOTAL_1="54" TOTAL_2="60" VAR="0.016856975552627728" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4794490556269135" CI_START="0.9065432671695085" DF="0.0" EFFECT_SIZE="1.158095238095238" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="45" I2="0.0" ID="CMP-009.02.02" LOG_CI_END="0.1701000149572517" LOG_CI_START="-0.04261146322369561" LOG_EFFECT_SIZE="0.06374427586677804" NO="2" P_CHI2="1.0" P_Z="0.24011328156105016" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="76" WEIGHT="100.0" Z="1.1747037441316728">
<NAME>desmopressin + psychology + retention control training vs desmopressin alone</NAME>
<DICH_DATA CI_END="1.4794490556269135" CI_START="0.9065432671695085" EFFECT_SIZE="1.158095238095238" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="45" LOG_CI_END="0.1701000149572517" LOG_CI_START="-0.04261146322369561" LOG_EFFECT_SIZE="0.06374427586677804" ORDER="104103" O_E="0.0" SE="0.12494777522228705" STUDY_ID="STD-Kahan-1998" TOTAL_1="70" TOTAL_2="76" VAR="0.015611946532999167" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9840262627077268" CI_START="0.677206523683356" DF="0.0" EFFECT_SIZE="0.8163265306122449" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="63" I2="0.0" ID="CMP-009.02.03" LOG_CI_END="-0.006993310514959279" LOG_CI_START="-0.16927886688614324" LOG_EFFECT_SIZE="-0.08813608870055126" NO="3" P_CHI2="1.0" P_Z="0.033263861509989515" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="75" WEIGHT="100.0" Z="2.128883967913994">
<NAME>desmopressin + psychology + retention control training vs placebo + psychology + retention control training</NAME>
<DICH_DATA CI_END="0.9840262627077266" CI_START="0.677206523683356" EFFECT_SIZE="0.8163265306122449" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="63" LOG_CI_END="-0.006993310514959329" LOG_CI_START="-0.16927886688614324" LOG_EFFECT_SIZE="-0.08813608870055126" ORDER="104104" O_E="0.0" SE="0.09532733913889332" STUDY_ID="STD-Kahan-1998" TOTAL_1="70" TOTAL_2="75" VAR="0.009087301587301583" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="37.85185589009337" CI_START="0.6604695968564918" DF="0.0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-009.02.04" LOG_CI_END="1.5780871779726027" LOG_CI_START="-0.18014716930056512" LOG_EFFECT_SIZE="0.6989700043360189" NO="4" P_CHI2="1.0" P_Z="0.11915467176373172" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.5583315579030255">
<NAME>desmopressin vs toileting, alarm clock, pelvic floor training, dietary and fluid adjustment etc</NAME>
<DICH_DATA CI_END="37.85185589009337" CI_START="0.6604695968564918" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5780871779726027" LOG_CI_START="-0.18014716930056512" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="104105" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Fera-2004" TOTAL_1="15" TOTAL_2="15" VAR="1.0666666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="16.12209848048574" CI_END="-0.8900940042200818" CI_START="-1.718232036109849" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3041630201649654" ESTIMABLE="YES" I2="93.79733350958993" I2_Q="93.79733350958993" ID="CMP-009.03" NO="3" P_CHI2="5.938828810636565E-5" P_Q="5.938828810636565E-5" P_Z="6.694018592011448E-10" Q="16.12209848048574" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="140" TOTAL_2="150" UNITS="" WEIGHT="200.0" Z="6.173155805100276">
<NAME>Number of wet nights per week at followup</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.5322281917011016" CI_START="-2.6677718082988986" DF="0.0" EFFECT_SIZE="-2.1" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.02" NO="2" P_CHI2="1.0" P_Z="4.1906073408277816E-13" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="76" WEIGHT="100.00000000000001" Z="7.249258077581975">
<NAME>desmopressin + psychology + retention control training vs desmopressin alone</NAME>
<CONT_DATA CI_END="-1.5322281917011016" CI_START="-2.6677718082988986" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="4.7" ORDER="104106" SD_1="1.7" SD_2="1.8" SE="0.28968481705654286" STUDY_ID="STD-Kahan-1998" TOTAL_1="70" TOTAL_2="76" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.20518079451659543" CI_START="-1.0051807945165954" DF="0.0" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.03" NO="3" P_CHI2="1.0" P_Z="0.19516268429899516" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="74" WEIGHT="100.0" Z="1.295456830288627">
<NAME>desmopressin + psychology + retention control training vs placebo + psychology + retention control training</NAME>
<CONT_DATA CI_END="0.20518079451659543" CI_START="-1.0051807945165954" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="3.0" ORDER="104107" SD_1="1.7" SD_2="2.0" SE="0.30877138523472075" STUDY_ID="STD-Kahan-1998" TOTAL_1="70" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.1790463440322365" CI_END="1.0828732942667363" CI_START="0.9708327454092186" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0253237796926882" ESTIMABLE="YES" EVENTS_1="182" EVENTS_2="193" I2="8.21672951209099" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="0.03457764331044144" LOG_CI_START="-0.012855583688789921" LOG_EFFECT_SIZE="0.010861029810825741" METHOD="MH" NO="4" P_CHI2="0.3363770916397023" P_Q="0.0" P_Z="0.369416951747051" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="194" TOTAL_2="211" WEIGHT="300.0" Z="0.897566056999634">
<NAME>Number failing to achieve 14 consecutive dry nights or relapsing after cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.240980142653807" CI_START="0.956202346999357" DF="0.0" EFFECT_SIZE="1.0893246187363834" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="51" I2="0.0" ID="CMP-009.04.01" LOG_CI_END="0.09376483226031421" LOG_CI_START="-0.0194501946627991" LOG_EFFECT_SIZE="0.037157318798757555" NO="1" P_CHI2="1.0" P_Z="0.19825974342732666" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="60" WEIGHT="100.0" Z="1.2865254478470651">
<NAME>desmopressin vs retention control training</NAME>
<DICH_DATA CI_END="1.240980142653807" CI_START="0.956202346999357" EFFECT_SIZE="1.0893246187363834" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="51" LOG_CI_END="0.09376483226031421" LOG_CI_START="-0.0194501946627991" LOG_EFFECT_SIZE="0.037157318798757555" ORDER="104108" O_E="0.0" SE="0.06650306723805843" STUDY_ID="STD-Hamano-2000" TOTAL_1="54" TOTAL_2="60" VAR="0.004422657952069722" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.763337243776224E-30" CI_END="1.0564767266458446" CI_START="0.9120388137559686" DF="0.0" EFFECT_SIZE="0.9816046966731897" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="73" I2="99.99999999999999" ID="CMP-009.04.02" LOG_CI_END="0.02385993432670009" LOG_CI_START="-0.03998667895080558" LOG_EFFECT_SIZE="-0.00806337231205275" NO="2" P_CHI2="0.0" P_Z="0.6205584964413606" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="76" WEIGHT="100.0" Z="0.4950589706887039">
<NAME>desmopressin + psychology + retention control training vs desmopressin alone</NAME>
<DICH_DATA CI_END="1.0564767266458448" CI_START="0.9120388137559686" EFFECT_SIZE="0.9816046966731898" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="73" LOG_CI_END="0.02385993432670018" LOG_CI_START="-0.03998667895080558" LOG_EFFECT_SIZE="-0.008063372312052702" ORDER="104109" O_E="0.0" SE="0.03750381668503971" STUDY_ID="STD-Kahan-1998" TOTAL_1="70" TOTAL_2="76" VAR="0.0014065362659450627" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1193456844522316" CI_START="0.9383220176922743" DF="0.0" EFFECT_SIZE="1.0248447204968945" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="69" I2="0.0" ID="CMP-009.04.03" LOG_CI_END="0.048964229214459976" LOG_CI_START="-0.02764809285034678" LOG_EFFECT_SIZE="0.010658068182056593" NO="3" P_CHI2="1.0" P_Z="0.5855278159094557" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="75" WEIGHT="100.00000000000001" Z="0.5453281983525504">
<NAME>desmopressin + psychology + retention control training vs placebo + psychology + retention control training</NAME>
<DICH_DATA CI_END="1.1193456844522316" CI_START="0.9383220176922742" EFFECT_SIZE="1.0248447204968945" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="69" LOG_CI_END="0.048964229214459976" LOG_CI_START="-0.027648092850346837" LOG_EFFECT_SIZE="0.010658068182056593" ORDER="104110" O_E="0.0" SE="0.045002457217978" STUDY_ID="STD-Kahan-1998" TOTAL_1="70" TOTAL_2="75" VAR="0.00202522115565594" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>DESMOPRESSIN VS COMPLEMENTARY METHODS</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0086608078120443" CI_START="0.2212640594748102" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="0.3029066058709399" LOG_CI_START="-0.6550891239823023" LOG_EFFECT_SIZE="-0.17609125905568127" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.47119849141664616" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.7205304052750208">
<NAME>Number failing to achieve 14 consecutive dry nights during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0086608078120443" CI_START="0.2212640594748102" DF="0.0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-010.02.01" LOG_CI_END="0.3029066058709399" LOG_CI_START="-0.6550891239823023" LOG_EFFECT_SIZE="-0.17609125905568127" NO="1" P_CHI2="1.0" P_Z="0.47119849141664616" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.7205304052750208">
<NAME>desmopressin vs laser acupuncture</NAME>
<DICH_DATA CI_END="2.0086608078120443" CI_START="0.2212640594748102" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3029066058709399" LOG_CI_START="-0.6550891239823023" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="104111" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Radmayr-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.876500413900387" CI_START="0.2718912705018658" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="0.27334866454160545" LOG_CI_START="-0.5656047358980814" LOG_EFFECT_SIZE="-0.146128035678238" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.49475282593972036" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6827689998296169">
<NAME>Number failing to achieve 14 consecutive dry nights or relapsing after cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.876500413900387" CI_START="0.2718912705018658" DF="0.0" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-010.04.01" LOG_CI_END="0.27334866454160545" LOG_CI_START="-0.5656047358980814" LOG_EFFECT_SIZE="-0.146128035678238" NO="1" P_CHI2="1.0" P_Z="0.49475282593972036" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6827689998296169">
<NAME>desmopressin vs laser acupuncture</NAME>
<DICH_DATA CI_END="1.876500413900387" CI_START="0.2718912705018658" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.27334866454160545" LOG_CI_START="-0.5656047358980814" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="104112" O_E="0.0" SE="0.49280538030458115" STUDY_ID="STD-Radmayr-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.24285714285714288" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>